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 i 
Abstract 
 
Purpose:  
The purpose of this research was to investigate the effect of glaucoma-related insults, specifically 
oxygen and/or glucose deprivation (OGD) on the survival and genes expression of human Müller 
cells (MIO-M1), and retinal ganglion cells (RGCs) using the human organotypic retinal culture 
(HORC) model.  
Methods:  
MIO-M1 cells and HORCs were exposed to different levels of OGD using a custom-built 
chamber to control oxygen levels.  Cell survival was evaluated using MTS and LDH assays while 
RGC death in HORCs was investigated using NeuN immunohistochemistry and TUNEL-
labelling. Expression of genes of interest was assessed using QRT-PCR. 
Results:  
Reduced levels of oxygen and glucose (1.11mMglucose/4%O2) caused proliferation of MIO-M1 
cells. Full deprivation of glucose caused cell death, but full hypoxia did not affect survival.  In 
HORCs, glucose deprivation and OGD, but not oxygen deprivation alone, caused loss of RGCs. 
Different levels of OGD regulated expression of genes associated with angiogenesis, glial 
activation, excitotoxicity and neuroprotection in MIO-M1 cells and HORCs.  VEGF expression 
significantly increased in MIO-M1 cells and HORCs treated with full OGD, and VEGF protein 
was secreted under reduced levels (1.11mMglucose/4%O2). Secretion of VEGF in MIO-M1 cells 
and HORCs was also increased under conditions of raised glucose. The PKCβ inhibitor 
LY333531 decreased VEGF secretion under conditions of raised glucose and hypoxia.  Co-
culture of MIO-M1 cells resulted in more damage/apoptosis to HORCs and reduced RGCs 
survival.  
Conclusions:  
Use MIO-M1 cells and the HORC model were effective in studying the effect of OGD in relation 
to glaucoma. Glucose rather than oxygen was the key survival factor for RGCs and MIO-M1 
cells. The secreted factors by Müller cells could have protective and detrimental effects on RGC 
survival.   Investigation of mechanisms using these models may be of benefit in development of 
potential therapeutic interventions for retinal neurodegenerative diseases including glaucoma. 
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Chapter 1 
Introduction 
1.  Anatomy of the Eye 
The eye is a complex photosensitive organ that takes in information from the environment in 
the form of light and analyses light intensity and colour reflection from objects through 
changing them into neuronal signals. The eyes are located in the protective bony structure of 
the skull called the orbits. Each orbit is pyramidal in shape. Its base is the orbital margin and 
its apex directed towards the optic canal at the posterior of the orbit (Grant-Kels and Kels, 
1992; Kels et al., 2015). There are four rectus muscles forming the ‘muscle cone’, situated 
within each orbit, two oblique muscles and a levator palpebrae superioris muscle (Al-lens et 
al., 2008). The size of the normal human eye is approximately 22 to 27 mm and 69 to 85 mm 
anteroposteriorly and in circumference respectively (Kels et al., 2015). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Gross anatomy of the globe. Source: http://biology-
forums.com/index.php?action=gallery;sa=view;id=11303  
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The main blood supply to the eye is via the ophthalmic artery, which is a major branch of the 
internal carotid artery. It reaches the orbit through the optic canal and branches to supply the 
eye and extra-ocular muscles (Presland, 2007). The ciliary body receives blood from the 
posterior and anterior ciliary arteries. Avascular structures like the cornea and lens receive 
their nutritional supply via the tear film and aqueous humour. The palpebral artery, which 
originates from the ophthalmic artery, supplies the conjunctiva and anterior episclera together 
with the anterior ciliary arteries (AL-lense et al., 2008).  A major branch of the ophthalmic 
artery is the central retinal artery, which supplies the innermost layer of the retina (Presland, 
2007). The outer retinal layers receive nutrition from the choroidal capillary bed. Metabolites 
diffuse through Bruch’s membrane and the retinal pigment epithelium (RPE) into the neural 
retina (Remington, 2005).  
The eye is divided anatomically into three layers: the sclera, which is the fibrous exterior and 
supporting layer; the vascular middle uveal layer, which encompasses the iris, ciliary body, 
and the choroid; and a third neural internal layer, the retina (Born et al., 1998; Grant-Kels et 
al., 1992). The lens and its suspensory ligament separate the anterior and posterior chambers 
and are located between two ‘fluid’ media: the aqueous humour and vitreous body (Figure 
1.1) (Presland, 2007). 
1.1 The Fibrous Coat: The Cornea and Sclera 
The fibrous coat is the exterior of the eye comprising the cornea and sclera. Both consist of 
collagen fibers. These fibers are arranged in highly regular laminae with cornea enabling it to 
be transparent. The cornea is the primary refractive structure in the visual pathway. Its 
transparency and avascularity are two important characteristics for optimal light transmission.  
The cornea is coated anteriorly by the tear film and posteriorly facing the aqueous humour 
(Remington, 2005).  
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The collagen fibers in the sclera are exteriorly interwoven and extend in all directions making 
it an opaque structure (Jayaram and Calder, 2004). The sclera forms the posterior five-sixths 
of the connective tissue coat of the globe. It is relatively inactive metabolically and nourished 
by the small vessel branches from episclera and choroid (Watson and Young, 2004). The 
sclera’s unique structure helps to determine the shape of the eye (Watson and Young, 2004).  
1.2 Uvea 
The uveal tract is the middle layer of the eye and is composed of three parts: the iris, ciliary 
body, and the choroid. The iris is a thin, circular and colored structure composed 
predominantly of smooth muscle and located anterior to the lens and attached peripherally to 
the ciliary body. The pupil is the central aperture and is located inferior to the iris centre.  The 
iris has the primary function of regulating the size of the pupil and to prevent excessive light 
from entering the retina and providing an optimal light condition for a good image (Al lens et 
al., 2008).  
The ciliary body lies between the iris and choroid. The ciliary muscles within the ciliary body 
are involved in the accommodation process by altering the shape of the lens. The ciliary 
processes are small, finger-like projections located posterior to the lens. The main function of 
these processes is to produce aqueous humour, which circulates through the pupil into the 
anterior chamber and exits the eye crossing the trabecular meshwork, a sieve-like structure, 
and flow out into Schlemm’s canal at the iridocorneal angle (Figure 1.2) (Karpinich and 
Caron, 2014). Drainage through the trabecular meshwork and Schlemm’s canal is referred to 
as the conventional pathway. A minor pathway for outflow of the aqueous humour is by 
diffusion through intercellular spaces between the ciliary muscle fibers (Alm, 2000; Alm and 
Nilsson; 2009). The juxtacanalicular or cribriform meshwork layer of trabecular meshwork is 
composed of cells embedded in a dense extracellular matrix and characterized by narrow 
intercellular spaces. This layer is in direct contact with the inner wall of endothelial cells 
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from Schlemm’s canal and tissue resistance to aqueous humour flow arise from this joint 
layer (Llobet et al., 2003). The flow of aqueous humour against resistance generates an 
average intraocular pressure (IOP) of approximately 15mmHg (Goel et al., 2010; Tamm, 
2009).  This pressure is important to inflate the eye maintaining the shape and optical 
properties of the globe (Goel et al., 2010). The impairment of aqueous humour outflow 
results in elevation of IOP, which is the main risk factor for of glaucoma (Braunger et al., 
2015). This will be discussed in a later section of this introduction.  
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Pathway of aqueous humor outflow. Source: adapted from  (Llobet et al., 2003) 
 
The ciliary body has both sympathetic and parasympathetic nerve endings. Stimulation of 
sympathetic receptors increases aqueous humour secretion by the ciliary epithelium, while 
parasympathetic innervation to ciliary muscle causes contraction and accommodation by 
changing the shape of the lens. It also reduces resistance to conventional aqueous humour 
trabecular outflow (Al lens et al., 2008). The suspensory ligaments (zonules) of the ciliary 
body are attached to the lens. The lens is avascular, clear, and biconvex in shape and is 
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contained within an elastic capsule. It receives its nutrients from the aqueous humor (Al lens 
et al., 2008; Presland, 2007).  
The choroid is the posterior part of the uvea. It is highly vascular tissue supplying oxygen and 
nutrients to the outer retina. In addition, the choroid acts as a thermo-regulator of the eye 
through heat dissipation.  
1.3 The Vitreous Humor 
The vitreous is the largest cavity of the eye, constituting two-thirds of the eye volume. It is 
avascular and transparent, which enables the transmission of light (Al lens et al., 2008).   The 
composition of the vitreous is 99% water with small amount of collagen giving it the 
consistency of a gel (Remington, 2005). Due to its viscoelastic properties it protects the retina 
during rapid eye movements and physical trauma (Remington, 2005). 
1.4 Retina 
The retina is the neuronal tissue lining of the posterior two-thirds of the eye, located between 
the choroid and vitreous. The retina is embryologically derived from the neural tube and is 
classed as part of the CNS (Ryan et al., 2006).  It consists of two parts: the neural retina layer 
and outer retinal pigment epithelium layer. The neural retina is composed of five major 
classes of neuronal cells: photoreceptors, horizontal cells, bipolar cells, amacrine cells, 
ganglion cells, and also Müller cells, the predominant macroglial cells. Anatomically, the 
retina is described as having ten layers. As shown in Figure 1.3 the retinal pigment 
epithelium (1), is the outermost retinal layer; the photoreceptor outer segment layer (2) 
contains the rod and cones. The external limiting membrane (3) is not a true membrane, and it 
contains intercellular junctions between photoreceptors and Müller cells (Remington, 2005).  
The outer nuclear layer (4) containing the rod and cone cell bodies. The outer plexiform layer 
(5) contains the synapses between the photoreceptors and the cells of the inner nuclear layer.  
The inner nuclear layer (6) consists of the cell bodies of horizontal cells, bipolar cells, 
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amacrine cells, Müller cells and some displaced ganglion cells. The inner plexiform layer (7) 
consists of synaptic connections between the bipolar cell and amacrine cells of the INL and 
the dendrites of ganglion cells. The ganglion cell layer (8) is a single cell layer in the 
peripheral regions of the retina (as shown in Figure 1.3), and about 8 to 10 cells near the 
macula, which is the central region of the retina. The nerve fiber layer (9) is simply ganglion 
cell axons, which exit the eye at the optic nerve head through the lamina cribrosa to become 
the optic nerve. The internal limiting membrane (10) is the innermost boundary of the retina 
composed of extensively expanded terminations of Müller cell (Forrester et al., 2002).  
 
 
 
 
 
 
 
 
Figure 1.3: The retina (A) Layers of the retina; (B) microscopic image of the same area: (1) 
retinal pigment epithelial layer;  (2 photoreceptor outer segment layer; (3) external limiting 
membrane; (4) outer nuclear layer; 95) outer plexiform layer; (6) inner nuclear layer; (7) 
inner plexiform layer; (8) ganglion cell layer; (9) nerve fiber layer; (10) internal limiting 
membrane. Source: from Leeson CR, Leeson S: Histology, Philadephia, 1976, Sauders and 
http://webvision.med.utah.edu/book/part-i-foundations/simple-anatomy-of-the-retina/ 
 
A central region of the retina is called the macula lutea, which appears as a darkened region, 
and is 3 mm lateral to the optic disc. It appears as a yellow area after dissection because of 
the presence of xanthophyll pigments (lutin and zaexanthin). These pigments have 
antioxidant properties and thus prevent damage from ultraviolet radiation (Remington, 2005). 
The fovea (fovea centralis) appears as a shallow depression at the center of the macula has a 
A B 
  
 7 
central diameter of 1.5 mm. There the retinal neurons are displaced, leaving only the 
photoreceptors in the center. This depression is known as the foveal pit. The concentration of 
cones in this area is around 300,000 cones per square millimeter, and there are no blood 
vessels (Forrester et al., 2002, Remington, 2005). The optic disc is also known as the blind 
spot as there are no normal retinal layers in this area and appears as a pale pink/whitish area. 
This is the site where ganglion cell axons meet and leave the eye (Forrester et al., 2002). The 
peripheral retina is rich in rods and considered as the remainder of the retina outside of the 
macula (Forrester et al., 2002). The ora serrata is located 5 mm anterior to the margin of the 
sensory retina and is the area where the retina and ciliary epithelium meet.  
1.4.1 Retinal Pigment Epithelium (RPE) 
The retinal pigment epithelium consists of a continuous monolayer of pigmented hexagonal 
cells, which form the outermost retinal layer and are a component of the blood-brain barrier 
(Boulton and Dayhaw-Barker, 2001). It is essential in the visual process through recycling of 
the visual pigment maintaining adhesion of the neurosensory retina; providing a selectively 
permeable barrier between the choroid and neurosensory retina; phagocytosis of rod outer 
segment; absorption of light; and transport of metabolites and vitamins (Forrester et al., 
2002). Cells contain numerous melanocytes and pigment granules, which extend to the apical 
area. The extended microvilli from the apical region envelop the outer segments of 
photoreceptors. The melanin in RPE helps in absorbing the light that passes through 
photoreceptors and preventing scattering the light, which would degrade the visual image. In 
addition, the RPE helps in scavenging reactive oxygen species (ROS) and phagocytosis, 
transport of nutrients, retinoids and waste products (Boulton and Dayhaw-Barker, 2001).  
1.4.2 Photoreceptors: Rods and Cones 
Photoreceptors are the photosensitive cells in the retina, which contain light-absorbing 
pigment and convert it into neuronal signals or impulses. The retina contains two types of 
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photoreceptors; rods account for 95% of all photoreceptors while cones make up only 5% 
(Luo et al., 2009). Photoreceptors are composed of the outer segment, containing the visual 
pigment, the cilium which connects the outer segment with the inner segment and acts as a 
channel between the two segments and the inner segment which contains the organelles and 
metabolic apparatus such as mitochondria, the endoplasmic reticulum, Golgi apparatus and 
the nucleus (Al lens et al., 2008, Remington, 2005).  
There are approximately 130 million rods in the human retina. They are specialized for high 
sensitivity and are responsible for night vision. They are also responsible for peripheral vision 
as the majority of the rods are in the periphery of the retina, with lower levels within the 
fovea (Remington, 2005). The visual pigment rhodopsin contained within the rod outer 
segments enables them to convert light into impulses. This pigment is regenerated in the dark 
and is capable of absorbing wavelengths of visible light with high sensitivity to blue light of a 
wavelength of 500 nm (Ryan et al., 2006).  Cones provide high acuity and colour vision in 
daylight condition. There are approximately six million cones in the retina, predominantly in 
the macula. The cone outer segment is shorter than that of the rod. Three different types of 
cone are present in the retina: red, green and blue with three different pigments, which allow 
them to absorb the specific wavelength of light, required. Photoreceptor axons start in the 
Outer Nuclear Layer (ONL) and terminate in the outer plexiform layer (OPL) (Al lens et al., 
2008, Remington, 2005).  
1.4.3 Horizontal Cells 
Horizontal cells are interneurons located in the outer rows of INL and adjacent to the OPL. 
They have one long axon and several short dendrites with branching terminals ending in the 
OPL and they transfer information in a horizontal direction parallel to the retinal surface. 
They synapse with photoreceptors, bipolar cells, and other horizontal cells in the OPL (Ryan 
et al., 2006, Remington, 2005).  
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1.4.4 Bipolar Cells 
Bipolar cells are interneurons, which receive input from the photoreceptors and conduct the 
signals into the inner retina. There are many kinds of bipolar cells, and they terminate deeply 
in the IPL (Ryan et al., 2006). The bipolar cells have a large nucleus and minimal cell body 
cytoplasm. Their dendrites synapse with photoreceptors and horizontal cells in the OPL, and 
the axons synapse with ganglion and amacrine cells in the IPL (Remington, 2005).  
1.4.5 Amacrine Cells 
Amacrine cells are inhibitory interneurons using either GABA or glycine as the 
neurotransmitter. Their synapses are located predominantly in the inner part of the IPL. The 
cell body of amacrine cells lie mainly within the proximal part of the INL, and many 
subtypes are displaced and can be found in the ganglion cell layer or lie within the IPL  
(Masland, 2005). 
1.4.6 Retinal Ganglion Cells (RGCs) 
Retinal ganglion cells (RGCs) are the final pathway output neurons in the retina, carrying the 
visual information to the brain. They receive signals from bipolar cells, which convey inputs 
from photoreceptors, and amacrine cells in the IPL (Marshak, 2009).  The cell bodies of the 
ganglion cells are located in the ganglion cell layer situated between the nerve fiber layer and 
the IPL, but displaced ganglion cell cells can also be found in the INL.  The axons of the 
ganglion cells form the nerve fiber layer and form bundles that are ensheathed by glial cells 
that leave the eye in the form of the optic nerve (Remington, 2005, Forrester et al., 2002).  
1.4.7 Optic Disc 
The optic disc is the site where the axons of the ganglion cells leave the eye. It is 
approximately 1.7 mm in diameter horizontally, and the vertical diameter is 1.9 mm with a 
depression in the surface, which is referred to as the cup (Jonas et al., 1992). It is pale-yellow 
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in colour and the two layers appearing in the optic disc are the nerve fiber layer and an 
internal limiting membrane only (Quigley et al., 1998).  
1.4.8 Neuroglial Cells  
The neuroglial cells found in the retina include microglial cells and two types of macroglial 
cells, astrocytes and Müller cells. They play very important roles in the support, metabolism 
and nutrition of the neuronal cells in the retina and in responding to infection or injury.  
1.4.8.1 Microglial Cells  
Microglial cells are resident of the CNS and the retina. Microglia precursors originate in the 
yolk sac and migrate through blood vessels into the retinal tissue during late embryonic 
development and in the early postnatal period (Barron, 1995).  They are abundant in human 
retina where they are found in every layer (Chan-Ling, 1994).  They are blood-derived 
phagocytes and play a role in retinal immunity via phagocytosis of cellular debris (Dheen et 
al., 2007). Activation of microglia cells in retinal injuries involves their proliferation, 
migration, and production of several cell-signalling factors (Dheen et al., 2007; Beynon and 
Walker, 2012).  
1.4.8.2 Astrocytes  
Astrocytes do not originate from the retinal embryonic epithelium and are thought to enter the 
developing retina from the brain along the developing optic nerve (Chan-Ling, 1994). They 
are restricted to the nerve fiber layer of the retina (Schitzer, 1987). They are flattened cells 
with radiating processes, which are filled with intermediate filament, GFAP. These processes 
envelop blood vessels in the conjunction with Müller cell processes in the superficial plexus 
and the basal lamina of the vitreal surface (Hollander et al., 1991).  
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Figure 1.4: Müller cells interact with all retinal neuronal cells forming columnar units. 
Source: Reichenbach and Bringmann, 2010.  M, Muller cells ensheathing: G, retinal ganglion 
cell; CB, cone-specific bipolar cells; A, amacrine cell; RB, rod bipolar cell; NFL, nerve fiber 
layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL; inner nuclear layer; OPL, 
outer plexiform layer; ONL, outer nuclear layer; SRS, sub-retinal space.  
 
1.4.8.3 Müller Cells  
Müller cells are radial macroglial cells, which provide structure and support. There are ten 
million Müller cells making up 10% of the total retinal volume.  Their processes are in 
contact with all the neuronal elements with as shown in Figure 1.4 (Bringmann and 
Reichenbach, 2009; Sarthy and Ripps, 2001).  In the following section, Müller cell function 
in healthy and disease will be discussed in greater detail.  
1.4.8.3.1 Characteristics of Müller Cells 
Müller cells span the entire thickness of the retina (Remington, 2005, Bringmann and 
Reichenbach, 2009). They terminate at their outer end in the photoreceptors layer while at the 
basal end they terminate in the inner retina. Müller cells ensheath most ganglion cell axons 
providing support and insulation. The horizontal fibers appear in the inner and outer limiting 
plexiform layers. The honeycomb meshwork can be found in ganglion cell layer, internal 
nuclear layer and the outer limiting membrane (Remington, 2005). The Müller cell and the 
retinal neurons that it interacts with is called a columnar unit (Reichenbach and Robinson, 
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1995). The human eye consists of 10,000,000 repetitive columnar units (Reichenbach and 
Bringmann, 2010).  
1.4.8.3.2 Müller Cells Energy Metabolism 
Phototransduction, maintenance of ionic gradients, and synaptic activity are complex 
processes that the retina performs and have a high-energy demand (Winkler, 1981; Ames et 
al., 1992). Normally, the retina derives its major source of energy, glucose, and oxygen from 
the choroidal circulation. Coles, (1996) suggested different routes by which the retina may 
take up glucose from the capillaries to be used by the neurons. The first is the direct route 
without the involvement of Müller cells where the glucose is directly transferred to neurons 
from the capillaries by diffusion. In the second pathway, Müller cells take up the glucose and 
act as a channel to feed the neurons. In the third pathway, Müller cells have a more active 
role in which they convert glucose to a metabolite such as lactate and release it for use by the 
neurons. In the final route, Müller cells take up the glucose and store it as glycogen and then 
break it down to glucose when needed.  Glucose is transported into retinal cells through the 
glucose transporters, GLUT1-4 (Hosoya et al., 2008). Endogenous breakdown of glycogen 
deposits that are stored in the Müller cells with the aid of glycogen phosphorylase generates 
more glucose and fuel for retinal neurons (Pfeiffer et al., 1994). 
It is well known that one mole of lactate can generate 18 moles of ATP via oxidative 
phosphorylation. Early studies have suggested that metabolites such as lactate and pyruvate 
rather than glucose are the preferred metabolic substrates to be exchanged between Müller 
cells and neurons (Larrabee, 1983 and 1992). This is supported by research in the brain, 
which has suggested that lactate production is not limited to anaerobic metabolism, but that it 
also occurs in the brain under aerobic conditions (Prichard et al., 1991; Raichle, 1991; 
Sappey-Marinier et al., 1992).  In rat hippocampal slices, a challenge with glutamate 
treatment was performed after perfusion with low versus high glucose medium (Schurr et al., 
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1999). Results showed that glia would produce more lactate under higher glucose 
concentrations, and subsequently this would protect against glutamate excitotoxicity (Schurr 
et al., 1999).  Moreover, mammalian retina and cell culture studies showed that lactate 
produced by Müller cells is a fuel for photoreceptors, bipolar, and ganglion cells (Poitry-
Yamate et al., 1995; Tsacopoulos and Magistretti, 1996; Tsacopoulos et al., 1998). Winkler 
(1995) found that 90% of the glucose metabolized by the retina was converted into lactate 
under aerobic conditions.  This is also supported by the findings that cultured human and 
transformed rat Müller cells consume oxygen at a lower rate in the presence of glucose and 
obtain ATP through glycolysis, which accounts for 99% of the produced lactate (Winkler et 
al., 2000; Winkler et al., 2003). Cultures of photoreceptor cells, Müller cells, ganglion cells, 
and retinal pigment epithelial cells incubated in 5mM glucose produced lactate aerobically 
and the production rate increased 2-3 fold under anaerobic conditions (Winkler et al., 2004). 
In another study, Winkler et al., (2003) found that hexokinase is present in the mitochondria 
and cytosol of rat retina and suggested that in the presence of enough glucose the retinal 
neurons use glucose rather than the lactate produced by Müller cells.  
It is now accepted that the resistance of Müller cells to a variety of injuries including 
ischemia, hypoxia and hypoglycemia is related to the dominant glycolysis pathway that 
functions under the aerobic and anaerobic conditions in these cells (Poitry-Yamate et al., 
1995; Winkler et al., 2000). Maintenance of stable physiological levels of ATP is important 
for cellular defense mechanism including the maintainance of high levels of glutathione 
(Reichelt et al., 1997; Paasche et al., 1998; Schuette and Werner, 1998).  
 1.4.8.3.3 Müller Cells in Healthy Retina  
Müller cells express different types of neurotransmitter receptors and transporters including 
for gamma-aminobutyric acid (GABA), glycine and glutamate (Biedermann et al., 2004; 
Keirstead and Miller, 1997; Newman and Reichenbach, 1996; Stevens et al., 2003).  GABA 
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is the major inhibitory transmitter in the retina. Müller cells take up GABA through sodium- 
and chloride-dependent high-affinity GABA transporters (GATs) (Yazulla, 1986; 
Biedermann et al., 2002).  Active uptake and release of GABA is found to increase in injured 
conditions such as diabetes and ischemia (Ishikawa et al., 1996; Napper et al., 2001). In these 
conditions, Müller cells remove GABA by converting it into glutamate by the GABA 
transaminase enzyme (Ishikawa et al., 1996; Napper et al., 2001).  
Glutamate is the major excitatory neurotransmitter in the retina that is utilized by different 
cells in the neuronal retina such as photoreceptors, bipolar and ganglion cells to transmit the 
visual signal (Massey and Miller 1987; Bringmann et al., 2013). There are five types of 
glutamate transporters, called excitatory amino acid transporters (EAAT1-5). EAAT5 appears 
to be predominant isoform in the retina (Fairman et al., 1995; Arriza et al., 1997; Eliasof et 
al., 1998). In astrocytes, GLAST (EAAT1) and GLT-1 (EAAT2) are the predominant 
glutamate transporters (Seal and Amara, 1999). Müller cells express, GLAST, which is 
required for normal function and prevention of neurotoxicity (Rauen et al., 1998; Barnett and 
Pow, 2000). It is a sodium-dependent transporter, which requires a negative membrane 
potential. A malfunction in the transport process by Müller cells causes accumulation of 
glutamate, which is associated with neurotoxicity (Barnett and Pow, 2000). Intracellularly, 
Müller cells convert glutamate into non-neuroactive glutamine by the enzyme glutamine 
synthetase (GS) in the presence of energy in the form of two molecules of adenosine 5′-
triphosphate (ATP).  This is also the route to detoxify glutamate produced through GABA 
metabolism (Biedermann et al., 2002).  The released glutamine from Müller cells is taken up 
by neurons as precursor for the neurotransmitters glutamate and GABA (Pow and Crook, 
1996). However, according to Umapathy et al., (2005), most of the glutamine is taken up 
again by Müller cells by the glutamine transporter SN1 and SN2 and used to synthesize 
glutamate in the Müller cells. In an alternative pathway, glutamine is transported into Müller 
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cell mitochondria, and it is further hydrolyzed to glutamate and ammonia by the phosphate-
activated glutaminase enzyme (Takatsuna et al., 1994).  
Regarding retinal homeostasis, Müller cells are responsible for regulating the potassium ion 
(K+) balance in the retina through a process termed ‘spatial potassium buffering’ 
(Reichenbach et al., 1992; Newman and Reichenbach, 1996).  During neuronal activity, rapid 
shifts of ions occur between intra and extracellular spaces in which sodium and calcium ions 
flow into the neurons, and K+ efflux is increased (Karwoski et al., 1989).  To correct the 
depolarization and excitability that results from extracellular K+, glial cells take up excess K+ 
and release it into the blood and vitreous fluid (Karwoski et al., 1989, Reichenbach et al., 
1992).  This mechanism will limit the spread of un-wanted excitation and thus maintain 
visual function (Reichenbach et al., 1993). The high permeability of Müller cells to K+ can be 
explained by the expression of a variety of potassium channels especially the inwardly 
rectifying K+ channel of the Kir4.1 subtype (Ishii et al., 1997). These channels are capable of 
mediating K+ influx rather than efflux and with, the assistance of the glial Na, K-ATPase, 
Müller cells maintain potassium homeostasis in the retina (Nilius and Reichenbach, 1988).  
Any shift in ion flux during neuronal activity is associated with water flowing through 
aquaporin-4 (AQP4) channels (Nagelhus et al., 1999). Normally, water is removed from the 
sub-retinal space and the inner retina by the retinal pigment epithelium and Müller cells 
respectively (Bringmann et al., 2004). The normal source of water in the retina is the 
endogenous production that is linked to ATP synthesis, glucose uptake or forced water by the 
intraocular pressure (Marmor, 1999).  Together, K+ (Kir4.1) and aquaporin-4 water channels 
control the osmolarity between the retinal tissue, blood and vitreous by K+ and water influx 
and efflux from Müller cells (Nagelhus et al., 1999).  
In addition, Müller cells remove metabolic waste such as carbon dioxide (CO2) and regulate 
retinal pH.  Carbon dioxide results from oxidative degradation of glucose and is rapidly 
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converted into bicarbonate and a proton by the enzyme carbonic anhydrase II that is localized 
in Müller cells (Oakley and Wen, 1989). Glial cells complete their cleaning and buffering 
activity by transporting bicarbonate to the vitreous humor by sodium-bicarbonate co-
transporters located in their endfeet (Nagelhus et al., 2005). This mechanism is responsible 
for maintaining the correct pH levels intracellularly.     
Müller cells also play a role in the immune response in the retina (Kim et al., 1987). It has 
been demonstrated that Müller cells inhibit antigen presentation in lymphocytes in vitro 
(Forrester et al., 1990). They express MHC (major histocompatibility complex) class II 
antigen during proliferation in experimental uveitis (Romeike et al., 1998) and when exposed 
to supernatant from activated lymphocytes (Roberge et al., 1988). The phagocytic activity of 
Müller cells has been reported in animal models and cultures from post-mortem eyes 
(Algvere and Kock, 1983; Francke et al., 2001; Mano and Puro 1990; Ponsioen et al., 2007; 
Stolzenburg et al., 1992). The phagocytosis of a variety of substances such as carbon, copper, 
collagen, erythrocyte debris, subretinal hemorrhage and cell debris have been all reported  
(Mano and Puro, 1990; Sarthy and Ripps 2002).  
In addition, Müller cells contribute to the recycling of photopigments. They express the 
cellular retinol binding protein (CRBP) that binds to all-trans retinol and cellular retinal 
binding protein (CRALBP) that binds 11 cis retinol and 11-cis retinal (Crabb et al., 1998). 
Opsin and 11-cis-retinal are the visual pigments of photoreceptors. Conversion of light into 
an electrical signal by photoreceptors (phototransduction) starts with the conversion of 11-
cis-retinal to all-trans retinal, which subsequently reduced, in the outer segment of 
photoreceptors to all-trans retinol (Tsacopoulos et al., 1998). Müller cells convert all-trans 
retinol to all-cis-retinol, which is subsequently oxidized to 11-cis retinal and released into the 
extracellular space, and taken up by photoreceptors (Das et al., 1992; Muniz et al., 2007). To 
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transfer the fat-soluble retinoid into the aqueous cytosolic and extracellular location, they 
need to bind to retinol binding proteins (Tsacopoulos et al., 1998).   
New functions of Müller cells have also been recently discovered such as light guidance 
(Reichenbach and Bringmann, 2013). As the light passes through the retina, it is scattered by 
retinal cells and their processes. Non-foveal Müller cells minimize light scattering by guiding 
light through the inner retinal layers towards the photoreceptors (Franze et al., 2007). In 
addition, Müller cells have been shown to concentrate the green-red wavelengths of the 
visible spectrum onto cones, to allow the blue-purple wavelengths to leak onto nearby rods 
(Labin et al., 2014).  
1.4.8.3.4 Müller Cells in Injured Retina 
In response to severe retinal injuries such as retinal detachment, trauma, ischemia, and 
chronic conditions such as glaucoma and diabetic retinopathy glial cells become activated 
(Bringmann and Reichenbach, 2001; Bringmann et al., 2004; Bringmann et al., 2006; 
Francke et al., 2005). This activation is termed gliosis and is accompanied by morphological, 
biochemical and physiological changes to Müller cells with release of inflammatory 
mediators and growth factors (Bringmann and Reichenbach, 2001).  It has been found that 
Müller cells do not all respond in the same way to an injury. For example, Fischer and Reh, 
(2003) reported that in response to NMDA-induced retinal damage, approximately 65% of 
the Müller cells re-entered the cell cycle but failed to increase their expression of GFAP, 
while the remaining 35% increased their expression of GFAP in response to the damage but 
did not proliferate. Based on this principle, gliosis is described as either conservative non-
proliferative or massive proliferative gliosis. The former type is characterized by up-
regulation of GFAP, cellular hypertrophy, a moderate or no decrease in potassium currents, a 
decrease in the expression of glutamine synthetase, cellular retinaldehyde-binding protein 
(CRALBP) and carbonic anhydrase (Lewis et al., 1992; Lieth et al., 1998; Joly et al., 2008; 
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Kacza et al., 2000). In proliferative gliosis, the cells form a “gliotic scar” within the retina, at 
subretinal and epiretinal surfaces to fill in spaces that resulted from any loss in neurons, 
pigment epithelium, blood vessels or photoreceptors (Bringmann et al., 2000). It has been 
also reported that Müller cells can trans-differentiate into contractile myo-fibrocytes in the 
epiretinal region (Guidry, 2005).  
Müller gliosis is associated with dependent and non-dependent responses to pathogenic 
stimuli. Three non-specific gliotic responses could take place including cellular hypertrophy, 
proliferation and up-regulation of the intermediate filaments nestin, vimentin, and GFAP 
(Bringmann and Reichenbach, 2001; Lewis and Fisher, 2000; Geller et al., 2001; Takeda et 
al., 2002; Tezel et al., 2003).  On the other hand, glutamine synthetase is a Müller cell-
specific gliotic enzyme normally involved in glutamate recycling. 
Gliosis is considered as an attempt by Müller cells to protect the retina in response to an 
injury (Burke and Smith, 1981; Bringmann et al., 2006). However, gliosis can result in 
harmful effects to the tissue.  In gliosis, Müller cells secrete mediators that have both 
cytoprotective and cytotoxic effects on retinal neurons (Bringmann and Reichenbach, 2001). 
These include growth factors such as vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) and transforming growth 
factor beta (TGF-β) (Eichler et al., 2004a; Geller et al., 2001; Volpert et al. 2002). 
Angiogenic factors are balanced by inhibitors of angiogenesis such as pigment epithelium-
derived factor (PEDF) (Duh et al., 2002; Eichler et al., 2004b; Gao et al., 2001), 
thrombospondin-1 (TSP-1) and prolactin (Behzadian et al., 1995; Rivera et al., 2008). 
Platelet-derived growth factor (PDGF) stimulates Müller cell growth and proliferation and is 
known to play a role in proliferative retinopathies. Many studies have reported that Müller 
cells produce pro-inflammatory cytokines in response to an injury in addition to their 
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phagocytosis properties (Caspi and Roberge, 1989; Roberge et al., 1991; Mano and Puro, 
1990; Francke et al., 2001).  
In glaucoma, Müller cells have been found to express GFAP, increase glutamate uptake and 
proliferate.  These responses have been linked to the pathophysiology of retinal ganglion cell 
death (Kanamori et al., 2005; Kawasaki et al., 2000; Lam et al., 2003; Tezel et al., 2003; 
Woldemussie et al., 2004). In the following section, the role of Müller cells in the 
pathogenesis of glaucoma will be discussed. 
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1.5 Glaucoma 
Glaucoma is defined as a neurodegenerative disease with a loss of visual field caused by 
retinal ganglion cell (RGC) degeneration and optical nerve head damage (Cherecheanu et al., 
2013).  It is therefore described as an optic neuropathy that is associated clinically with a high 
cup to disc ratio as more ganglion cells, and their axons are affected and finally results in 
visual field loss (Foster et al., 2002).  According to the World Health Organization (WHO), 
glaucoma is the second leading cause of blindness globally after cataract (Cook and Foster, 
2012; Resnikoff et al., 2004) with estimated 80 million people worldwide predicted to be 
suffering from glaucoma in 2020 and 111.8 million by 2040 (Cook and Foster, 2012; Tham et 
al., 2014).  In the United Kingdom, the NHS report more than one million glaucoma visits per 
year, which account for 23% of attendance at UK hospital eye services. Therefore, glaucoma 
imposes a significant social and economic burden, which is increasing as the aged population 
rises (Burr et al., 2007; Coleman and Miglio; 2008; Spry et al., 1999). 
Increased intra-ocular pressure (IOP) is considered the most important risk factor in the 
pathophysiology of the disease and the reduction of IOP is the basis of glaucoma therapy 
(Coleman and Miglior, 2008). IOP is regulated through the balance of aqueous humor 
production by the epithelium of the ciliary body and outflow via the trabecular meshwork 
into Schlemm’s canal. This generates an IOP of approximately 15 mmHg (Goel et al., 2010). 
A small volume of the aqueous humor also leaves the eye through the uveoscleral outflow 
pathway, which is independent of the IOP (Alm and Nilsson; 2009).  The aqueous humor is a 
clear fluid containing the nutrients as well as electrolytes, proteins, cytokines, organic solutes, 
and growth factors necessary for the maintenance of the avascular structures of the eye 
specifically the lens and cornea (Chowdhury et al., 2010).  The rate of aqueous humor 
turnover is estimated to be 1.0% to 1.5% of the anterior chamber volume per minute, which is 
equal to 2.4 ± 0.6μl/min (Gabelt and Kaufman; 2003).  In the normal human aging eye, a 
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reduction in the production of aqueous humor is accompanied with a reduction in its drainage 
enabling a stable IOP level (Toris et al., 1999). However, changes in the structure of the 
endothelium lining Schlemm’s canal or trabecular meshwork can cause resistance to drainage 
while the inflow remains normal and thus IOP can become elevated (Goel et al., 2010).   
When associated with an increase in IOP, glaucoma is classified into two major categories 
according to the obstruction of the drainage pathway at the iridocorneal angle: Primary 
Angle-Closure Glaucoma (PACG) and Primary Open Angle Glaucoma (POAG). The term 
ocular hypertension refers to high IOP above 21mmHg with no apparent cause but with 
normal optic nerve head and no visual field damage. In some patients, despite the presence of 
open and normal-appearing anterior chamber angles and normal IOP, there is optic nerve 
head damage and visual field defects, these patients are said to have normal tension glaucoma 
(NTG) (Lee et al., 1998; Shields, 2008). Thus, it should be noted that the level of IOP in 
open-angle glaucoma is not a real definition criterion of the disease as the IOP levels could 
fall within the normal range. Angle-closure glaucoma occurs when there is physical 
obstruction of the trabecular meshwork caused by the peripheral iris, which prevents the 
drainage of aqueous humor. The accumulation of fluid inside the eye results in a sudden 
symptomatic increase in IOP of more than 21mmHg and results in symptoms including 
blurred vision, ocular pain, and corneal epithelial edema. The condition could be unilateral or 
bilateral and results in visual field loss if not treated rapidly (Vetrugno et al., 2008). The 
Shaffer system is one of the common systems to diagnosis angle closure glaucoma and is 
based on the assessment of the angle between the iris and the cornea. According to this 
system, there are five stages of angle glaucoma ranging from zero to five, where five 
indicates total occlusion of the angle (Amerasinghe and Aung, 2008). 
The aim of the treatment is to control IOP and to decrease the complications concerning 
visual loss. Two different approaches are used to manage angle closure glaucoma; the first is 
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medication while the latter is the surgery. Drugs that control IOP such carbonic anhydrase 
inhibitors, beta-blockers or alpha2 adrenergic agonists are used.  Miotics are sometimes used 
to open the angle by pulling the peripheral iris, but must be used with caution as they might 
cause further angle closure and exaggerate the condition (Vetrugno et al., 2008; Amerasinghe 
and Aung, 2008). Surgical intervention such as laser peripheral iridotomy, lens extraction, 
and trabeculectomy can also be used (Amerasinghe and Aung, 2008; Vetrugno et al., 2008).  
1.5.1 Primary Open Angle Glaucoma (POAG) 
This is also known as chronic open angle glaucoma (COAG). It is characterized by an open, 
normal-appearing anterior chamber angle, optic nerve head damage and increased intraocular 
pressure (IOP) without any apparent ocular or systemic abnormality (Allingham et al., 2009).  
Several mechanisms have been proposed to explain POAG including the obstruction of 
aqueous humour outflow due to histological changes in the structure of the juxtacanalicular 
tissue of the trabecular meshwork and the inner wall of Schlemm’s canal. These changes 
include an increase in the extracellular matrix and an accumulation of plaque material in 
trabecular meshwork (Tamm and Fuchshofer, 2007).  An early study by Zatulina et al., (1978) 
revealed that narrowed Schlemm’s canal with adhesions between the inner and outer walls 
leads to the collapse of the Schlemm’s canal, which will increase resistance to aqueous 
outflow. Genetic factors may play a role in the development of POAG, and some studies have 
found a link between a mutation in the myocilin gene and development of the disease 
(Tomarev et al., 1998). Myocilin is a protein present in the trabecular meshwork, cornea, 
retina, optic nerve and ciliary nerves (Fingert et al., 1998; Tomarev et al., 1998). It is 
produced in high amounts during stress conditions such as dexamethasone treatment, 
oxidative stress, and treatment with transforming growth factor β (TGF- β) (Polansky et al., 
1997; Tamm et al., 1999). It has been also found that the aqueous humour of patients with 
POAG has a significant concentration of TGF-β, which may be responsible for increasing the 
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resistance through decreasing the cellularity of the trabecular meshwork and promoting a 
build-up of plaques (Tamm and Fuchshofer, 2007). There is evidence that patients under 
corticosteroid treatment develop POAG with abnormal resistance to aqueous outflow and 
variable degrees of elevated IOP (Lewis et al., 1988; Klemetti, 1990). Suppression of 
phagocytic activity of endothelial cells lining the trabecular meshwork, which removes debris 
in aqueous humour and prevents blocking of the Schlemm’s canal (Bill, 1975).  
Changes have been also observed in the optic nerve head. Astrocytes and microglia in the 
region of ONH have been shown to be activated with detrimental consequences (Yuan and 
Neufeld, 2000). Activated glial cells were found to increase secretion of matrix 
metalloproteinase (MMPs), the proteolytic enzymes that degrade components of extracellular 
matrix (ECM) (Okada et al., 1990). Increased immunostaining for MMP-1, -2 & -3 in 
glaucomatous ONH sections from post-mortem eyes has also been observed                     
(Yan et al., 2000). Characteristics of a glaucomatous ONH include generalized/focal 
enlargement of the cup, disc hemorrhage, thinning of neuroretinal rim, loss of the nerve fiber 
layer and parapapillary atrophy (Bourne, 2006).  
1.5.2 Management of Primary Open Angle Glaucoma (POAG) 
Initiating a medical treatment is required when a patient presents with high IOP and 
glaucomatous damage. The treatment for open angle glaucoma includes the use of mainly 
topically administered drugs to lower IOP by enhancing aqueous outflow, reducing aqueous 
production, or with a combined mechanism.  Currently, five different classes of glaucoma 
medications are available for the treatment of glaucoma: prostaglandin analogues, β-
adrenergic receptor antagonists, adrenergic receptor agonists, carbonic anhydrase inhibitors, 
cholinergic, or miotic agents. A brief overview of currently available glaucoma drugs is 
provided below.  
 
  
 24 
1.5.2.1 Prostaglandin Analogues 
Prostaglandin Analogues are the most commonly prescribed drugs for the treatment of POAG. 
Prostaglandin F2α analogues such as latanoprost, unoprostone, travoprost, and bimatoprost 
have been found to reduce intraocular pressure by increasing the uveoscleral outflow through 
the iris and ciliary body (Toris et al., 1997). This has been explained by either decreasing the 
extracellular matrix that surrounds the muscle bundles or by relaxing the ciliary musculature 
(Crawford and Kaufman, 1987; Lutjen-Drecoll and Tamm 1988).  The most commonly 
reported side effects of prostaglandin analogues are muscle and joint pain, skin allergy and 
colour discoloration of the iris (Alm and Stjernschantz; 1995). 
1.5.2.2 Beta-adrenergic Blockers 
Beta-blockers were introduced for glaucoma treatment in 1979 and were rapidly considered 
the first line therapy (Obstbaum et al., 1978).  They work by decreasing the production of 
aqueous humour. Neufeld (1979) showed that ß-blockers inhibit the endogenous adrenergic 
stimulation that stimulates the formation of aqueous humour by the ciliary processes. The 
non-selective β-blocker timolol was recognized as an effective drug for the management, of 
raised IOP. It remained the gold standard therapy for POAG for a long time due to its 
efficacy in decreasing the pressure, tolerability and convenient administration (Demailly et al., 
1978; Obstbaum et al., 1978). Other selective ß1-blockers such as betaxolol were added to 
glaucoma management, but they were less effective compared to timolol (Caprioli and 
Garway-Heath, 2007). Generally, β-blockers are associated with well-known systemic side 
effects that may exacerbate other conditions such as asthma, chronic obstructive pulmonary 
disease, and heart conditions. Moreover, they should be used with caution in diabetic patients 
as they mask the symptoms of hypoglycemia (Schwarzt and Budenz, 2004). 
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1.5.2.3 Alpha-agonists  
The α-adrenergic agonists act by decreasing aqueous humour production through constricting 
blood vessels supplying the ciliary body and by decreasing aqueous humour production 
(Sears and Neufeld, 1975). Apraclonidine and brimonidine are α2-adrenergic–agonist drugs 
that can be used in the treatment of glaucoma, although they are not widely prescribed. The 
major complaints reported with these medications are dry mouth and dry nose (Schuman, 
1996).   
1.5.2.4 Carbonic Anhydrase Inhibitors (CAIs) 
Acetazolamide, brinzolamide, and dorzolamide are carbonic anhydrase inhibitors, which 
work by blocking the formation of aqueous humour by inhibiting the key enzyme responsible 
for bicarbonate production. As the level of bicarbonate drops, sodium and water flow to 
posterior chamber decreases and thus a reduction in intraocular pressure through a reduction 
in aqueous humour production is achieved (Becker, 1954). This class of medications is 
associated with a series of side effects such gastrointestinal disturbance, a metallic taste in the 
mouth and cramps (Epstein and Grant, 1977).  More serious side effects are blood dyscrasias 
including aplastic anaemia, agranulocytosis, thrombocytopenia, neutropenia, and haemolytic 
anaemia (Werblin et al., 1980).  
1.5.2.5 Miotics 
Muscarinic agonists such as pilocarpine, aceclidine and carbachol, have been used for the 
management of glaucoma due to their miotic effect. However, they are now obsolete because 
of common adverse reactions resulting from stimulation of the parasympathetic system. This 
may include but are not limited to intestinal cramps, bronchospasm, cardiac irregularities, 
ocular stinging, lacrimation, small pupil, conjunctival thickening, cataract, and retinal 
detachment (Vetrugno et al., 2008).  
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1.5.3 Pathogenesis of Primary Open Angle Glaucoma (POAG) 
1.5.3.1 Increased IOP and Retinal Ganglion Cells (RGCs) Death 
The death of RGCs in IOP-induced glaucoma is a multifactorial process. Mechanical injury 
to the axons at the optic disc as a result of high intraocular pressure, which is then transmitted 
to the retinal ganglion cell body in the retina, is a major proposed mechanism by which RGCs 
die (Anderson and Hendrickson, 1974; Mabuchi et al., 2003). Clinically, this can be 
recognized by ophthalmoscopy, which reflects the structural changes at the optic nerve head 
where ganglion cell axons exit the eye to form the optic nerve leaving a central depression 
called the cup. As glaucoma progresses and there is a loss of the RGC axons, the cup-to-disc 
ratio is increased (Quigley, 2011). The optic nerve fibers exit the eye through a mesh-like 
structure known as the lamina cribrosa. Structural changes such as compression or 
displacement of the lamina cribrosa as a consequence of high intraocular pressure has also 
been documented, which could mediate mechanical injury (Quigley, 2011). Several animal 
models have shown that raised IOP results in RGCs death. For example, in a mouse model of 
hereditary glaucoma (the DBA/2J mouse), IOP was elevated as a result of reduced aqueous 
humour outflow that caused the death of RGCs, optic nerve atrophy, and optic nerve cupping 
(John et al., 1998).   
In addition to mechanical damage, RGCs are subjected to hypoxic (Tezel and Wax, 2004) 
and tissue oxidative stress (Tezel et al., 2000) as a result of elevated IOP. Although controlled 
or reduced IOP level with treatment has been shown to improve the prognosis of patients, it 
can not stop progression in all patients and therefore, elevated IOP level cannot solely 
account for all of the damage occurring to the RGCs. Important factors such as glial 
activation, vascular dysregulation induced hypoxia and ischemia as well as excitotoxicity are 
also proposed to be involved in the pathogenesis of POAG and will be discussed in the next 
sections.  
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1.5.3.2 Activation of Müller Cells in Glaucoma  
Several studies have shown that glial cells are involved in the pathophysiology of glaucoma. 
Astrocyte activation at the optic nerve head has been reported in post-mortem eyes with open 
angle glaucoma (Varela and Hernandez, 1997). Reactive astrocytes in glaucomatous optic 
nerve heads in culture have been shown to produce an excessive nitric oxide, which exert a 
neurotoxic effect on the RGCs (Liu and Neufeld, 2000).  
In a chronic model of elevated IOP in rats induced by episcleral vein cauterization, Müller 
cells gained GFAP immunoreactivity lasted even after normalization of IOP (Kanamori et al., 
2005). In this model, Vidal et al. (2010) also reported hypertrophy of Müller cells with a 
significant increase in GFAP. Non-proliferative reactivity of glial has been reported in a 
chronic model of glaucoma using the DBA/2J mouse (Inman and Horner, 2007).   
In addition, in ischemic rat retina, induced by high IOP, GFAP immunoreactivity was 
detected in the endfeet and distal processes of Müller cells immediately after reperfusion and 
continued to increase with a correlation to neuronal degeneration (Kim et al., 1998). 
Permanent occlusion of the carotid arteries in rats has also been show to cause GFAP 
expression in retinal Müller cells (Osborne et al., 1991).  
1.5.3.3 Reduced Ocular Blood Flow and Vascular Dysregulation 
The retinal blood supply is derived from the central retinal artery, which is a branch of the 
ophthalmic artery. It is characterized by a very small flow rate but with a high oxygen 
extraction level (Grant-Kels and Kels, 1992; Kels et al., 2015). The regulation of retinal 
blood flow depends on the relationship between perfusion pressure and local resistance. 
Perfusion pressure is defined as the difference between retinal arterial and retinal venous 
pressure while the local resistance is controlled by the size of the local vessels. In the normal 
eye, the venous pressure is less than or equal to IOP (Flammer et al., 2002; Stodtmeister, 
2008). Local mediators control local resistance, for example endothelium-derived nitric oxide 
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and endothelin (ET) are very potent modulators of vascular tone (Haefliger et al., 1992; 
Haefliger et al., 2001).  
In glaucoma, decreased optic nerve head and juxtapapillary retinal capillary blood flow was 
found in early and advanced stage POAG patients (Michelson et al., 1996). In addition, a 
reduction in blood flow was found in the retina, choroid and optic nerve head in glaucoma 
patients with high IOP (Arnold, 1995; Harju and Vesti, 2001; Sugiyama et al., 2000; 
Yamazaki et al., 1996). In patients with POAG and visual field deterioration, low blood 
perfusion was detected and seems to be associated with the progression of the disease 
(Gherghel et al., 2000). 
Patients with NTG have been reported to have a greater reduction in the choroidal circulation 
(Geijssen and Greve, 1995; Duijm et al., 1997) and blood flow disturbances generally are 
reported to be more marked in NTG than patients with high IOP (Drance et al., 2001; Findl et 
al., 2000; Schmidt et al., 1998). Earlier studies have shown that some patients may present 
with a number of signs related to compromised blood flow such as changes in conjunctival 
capillaries (Orgul and Flammer, 1995), local vasoconstriction in the retina (Rankin and 
Drance, 1996), increased prevalence of ONH haemorrhage (Drance et al., 2001; Sugiyama et 
al., 1997; Orgul and Flammer, 1994) and increased prevalence of venous thrombosis 
(Malayan et al., 1999; Sonnsjo and Krakau, 1993). Flammer et al., (2002) argued that reduced 
ocular blood flow occurs due to primary rather than secondary causes (i.e., due to elevated 
IOP). The author also proposed that increased resistance to flow could be caused by structural 
changes such as vasculitis or arteriosclerosis, or it might be due to a functional dysregulation 
of the vascular diameter.  Endothelial leukocyte adhesion molecule-1 (ELAM-1) is an early 
marker of arteriosclerosis and was found in the trabecular meshwork (TM) cells in the 
outflow pathways of eyes with glaucoma, which may support the role of atherosclerosis in 
the aetiology of reduced blood flow in glaucoma (Wang et al., 2001).   
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Vascular dysregulation is a phenomenon used to describe the imbalance between vasodilator 
and vasoconstrictor mechanisms and could be due to the release of circulating hormones or 
local mediator produced by the vascular endothelium such as endothelin-1 (ET-1), nitric 
oxide or prostacyclin, which regulates local blood flow. A relationship between the 
endothelin system and between glaucomatous optic neuropathy has been documented. 
Animal studies have also shown that the level of ET-1 in aqueous humour was found to be 2-
4 fold higher compared to control (Kallberg et al., 2002; Prasanna et al. 2005). In vivo studies 
have shown that chronic administration of endothelin-1 to the optic nerve of rats resulted in a 
time and dose-dependent loss of RGCs and their axons (Chauhan et al., 2004; Cioffi et al., 
1995). In patients with POAG, the level of ET-1 and nitric oxide (NO) concentrations in 
aqueous humour were found elevated (Ghanem et al., 2011). Few studies have shown that 
patients with NTG demonstrated an impaired peripheral endothelium-mediated vasodilation 
and peripheral abnormal contractile responses to 5-HT (5-hydroxytryptamine), ET-1 and ET-
1 antagonist (Buckley et al., 2002). The plasma levels of ET-1 tended to be higher in patients 
with NTG compared to high-tension glaucoma (Sugiyama et al., 1995).  
In these patients, the plasma ET-1 levels were higher in the initial stage of visual field loss 
than those in the middle phase (Sugiyama et al., 1995). To the contrary, in a study, which 
involved patients with POAG, endothelin levels were comparable to control (Tezel et al., 
1997). Moreover, dual inhibition of endothelin receptors (ETA and ETB) increases ocular 
blood flow in patients with glaucoma and also healthy subjects (Resch et al., 2009). 
Moreover, ET-1 has also been found to play a role in the development of visual impairment 
in non-glaucoma related conditions. High levels of ET-1 were found in cerebrospinal fluid 
and circulating blood in patients with multiple sclerosis (Speciale et al., 2000). Interestingly, 
in this subgroup of patients, the raised ET-1 was associated with a decrease in the macular 
thickness (Gugleta et al., 2008), sub-clinical visual defect (Mienberg et al., 1982), thinner 
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arterioles and subclinical swelling of the optic nerve (Gugleta et al., 2009). Similarly, ET-1 
was found in high levels in optic neuritis (Haufschild et al., 2003), and retinal vein occlusion 
(Haufschild et al., 2004).  In addition to its role as a vasoconstrictor, ET-1 was found to be a 
potent mitogenic factor for different cells including the astrocytes (Baba, 1998). Nicolela, 
(2008) suggested that vascular dysregulation is unlikely to lead to ischemic damage at the 
level of the optic nerve head. Instead, it is suggested that vascular dysregulation impairs auto-
regulation in the retina, which causes relative ischemia and damage as a result of subsequent 
reperfusion. The reperfusion injury results from inflammatory mediators and oxidative stress 
generated by restoring the blood flow (Flammer, 2002). Elevated IOP and induction of 
ischemia in rats followed by reperfusion has been reported to cause damage to the retinal 
ganglion cell layer and the optic nerve (Adachi et al., 1996).  
Other conditions that may be associated with the development of glaucoma include low blood 
pressure, which leads to low ocular perfusion (Pache et al., 2002). Also, ischemia due to 
occlusion of the retinal artery, retinal hypoperfusion secondary to systemic diseases such as 
diabetes and Alzheimer’s disease (Kaur et al., 2008). Furthermore, several authors have 
shown that patients with optic nerve damage tend to have several characteristics such as high 
prevalence of a migraine, cold hands, and a vasospastic response to cold in the finger 
circulation (Broadway and Drance, 1998; Nicolela and Drance, 1996). Grieshaber et al. 
(2007), found that activated retinal astrocytes and Müller cells were associated with vascular 
dysregulation in patients with POAG and glial cells activation was found to be unilateral or 
bilateral. Dysregulation of perfusion will therefore deprive the tissue of the necessary supply 
of oxygen and nutrients and possibly activate glial cells, which may, in turn underlie 
pathogenic events in POAG and NTG.  The next section will focus on important mechanisms 
that follow vascular dysregulation and reduction of ocular blood flow specifically oxygen-
glucose deprivation (OGD) and their consequences to RGC survival in glaucoma.  
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1.5.4 Hypoxia-Ischemia  
The retina is a highly metabolically active tissue with the highest oxygen consumption rate in 
the body (Ames, 2000). It absolutely depends on blood to supply oxygen and glucose in order 
to maintain the structural and functional integrity. The choroidal circulation provides oxygen 
mainly to the outer retina while the retinal vasculature nourishes the inner retina. The retina is 
less vascularized compared to the choroid to allow passage of light to the photoreceptors and 
is characterized by a high arteriovenous oxygen difference and well developed auto-
regulatory mechanisms (Pournaras et al., 2008). In the rat retina, the highest level of oxygen 
is in the choroid, the inner segments of the photoreceptors, the outer plexiform layer, and the 
inner plexiform layer (Cringle and Yu, 2002; Yu and Cringle, 2001).  It has been reported 
that photoreceptor oxygen consumption increased in dark, but it decreases in the inner retina 
(Cringle et al., 2002).  Systemic factors such as oxygen tension, carbon dioxide level, and 
blood pressure can influence the vascular structures supplying the retina. It has been found 
that systemic hyperoxia to increase the oxygen levels in the choroid and all layers of the rat 
retina (Yu et al., 2009).  In hypoxemia, a reduction in oxygen tension in the choroid was 
observed, because of reduction in choroidal blood flow (Ahmed et al., 2001).  When the IOP 
increases, the choroidal blood flow decreases, which leads to a reduction in oxygen tension 
and subsequently a decrease in photoreceptors oxygen tension (Yancey and Linsenmeier, 
1989).  
Hypoxia refers to a reduction in oxygen supply to a tissue. Ischemia is a combined reduction 
of oxygen and blood flow with a subsequent reduction in nutrients and removal of waste 
products. Hence, ischemia could be partial or complete as occurs in vasospasm, artery 
occlusion or venous thrombosis.  Hypoxia-induced expression and release of VEGF regulates 
vascular permeability and induce proliferation and differentiation of endothelial cells as well 
as Müller cells (Shima et al., 1995; Stone et al., 1995). In a recent study by Huang et al., 
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(2015); VEGF was detected in the aqueous humour samples of PACG patients, which could 
be attributed to hypoxia/ischemia observed in glaucoma patients. Oxidative stress has been 
acknowledged as an important mechanism of RGCs death as a result of hypoxic-ischemic 
insult. Reactive oxygen species (ROS) are produced in the retina in two stages; both during 
ischemia and the reperfusion stage (Ophir et al., 1993).  During ischemia, degradation of ATP 
leads to the formation of hypoxanthine that increase Ca2+ activated enzymes such as calpain, 
which converts xanthine dehydrogenase into xanthine oxidase (Cazevieille et al. 1994). When 
reperfusion occurs, the xanthine oxidase oxidizes the accumulated hypoxanthine to uric acid 
resulting in the release of superoxide (Cazevieille et al. 1994).   
Several mechanisms have been proposed by which hypoxia-ischemia causes neuronal death 
including excitotoxicity, oxidative stress, inflammation and glial cells activation (Lipton, 
1999). Selective mechanisms will be discussed in detail.  
1.5.4.1 Hypoxia-Ischemia Induced Glutamate Excitotoxicity  
Glutamate is an excitatory amino acid and an important neurotransmitter in the CNS 
including the retina. It is involved in the different physiological processes and 
pathophysiological conditions (Ozawa et al., 1998). Glutamate is released by photoreceptors, 
bipolar cells, and ganglion cells and mediates the transfer of visual signals in the retina 
(Massey and Miller 1987; Yang, 1997). Excess glutamate is also known to cause 
excitotoxicity (Dallas et al., 2007) and early evidence of glutamate toxicity was obtained 
from Lucas and Newhouse (1957), who found that parenteral injection of glutamate 
selectively damaged the RGCs in mice. This has been also suggested by many subsequent 
studies. For example, chronic intravitreal injection of low dose glutamate in rats resulted in 
loss of 42% of the RGCs (Vorwerk et al., 1996). The response of rat and pig retinal cultures 
to glutamate was compared in a study by Luo et al., (2001). The author reported that the loss 
of RGCs varied between the two species with a close resemblance of pig RGCs to human 
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(Luo et al., 2001). These responses were found to be mediated by both NMDA and non-
NMDA receptor pathways such as kainate and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPA) (Luo et al., 2001). It has been found that 
glutamate levels were elevated in patients with glaucoma undergoing vitrectomy (Honkanen 
et al., 2003). In addition, elevated glutamate was found in different disease models and 
species including chronic elevation of IOP in rats (Levkovitch-Verbin et al., 2002), 
glaucomatous eyes in dog (Brooks et al., 1997; Källberg et al., 2007) and in a rabbit model of 
optic nerve ischemia (Kim et al., 2000). Animal studies have suggested that glutamate 
excitotoxicity causes RGCs death in central retinal ischemia (Dallas et al., 2007; Duker and 
Brown, 1988; Ffytche, 1974; Hayreh and Jonas, 2000). Elevated and toxic concentrations of 
glutamate to RGCs have been found in the vitreous humour in animal models of glaucoma 
(Brooks et al., 1997). These findings however were questioned by Kwon et al., (2005) who 
failed to show any significant increase in the vitreous and retinal concentrations of glutamate 
following acute central retinal artery occlusion in rhesus monkeys. However, local increase 
has been proposed to occur. For example, accumulation of glutamate as a result of decreased 
clearance might happen due to the inefficient uptake by the glutamate transporter (GLAST) 
in glial cells, which has been observed in an experimental rat model of glaucoma (Martin et 
al., 2002).  
Hypoxia can contribute to the accumulation of glutamate in retinal tissue. A recent study by 
Kaur et al., (2012) reported hypoxia-induced glutamate overload in neonatal rat retina with 
increased intracellular calcium (Ca2+), and increased expression of caspase-3 and NMDA 
receptor, which mediate damage to the neurons. Studies using neuronal cultures have also 
shown that excess glutamate is one source of reactive oxygen species (ROS) generation in the 
ischemic retina (Cazevieille et al. 1993; Dutrait et al. 1995; Dykens et al. 1987; Lafon-Cazal 
et al. 1993). In addition, Aizenman et al., (1988) showed that rat RGCs are sensitive to 
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glutamate and excitatory amino acid analogues such as kainite, quisqualate, and N-Methyl-D-
aspartate (NMDA). Increased Ca2+ accumulation and ROS generation with the involvement 
of ionotropic AMPA glutamate receptors has been reported as a mechanism of RGC loss 
(Sivakumar et al., 2013).  Systemic treatment with NMDA and non-NMDA receptor 
antagonists prevented IOP-induced RGCs loss in rats (Nucci et al., 2005). Further studies 
indicate that NMDA receptor antagonists, are neuroprotective against RGC loss in in vitro 
and in vivo animal models (Chen and Lipton, 1997; Osborne, 1999; WoldeMussie et al., 
2002). Evidence therefore suggests that glutamate toxicity plays a major role in hypoxia-
ischemia induced RGC loss.  
1.5.4.2 Hypoxia-Ischemia Induced Purinergic Excitotoxicity   
ATP and adenosine act as neurotransmitters and mediators in the retina and purine receptors 
are expressed throughout the eye, including in the RPE, RGCs and Müller cells (Hodges et al., 
2011; Kiel et al., 2011; Mathias et al., 2007; Mitchell and Reigada, 2008; Sanderson et al., 
2014; Oswald et al., 2012; Wurm et al., 2011).  
In normal healthy retinal tissue, the majority of the endogenous purine exists in the form of 
ATP, and a small amount exists as adenosine (Perez et al., 1986). Müller cells express both 
adenosine and nucleotide receptors (Bringmann et al., 2001). Adenosine receptors (A1-3) are 
G protein-coupled receptors, while the nucleotide receptors are either G protein-coupled 
receptors (P2Y) or ligand-gated cation channels (P2X). Both types are expressed in human 
Müller cells (Bringmann et al., 2001; Pannicke et al., 2000). Activation of the P2X7 receptor 
in human Müller cells by external ATP resulted in the release of Ca2+ from intracellular 
stores, which in turns activate big conductance K+ channels (BK). This may contribute to 
Müller cell proliferation as seen in proliferative vitreoretinopathy (Bringmann et al., 2001; 
Pannicke et al., 2000). This is also seen in retinal detachment and transient retinal ischemia 
(Uckermann et al., 2005; Uckermann et al., 2003). Activation of P2X7 also increases sodium 
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ion influx resulting in cell depolarization and decreases the efficiency of sodium-dependant 
glutamate uptake (Pannicke et al., 2000).  
It is also proposed that elevated extracellular ATP can be associated with high IOP and RGCs 
death (Resta et al., 2007; Sanderson et al., 2014; Zhang et al., 2007). Sustained stimulation of 
P2X7 receptor caused RGCs death in vitro (Zhang et al., 2005) and in vivo (Hu et al., 2010) 
and blocking of purinergic receptors or dephosphorylating ATP attenuated elevated IOP 
induce RGCs damage in rats (Resta et al., 2007).  Simulated ischemia in human organotypic 
retinal cultures (HORCs), as well as P2X7 receptor stimulation, caused a marked loss in 
RGCs, which was inhibited by P2X7 receptor antagonism (Niyadurupola et al., 2013). P2X7 
receptor activation has been shown to be involved in hypoxia-mediated retinal neuronal cell 
death (Sugiyama et al., 2010).  
Pannexin 1 (PANX1) is a high-conductance channel, which respond to different retinal insults 
by mediating the release of ATP (Kurtenbach et al., 2014). The released ATP is hydrolysed 
by autotaxin or nucleotide pyrophosphatase/phosphodiesterase 2 (NPP2), a plasma 
lysophospholipase D (lysoPLD), which generates lysophosphatidic acid (LPA). LPA 
receptors are expressed in astrocytes, microglia, and oligodendrocytes (Rao et al., 2003; 
Tabuchi et al., 2000; Yu et al., 2003). In addition, it has been found that LPA can inhibit gap 
junction channels and resulting in inhibition of ATP release (De Vuyst et al., 2007). A study 
by Newman, (2003) reported that LPA induces calcium responses in Müller cells, which 
causes ATP release from the cells. Inhibition of ecto-ATPase and ectonucleaotidase reduced 
glial mediated hyperpolarization in neighbouring ganglion cells indicating that this response 
is mediated by ATP release from Müller cells in mammalian retina (Newman, 2006).  
Activation of LPA receptor in primary rat brain astrocytes caused a reduction in glutamate 
and glucose uptake (Keller et al., 1996). Moreover, LPA induces VEGF via HIF-1α 
activation in cancer cells (Jeon et al., 2010; Lee et al., 2006; Park et al., 2007). In patients 
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with PDR, significant high levels of VEGF and LPA were detected in the vitreous samples 
suggesting that LPA inducing VEGF play an important role in the progression of diabetes 
(Abu El-Asrar et al., 2013). LPA and its receptor LPA1 were also expressed in epiretinal 
membranes of patients with proliferative vitreoretinopathy (Abu El-Asrar et al., 2012).   
1.5.4.3 Effects of Hypoxia-Ischemia on Müller Cells  
Retinal hypoxia is proposed to play a role in many retinal disease including ischemia, 
glaucoma, diabetic retinopathy, retinal vein occlusion and age-related macular degeneration 
(Kaur et al., 2008). Retinal hypoxia may affect the survival of RGCs by inducing apoptosis 
(Kitano et al., 1996). Several mechanisms have been proposed in the pathogenesis of 
hypoxia-induced RGCs death including glutamate excitotoxicity (Kaur et al., 2008), calcium 
overload (Sivakumar et al., 2013), and oxidative stress (Love, 1999). In addition, 
inflammatory markers such as tumor necrosis factor-alpha (TNF-α) have been reported to 
induce neuronal death in hypoxia (Martin-Villalba et al., 1999).   
Moreover, hypoxia-inducible factor-1α (HIF-1α), has been found to increase in glaucomatous 
human eyes (Tezel and Wax 2004). Hypoxia is associated with neovascularization and 
expression of hypoxia-HIF-1α and its downstream gene, vascular endothelial growth factor 
(VEGF), is a well-known pathway of angiogenesis (Bernaudin et al., 2002). Müller cells are 
important producers of angiogenic and anti-angiogenic factors in the neural retina 
(Bringmann et al., 2009), and they have been identified as the cells in the inner nuclear layer 
of the retina responsible for producing VEGF (Pierce et al., 1995). It is believed that VEGF is 
the main growth factor that mediates retinal angiogenesis, and it is controlled by local oxygen 
concentrations (Shima et al., 1995). In a mouse model of proliferative retinopathy, VEGF 
mRNA expression increased early after hypoxia induction and remained elevated during the 
development of neovascularization (Aiello et al., 1994). This is also supported by high VEGF 
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levels in the retina and the vitreous of patients with ocular ischemic disorders (Adamis et al., 
1994).  
Exposure of human Müller cells (MIO-M1) to hypoxia has been shown to cause VEGF 
release and cell proliferation that was inhibited by TGF-β2 and PEDF (Eichler et al., 2004a).  
Findings by Eichler et al., (2004b) also showed that human and guinea pig Müller cells 
express and release the antiangiogenic factor, PEDF in response to hypoxia. Exposure of 
Müller cells to VEGF suppressed PEDF release in a dose-dependent manner.  It has also been 
reported that VEGF protects primary cultures of rat cerebral cortical neurons from oxygen 
and glucose deprivation (Jin et al., 2000).  
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1.5 Aims of the Study 
It is accepted that IOP is an important risk factor in glaucoma. However, despite the 
treatment with pressure controlling medication, the progression of disease continues to cause 
loss of vision. Furthermore, classification of some patients as having normal tension 
glaucoma indicates that the relationship between IOP and progression of the disease is not 
simple. The underlying mechanisms of glaucoma are diverse and poorly understood. 
Vascular dysregulation and reduction of ocular blood flow is one mechanism by which 
oxygen and glucose deprivation (OGD) occurs in ocular tissues. Simulating oxygen and 
glucose deprivation is one approach to study glaucoma by mimicking the restriction of 
metabolite and oxygen supply caused by ischemia.  The aim of this study was to investigate 
the effects of oxygen and glucose deprivation on Müller cells (the MIO-M1 cell line) and the 
human retina using human organotypic retinal cultures (HORCs).  
In both models, two selected levels of OGD were chosen to study the survival of MIO-M1 
cells and RGCs in HORCs and the expression of key growth factors, excitotoxicity markers 
and Müller cells specific markers under conditions of OGD. It is hoped that understanding 
more about these responses in human retina will lead to new approaches in managing vision 
loss in glaucoma.  
The specific aims of the current work are listed below:  
1- To investigate the viability and cytotoxicity of human Müller cells using the MIO-M1 cell 
line under different levels of oxygen and glucose deprivation ranging from 70-100% 
deprivation for up to 72hrs.  
2- To investigate the gene expression of different angiogenic and anti-angiogenic growth 
factors, excitotoxicity markers, glial markers and heat shock protein under two levels of 
deprivations (80% and full deprivation) of both oxygen and glucose in MIO-M1 cells.  
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3- To investigate RGC survival in HORCs and gene expression of different angiogenic and 
anti-angiogenic growth factors, excitotoxicity markers, glial markers and heat shock protein 
were also evaluated under under two levels of deprivations (80% and full deprivation) of both 
oxygen and glucose.  
4- To investigate the effects of co-culture of MIO-M1 cells and HORC in protectection of  
RGC death under conditions of glucose deprivation.  
5-To investigate the effects of high glucose on the survival and gene expression of MIO-M1 
and HORCs.     
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Chapter 2 
 Materials and Methods 
2. Tissue and Cell Culture 
Human eyes for the research purposes were provided by the East Anglian Eye Bank (Norfolk 
and Norwich University Hospital, UK). Human donated eyes were retrieved after obtaining 
the informed consent from next of kin and under the tenets of the Declaration of Helsinki. 
Donor identity was hidden and replaced with a sequential number. Each pair of eyes was 
accompanied by brief information on the donor’s medical history, age, gender, cause, and 
time of death and retrieval time. Only eyes within 24 hours post-mortem were used for 
research and those with evidence of retinal diseases such as glaucoma, age-related macular 
degeneration, diabetic retinopathy and haemorrhages were excluded. In total 58 human eyes 
were used from donors with an average age of 69.8±1.31 years in which males represented 
60.34% of the total number of donors.  
Corneas were removed at the Eye Bank for transplantation and the remaining globes were 
transported to the University of East Anglia (UEA) in Eagle’s Minimum Essential Medium 
(EMEM) (Sigma-Aldrich, Poole, UK) supplemented with 10μl/ml antibiotic/antimycotic 
solution (10,000 units/ml penicillin G, 10,000μg/ml streptomycin sulphate and 25μg/ml 
amphotericin B; Invitrogen, Paisley, UK). The lens was extracted before retinal dissection 
and usually used for cataract-related research at UEA. 
2.1 Human Organotypic Retinal Culture (HORC) Dissection  
HORC dissection was performed as has been previously described (Niyadurupola et al., 
2011).  The procedure is shown in (Figure 2.1). Under sterile condition, the globe was placed 
in a sterile 60 mm Petri dish (Thermo Fisher Scientific, Leicestershire, UK). A 10mm cut was 
made, and the ciliary body and anterior sclera removed via circumferential cut (Figure 2.1B).   
The globe was then slowly rotated to dissociate the neuronal retina from the underlying 
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retinal pigment epithelium and choroid (Figure 2.1C). A single cut was performed at the optic 
nerve head (Figure 2.1D) and with the aid of forceps, the neural retina, with the vitreous still 
attached, was removed. Warmed serum-free (SF) Dulbecco’s Minimum Essential Medium 
(DMEM; 500μl), was added (Gibco Invitrogen, Paisley, UK), supplemented with 50mg/l 
Penicillin/Streptomycin (Gibco Invitrogen, Paisley, UK). The vitreous was dissociated 
carefully, and the retina edges were cut to allow the retina to lie flat (Figure 2.1E). A micro-
dissecting trephine (Biomedical Research Instruments, Rockville, Maryland, USA), of 4 mm 
in diameter, was used to take sections of the retina. Initially, the central macula then five 
para-macular retinal explants were removed using a template (Osborne et al., 2015). 
Niyadurupola et al., (2010) have shown there to be comparable RGCs in each paramacular 
explant (Figure 2.2). Explants were placed into a 35 mm dish containing 1.5 ml of serum-free 
DMEM (Figure 2.1F) and randomized to different treatments.  
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Figure 2.1: Dissection of the human retina. (A) The globe with anterior section, including lens 
removed. (B) Circular ring of tissue was removed approximately 10mm below the ciliary body. (C) 
The globe was rotated to dissociate the retina from the underlying RPE and choroid. A single cut was 
performed at the optic nerve head (arrow) to detach the retina. (D) The vitreous attached to the retina. 
(E) The vitreous was removed and the retina flattened, ganglion cell side up. The macula was 
removed as a reference for the para-macular sections and a template used to remove 5 paramacular 
sections. (F) Five paramacular samples were taken and placed into warmed culture medium. 
 
 
 
 
 
 
 
 
 
Figure 2.2: Retinal dissection template (A) Retinal Ganglion cell distribution of a mammalian 
retina. Source: http://www.nervenet.org/main/papers05.html (B) Template used to dissect the five-
paramacular regions of a human donor retina around a central macula. Arrow shows the direction of 
the optic nerve 
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2.2 MIO-M1 (Moorfields/Institute of Ophthalmology-Müller-1) Cells 
MIO-M1 cells are a spontaneously immortalized human cell line derived from an eye of a 68-
year-old female corneal donor 36 hours after death (Limb et al., 2002). They were named 
after the institution where they were isolated, Moorfields/Institute of Ophthalmology-Müller 
1. MIO-M1 have been shown to express Müller cell markers specifically glutamine 
synthetase, glial fibrillary acidic protein (GFAP), α-smooth muscle actin (α-SMA), vimentin, 
cellular retinaldehyde-binding protein (CRALBP), epidermal growth factor receptor and 
neuronal Thy-1 cell surface antigen (Limb et al., 2002; Hollborn et al., 2011). MIO-M1 cells 
were a gift from G.A. Limb, Institute of Ophthalmology and Moorfields Eye Hospital, 
London, UK 
2.2.1 Culture of the MIO-M1 Glial Cell Line 
MIO-M1 cells were used between passage numbers 28 and 38. MIO-M1 cells were cultured 
in Dulbecco’s Minimal Essential Medium containing GLUTAMAX and physiological 
glucose levels of 1g/L (DMEM GLUTAMAX, Gibco-invitrogen, Paisley UK). The medium 
was supplemented with 10% foetal bovine serum (FBS) (Invitrogen, Paisley, UK) and 50mg/l 
Penicillin/Streptomycin (Invitrogen, Paisley, UK). Cells were passaged when confluent by 
washing in Dulbecco’s Phosphate Buffered Saline solution (DPBS) and trypsinised using 
0.05% (w/v) trypsin and 0.02% (w/v) ethylenediaminetetraacetic acid (EDTA) in Hank’s 
balanced saline solution (HBSS) (Invitrogen, Paisley, UK) for 5 minutes at 37ºC, followed by 
gentle tapping before addition of 10ml cell culture medium supplemented with FBS to 
neutralise the trypsin.  
Total cell number was determined using a haemocytometer (Assistant, Sondheim-Rhön, 
Germany) and the cell suspension transferred to a 25ml universal tube (Sterilin, Aberbargoed, 
UK) for 10 minutes centrifugation at 800 rpm to obtain a pellet. The supernatant was 
aspirated and the pellet re-suspended in 5 ml of culture medium. 
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Cells were re-seeded at a density of 1:5 per 75cm2 sterile culture flask (Nunc A/S, Roskilde, 
Denmark) for future use and passaged every 5-7 days. For preparation for the experiments, 
cells were seeded at 5,000 cells per well in 96 well plates (100μl medium) (Nunc A/S, 
Roskilde, Denmark) and 75,000 cells per 35mm culture dish (Corning, NY, USA) (1.5ml 
medium). Cells were grown for three days to achieve >80% confluency and starved with 
DMEM without FBS (serum free DMEM) for at least 24 h before any experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Cell morphology of (A) growing Müller cells (MIO-M1), (B) & (C) 80-100% 
confluence  
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2.3 Co-culture of Retinal Explants and Müller Cells 
The retina was dissected as described earlier and retinal explants were placed into the 
medium of a 35 mm culture dish containing a Müller cell monolayer in a total volume of 1.5 
ml with 1.11mM glucose. At the end the 24hrs experiment period, the medium was collected 
for LDH assay and VEGF protein. Explants were fixed as will be described later, for 
immunohistochemistry with TUNEL. 
2.4 Oxygen and Glucose Deprivation Experiments  
2.4.1 Glucose Deprivation  
Cultured MIO-M1 cells were grown in 35mm dishes for 72hrs in serum-supplemented 
DMEM medium and then incubated in serum-free DMEM for 24hrs before being randomized 
to experimental conditions. All culture medium was supplemented with 50mg/l 
Penicillin/Streptomycin and control medium contained glucose (1g/L), which is equivalent to 
the physiological blood glucose level (5.55 mmol/L). In human retina experiments, HORC 
explants (four in total) were randomized to a control (SF-DMEM), glucose deprivation, 
oxygen deprivation or oxygen and glucose deprivation (OGD).  
Four different levels of glucose-deprived medium were prepared to achieve 30, 20 and 10% 
of the glucose at the control level, equivalent to 1.67, 1.11 and 0.56mM respectively. This 
was achieved by mixing appropriate volume from glucose-free DMEM and DMEM 
containing glucose (1g/L), as shown in Table 2.1. Since glucose was not added directly to the 
medium, the osmolarity was not adjusted. This leads to differences in final osmolarity of the 
medium (Table 2.2). It is important to note here that VEGF expression has been shown to be 
stable with an increase in osmolarity of 20mOsmols in RPE cells (Holborn et al., 2015), 
which is greater than the differences in glucose deprivation experiments (Max. of 12 
mOsmols) and high glucose experiments (11 mOsmols).  
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Level of 
Deprivation 
(%) 
Glucose 
Concentration in 
DMEM medium 
(mmol/L) 
Oxygen level 
(%) 
Control  
(No deprivation)  
5.55 20 
70 1.668 6 
80 1.112 4 
90 0.556 2 
Full starvation 
(OGD) 
0 0 
 
Table 2.1 Levels of glucose and oxygen in OGD experiments 
Type of Medium Glucose 
Concentration in 
DMEM medium 
(mmol/L) 
Osmolarity 
mOsm 
High Glucose  25 326±2.08 
10% Cell culture 5.55 310±0.57 
Serum free  5.55 315±1.32 
20% glucose 
medium 
1.112 304±3.5 
Full glucose 
starvation  
0 303±0.76 
 
Table 2.2 Osmolarity of the different medium used in the experiments (average ±s.e.m, n=4).  
 
2.4.2 Oxygen Deprivation (Hypoxia)  
2.4.2.1 Hypoxia Chamber  
A custom-made chamber was constructed from aluminum with a window at the front of the 
chamber (UEA mechanical workshop, Norwich, UK) to expose cultured cells or tissue to low 
oxygen conditions (Figure 2.3). Chamber dimensions were 260mm x 130mm x 140mm 
giving an overall volume within the chamber of 4732ml. A door was used to seal the chamber 
by tightening 6 wing-nuts against a continuous rubber O-ring. The chamber was housed 
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inside a standard cell culture incubator to maintain a constant temperature (35°C). This 
temperature was chosen since Landers et al., (2012) has found that retinal surface 
temperature (measured prior to vitrectomy) is 34.8-35.2ºC. Retinal explants are therefore 
routinely cultured at 34-35ºC (Bull et al., 2011; Johnson and Martin, 2008; Niyadurupola et 
al., 2013; Osborne et al., 2015a; Osborne et al., 2015b). Control experiments were performed 
outside the hypoxia chamber in the same incubator. Inside the chamber, humidity was 
maintained by a reservoir of distilled water at the base of the chamber. The chamber used 
mass flow controllers (MFC), positioned at the inlet and outlet ports, to simultaneously 
regulate the internal pressure and the rate of gas flow through the chamber. The chamber was 
attached to two gas sources (95% air/ 5% CO2 and 95%N2/ 5% CO2), which could be rapidly 
pumped into the chamber using 1000ml/min MFCs, and released via a solenoid exhaust 
valve.  The gases were mixed to give the level of O2 required. Pressure inside the chamber 
was measured by a high accuracy digital pressure sensor (Omega Engineering Inc, 
Manchester, UK). Oxygen and pressure measurements were fed into a computer-controlled 
regulator unit. Control of gas flow to achieve the desired O2 and pressure was via an analogue 
to digital interface. A third MFC positioned on the outflow ensured a constant flow of gas 
through the chamber at 100ml/min that was independent of pressure (Figure 2.3). 
2.4.3 Simulated Ischemia (Oxygen-Glucose Deprivation, OGD) 
Oxygen-glucose deprivation was performed by incubating cultured cells/HORCs in glucose-
free DMEM medium to simulate complete deprivation of glucose or full OGD when oxygen 
deprivation accompanies it. Each level of ischemia was induced when oxygen and glucose 
were deprived to the same level as shown in Table 2.1.  
The plates or dishes were exposed to experimental conditions and incubated in the hypoxia 
chamber for 24-72 hours where the degree of 5% Carbon dioxide/oxygen and nitrogen flow 
was controlled using computer software. This allowed induction of variable hypoxic 
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conditions between 0.0–6.0% oxygen. At the end of the experiment, 96 well plates were used 
for viability assays (MTS-MIO-M1 only) while medium from dishes was used for 
cytotoxicity assays (LDH). Cells and tissue for PCR analysis were lysed with RNeasy lysis 
buffer (RLT) and frozen immediately in liquid nitrogen and stored at -80°C before to RNA 
isolation.  
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Figure 2.4 Schematic diagram of hypoxia chamber 
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Figure 2.5: Photographic images of the hypoxia chamber (A) the hypoxia chamber inside a 35°C incubator. (B) The whole unit 
connected to gases and computer controlling the oxygen and pressure levels inside the chamber. (C) Images of a computer-based 
software controlling the pressure and oxygen levels. 
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2.5 Cytotoxicity Assay (Lactate Dehydrogenase, LDH) 
Lactate dehydrogenase (LDH) is a soluble cytosolic enzyme that is rapidly released into the 
culture medium when the plasma membrane is damaged (Bonfoco et al., 1995).  
The LDH activity is determined in an enzymatic reaction consists of two steps. In the first 
step, NAD+ is reduced to NADH/H+ by the LDH-catalyzed conversion of lactate to pyruvate. 
Secondly, the catalyst (diaphorase) transfers H/H+ from NADH/H+ to reduce the tetrazolium 
salt INT (2-[4-iodophenyl]-5-phenyltetrazolium chloride) to form a coloured formazan 
product, which can be measured by absorbance at 490 nm (Korzeniewski & Callewaert, 
1983).  
Cytotoxicity Detection Kit (LDH assay) was purchased from Roche (Burgess Hill, UK). 
TritonX-100 was purchased from Sigma-Aldrich (Dorset, UK). The assay was performed 
according to the manufacturer’s instructions. The catalyst and dye solution were mixed in a 
ratio of 1:45 respectively. The cell-free culture supernatant medium (750 µl) was removed 
and centrifuged at 13,000 RPM for 5 min. To measure the maximum releasable LDH, Triton 
X-100 (concentration 2%, volume 750 µl) was added to each dish, mixed thoroughly and 
placed on a shaker for at least 30 min. A total volume of 350 µl was then removed and 
centrifuged for 5 min at 13,000 RPM. In HORCs, the released LDH was measured by 
removing 750 µl of the medium at the end of the experimental period and centrifuged at 
13,000 RPM for 5 min.  
One non-sterile, clear 96 well plate was used to load 100µl of each sample (i.e. supernatant 
medium from MIO-M1 or HORCs) in triplicate.  Background controls were used in this assay 
measured using the appropriate medium.  A volume of 100 µl of the mixed detection kit 
reagent was then added to each of the assay wells and absorbance at 490 nm was measured 
with a micro-plate reader (BMG LABTECH, Bucks, UK) at 5 min.    
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Results were expressed as a percentage of total releasable LDH using the following formula: 
% 𝒐𝒇 𝑻𝒐𝒕𝒂𝒍 𝑹𝒆𝒍𝒆𝒂𝒔𝒂𝒃𝒍𝒆 𝑳𝑫𝑯 =
𝒂
𝒂+𝒃 
 𝑿 𝟏𝟎𝟎  
a= Sample absorbance-background absorbance 
b= TritonX100 positive control absorbance – TritonX100 control absorbance 
In other experiments, LDH release is expressed as a percentage of the control. 
2.6 Cell Viability Assay (MTS) 
Cell viability was assessed using the CellTiter 96 Aqueous Proliferation Assay (Promega, 
UK). The MTS test is a colorimetric assay used to determine the number of viable cells. It is 
based on the conversion of a 3- (4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) into a brown formazan product when reduced by 
active cells (Cory et al., 1991). The tetrazolium reduction takes place in the mitochondria and 
measures mitochondrial metabolic rate as a measure of cell viability (Riss et al., 2011).  
 
Figure 2.6: Conversion of MTS tetrazolium into Formazan by living cells. Image from 
CellTiter 96® AQueous One Solution Cell Proliferation Assay.  
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Figure 2.7:  Standard curve of MTS absorbance values in relation to number of cell seeded. 
MIO-M1 cells (0 to 10,000 cells per well) were seeded into 96 well plates and cultured for 72 
hrs and kept in in SF medium for 24hrs hours before the addition of MTS solution (n=4). 
 
The assay was carried out according to the manufacturer’s protocol. Briefly, after exposing 
cells to experimental conditions, the medium was removed from the 96 well plate and 
replaced with 100 µl MTS solution which is a mixture of 10 µl of the 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and 90µl 
DMEM+Glutamax (serum free) and incubated for 2 hours at 37ºC. Absorbance at 490nm was 
measured with a micro-plate reader (BMG LABTECH, Bucks, UK). The quantity of 
formazan product is proportional to the number of living cells in culture (Figure 2.7). Data 
was presented as percentage cell viability compared to control. 
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2.7 Glucose Assay 
The glucose assay kit, GAGO-20 (Sigma-Aldrich, Poole, UK) was used to assess the rate of 
glucose utilization by human Müller cells (MIO-M1) under normal (5.55mM) and low 
glucose levels (1.11mM) for 24hrs.    
The principle of the assay is based on oxidation of glucose to gluconic acid and hydrogen 
peroxide by glucose oxidase (step1). Hydrogen peroxide then reacts with o-dianisidine in the 
presence of peroxidase to form oxidized o-dianisidine, which has brown colour (step 2). This 
product reacts with sulphuric acid to form a more stable coloured product that is pink in 
colour (step 3). The intensity of the pink colour measured at 540 nm and is proportional to the 
original glucose concentration. 
 
(1) D-Glucose + H2O + O2                               D-Gluconic Acid + H2O2 
(2) H2O2 + Reduced o-Dianisidine (colourless                        Oxidized o-Dianisidine (brown) 
(3) Oxidized o-Dianisidine (brown)                              Oxidized o-Dianisidine (pink) 
The assay was carried out according to the manufacturer’s protocol, although the reaction 
was scaled down to enable use of a 96-well plate.  Glucose oxidase/peroxidase enzyme was 
provided as one capsule containing 500 units of glucose oxidase (Aspergillus niger), 100 
purpurogallin units of peroxidase (horseradish) and buffer salts. The contents of the capsule 
were dissolved in an amber bottle with 39.2 ml of deionized water. The o-Dianisidine 
Reagent was provided as preweighed vial contains 5 mg of o-dianisidine dihydrochloride. 
The vial was reconstituted with 1.0 ml of deionized water. The assay reagent was prepared by 
mixing 0.8 ml of the o-Dianisidine reagent to the amber bottle containing the 39.2 ml of 
glucose oxidase/peroxidase reagent. This product was stable for one month at 2-8 ºC. 
Glucose 
Oxidase 
Peroxidase 
H2SO4 
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Figure 2.8:  Standard curve of glucose concentration (mM) against absorbance (n=4). 
 
Müller cells (MIO-M1) were cultured in 35 mm dishes (1.5 ml) for 24hrs under normal 
oxygen level and both in normal glucose medium (5.55 mM) and low glucose medium (1.11 
mM).  The dishes were divided into two sets, the first were sampled sampled every 2 hours 
for 12hrs and the second were samples to cover the next 12 hrs of the next day. A sample of 
50µl medium was frozen immediately in liquid nitrogen and stored in -80 °C prior to analysis. 
The kit was designed to be used in cuvettes, but was adapted to work in a 96 well plate 
format as following: 40 µl of each sample was pipetted followed by addition of 80µl assay 
reagent. The plate was incubated for 30 minutes at 37ºC. The reaction was terminated by 
adding 80µl sulphuric acid (12 N H2SO4) and read at 540 nm. A standard curve using 
glucose standard solution 1.0 mg/ml in 0.1% benzoic acid provided in the kit with standard 
linearity in the glucose range of 0-100 µg/ml (Figure 2.8) 
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2.8 RNA Extraction 
Total RNA was extracted using an RNeasy® mini kit according to the manufacturer’s 
instructions (Qiagen, Crawley, UK).  Following experimentation, MIO-M1 cells were lysed 
in 350 µl of buffer RLT containing 10% β-mercaptoethanol (Sigma-Aldrich, Poole, UK) 
using a plastic cell scraper and the lysate collected and placed into 1.5 ml Eppendorf tubes. 
The samples were immediately placed in liquid nitrogen and then stored in -80ºC until the 
time of processing. HORCs were homogenised in 350 µl of RLT containing 10% β-
mercaptoethanol using a 20-gauge needle (Becton Dickinson, Oxford, UK) 8 times. The 
samples (either cell lysate or tissue homogenate) were treated with 350 µl of 70% ethanol and 
mixed by repeated pipetting. A total volume of 700µl of each sample was collected and 
transferred to RNeasy mini columns placed in 2 ml collection tubes and centrifuged for 15 
seconds at 13,000 rpm, allowing the RNA to bind to the column membrane.  The flow 
through was discarded and 700µl of buffer RW1 was directly applied to the RNeasy columns 
which were then centrifuged for 15 seconds at 13, 0000 rpm.  
This was followed by digestion of DNA using DNase 1 (Qiagen, Crawley, UK) in RDD 
buffer for 15 minutes at room temperature. The columns were washed again with buffer 
RW1and flow through was discarded. Columns were placed into new 2 ml collection tubes 
and then 500 µl of buffer RPE was pippeted onto each column. Columns were centrifuged for 
15 seconds at 13,000 rpm and flow through flow was discarded. An additional 500µl of 
buffer RPE was pipetted onto each column and centrifuged for 2 minutes at 13,000 rpm to 
dry the membranes and flow through was discarded. Columns were placed in 1.5 ml RNase-
free Eppendorf tubes and 30µl of RNase-free water was applied directly onto the silica-gel 
membrane of the RNeasy columns, which were then centrifuged for 1 minute at 13,000 rpm 
and flow through was collected. Total RNA was quantified (ng/µl) using a Nanodrop ND-
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1000 spectrophotometer (NanoDrop Technologies, Delaware, USA) and the purity of RNA 
was judged by A 260/280 ratio of ~2.0.   
2.9 cDNA Synthesis 
Extracted RNA was converted to complementary DNA (cDNA) in a reaction catalysed by 
Reverse Transcriptase (Invitrogen, Paisley, UK). Each sample was diluted with distilled 
water to get a total volume of 10µl (100ng/µl) using thin walled Eppendorf tubes. Random 
primers (500μg/ml) (Promega, Southampton, UK) and 10 mM dNTP (Bioline, London, UK) 
were mixed in a ratio of 1:1 and 2 µl of this mixture was added to each of the diluted RNA 
samples, and centrifuged for 15 seconds. Samples were placed in a Peltier Thermal Cycler-
DNA engine (MJ Research Inc, Reno, NY) and incubated at 65 ºC for five minutes, followed 
by brief incubation in ice. A mixture of 5x first Strand Buffer (4µl) (Invitrogen, Paisley, UK), 
0.1M DTT (2µl) (Invitrogen, Paisley, UK) and RNase inhibitor (1µl) (Promega, Southampton, 
UK) was prepared and 7µl of this mixture was then added to each sample. The samples were 
centrifuged for 15 seconds at 10,000 rpm before incubation at 25 ºC for 10 minutes in the 
Peltier Thermal Cycler followed by 2 minutes at 42ºC. Samples were briefly chilled and 1µl 
of superscript II was pipetted to each tube. Samples were returned back to into the thermal 
Cycler and incubated at 45ºC for 50 minutes followed by heating at 70ºC for 15 minutes. The 
generated cDNA samples were then stored at -20ºC till further processing.  
2.10 Quantitavive Reverse Transcriptase-Polymerase Chain Reaction                        
(QRT-PCR, TaqMan) Amplification 
QRT-PCR amplification of targeted genes was performed using the ABI Prism 7700 
Sequence Detection System (Applied Biosystems, Warrington, UK). The generated cDNA 
was diluted with RNA free water such that 5ng total cDNA in 10μl was added to each well of 
a microAmp Optical 96 well reaction plate (Applied Biosystems, Warrington, UK). Each 
reaction was composed of 10µl of diluted cDNA, 8.33µl Taqman Mastermix (Applied 
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Biosystems, UK), 1.25 µl of each probe (Table 2.2) and RNase-free water to give an overall 
reaction volume of 25 µl per well.  Plates were sealed with clear adhesive PCR film (Thermo 
Scientific, Surrey, UK) and reaction was performed using the Applied Biosystems 7500 Fast 
Real-Time PCR System, (Applied Biosystems, UK).  
Reaction conditions for the PCR amplification were initiated by heating to 50 ºC for 2 min, 
followed by 10 min at 95 ºC. Amplification of cDNA was through 40 cycles, each consisting 
of one minute at 95 ºC and 30 seconds at 60 ºC. Results were generated in an Excel file and 
cycle threshold (CT) value, the point at which the fluorescent signal becomes statistically 
significant above background, for each sample was determined.  Gene expression was 
determined using a standard curve of gene of interest.   Normalization of data was performed 
using the geometric mean of two housekeeping genes; CYC-1 (cytochrome c-1) and TOP1 
(Topoisomerase I) and was expressed as a percentage of control. Each sample was run as a 
single replicate, and the average (mean±s.e.m) of four separate experiments is presented.  
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Table 2.2:  The Primers used for QRT-PCR Experiments showing the gene symbol, gene name, the assay ID number and the supplier. 
Gene name Assay ID No Company 
PDGF-A Platelet-derived growth factor alpha polypeptide-A Hs00964426_m1 Applied Biosystem 
VEGF-A Vascular endothelia Growth Factor Hs00900055_m1 Applied Biosystem 
FGF2 Fibroblast growth factor 2 (basic) Hs00266645_m1 Applied Biosystem 
SERPINF1 Serpin peptidase inhibitor or pigment epithelium 
derived factor (PEDF) 
Hs01106934_m1 Applied Biosystem 
LIF Leukemia inhibitory factor Hs01055668_m1 Applied Biosystem 
GLUL  Glutamate-ammonia ligase (Glutamine Synthetase) Hs00365928_g1 Applied Biosystem 
SLC1A3 Glial high affinity glutamate transporter Hs00188193_m1 Applied Biosystem 
GAD1 Glutamate decarboxylase 1 Hs01065893_m1 Applied Biosystem 
ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase 
2 (ENPP2) 
Hs00905117_m1 Applied Biosystem 
PANX1 Pannexin 1 Hs00209790_m1 Applied Biosystem 
GFAP Glial fibrillary acidic protein Hs00909233_m1 Applied Biosystem 
HSPA1B Heat shock 70kDa protein 1B Hs01040501_sH Applied Biosystem 
CYC-1 Cytochrome c1 HK-DD-hu-300 Primerdesign  
TOP-1 DNA topoisomerase 1 HK-DD-hu-300 Primerdesign 
   
 60 
2.11 Immunohistochemistry 
2.11.1 Cryosectioning 
After experiments, HORC explants were fixed in 4% formaldehyde for 24 hours at 
4°C. Tissue was then dehydrated with 30% sucrose in PBS for another 24 hours at 
4°C. Subsequently, each retinal explant was mounted vertically into tinfoil circular 
cups filled with Optimal Cutting Temperature (OCT) medium (Sakura Finetek, 
Zoeterwoude, Netherlands). Cups were frozen on dry ice for few minutes and stored 
at -80°C until use.  Retinal slices of 13μm were sectioned using a Bright OTF 5000 
cryostat (Bright Instruments, Huntingdon, UK) as follows. Frozen cups were sliced 
until a retinal piece of approximately 4mm was visible to ensured that sections were 
taken at the center of the circular retinal sample. This was measured using a digital 
vernier calliper (Clarke, Essex, UK). At least 6-8 non-consecutive slices were 
collected per glass slide (Sigma-Aldrich, Poole, UK). Slides were coated with 3-
triethoxysilylpropylamine (TESPA) (Sigma-Aldrich, Poole, UK) to aid adhesion. The 
slides were kept in a slide-box in -20°C until the time of immunohistochemistry 
staining.  
2.11.2 Staining 
Retinal slices were washed three times in PBS, each for 10 minutes to remove OCT 
medium from the slides. Slides were then incubated in blocking solution consisting of 
5% normal goat serum (Sigma-Aldrich, Poole, UK) and 0.2% TritonX-100 in PBS for 
90 minutes at room temperature to block binding sites and to permeabilize cell 
membranes. Afterwards, retinal slices were incubated in a primary antibody (Table 
2.3) made up in blocking solution, overnight at 4°C.  
Following primary antibody binding, retinal slices were washed in PBS three times 
for 10 minutes before the addition of a secondary antibody (2mg/ml; 1:1000) diluted 
   
 61 
in blocking solution in the dark for 2 hours at room temperature. Samples were 
protected from light exposure from this point onwards. Samples were then washed 
three times in PBS for 10 minutes to remove unbound antibody and stained with 
DAPI (0.5μg/ml) for 10 minutes at room temperature. Slides were washed again 
before the addition of a drop of Hydromount (Fisher Scientific, Leicestershire, UK) 
onto each retinal slice. 12mm coverslips (Warner Instruments, Kent, UK) were placed 
over each sample which were then allowed to set at room temperature, protected from 
light, for at least 12 hours before they were imaged using Widefield microscope Zeiss 
AxioPlan 2ie.  
 
Target  
 
Source  
 
Clonality/ 
Conjugate  
 
Dilution  
 
Supplier  
 
Primary Antibodies  
 
Neuronal 
Nuclei (NeuN) 
 
Mouse Monoclonal 
 
1:200 
 
Chemicon 
International, 
Millipore, 
Watford, UK 
Glial Fibrillary 
Acidic Protein 
(GFAP) 
 
Rabbit 
 
Polyclonal 
 
1:1000 Dako, Z0334, 
Glostrup, 
Denmark 
 
Secondary Antibodies  
 
Mouse IgG 
(H+L)  
 
Goat 
 
AlexaFluor 
568 
 
1:1000 
 
Invitrogen, 
Paisley, UK 
 
Rabbit IgG 
(H+L)  
 
Goat 
 
AlexaFluor 
568 
 
1:1000 
 
Invitrogen, 
Paisley, UK 
 
 
Table 2.3: Immunohistochemistry primary and secondary antibodies. 
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2.11.3 Immunohistochemistry with Terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling (TUNEL) assay 
To assess apoptotic cell death within the ganglion layer, immunohistochemistry 
combined with TUNEL-labelling was performed. Immunohistochemistry was 
performed as previously described until the end of the overnight primary antibody 
incubation stage.  Retinal slices were washed three times for 10 minutes with PBS and 
immersed in TUNEL equilibration buffer for 10 minutes at room temperature. The 
assay was carried out according to manufacturer’s instructions. TUNEL reaction 
mixture was prepared and added to samples and incubated in dark for one hour at 
37°C. The reaction was terminated by washing the slides twice with 2X SCC solution 
and washing three times for 10 minutes with PBS.  The immunohistochemistry 
protocol was continued from the addition of the secondary antibodies. Retinal 
sections were imaged using a wide-field Zeiss Axiovert 200M fluorescence 
microscope and analysed with Zeiss Axiovision 4.7 software. 
2.11.4 TUNEL-Positive RGC Quantification 
The numbers of RGCs were counted after image coding by another member of the 
laboratory. Three images were taken from each section (note there were 6-8 sections 
from each HORC) and 2-3 areas corresponding to a distance of 200μm were selected 
and the number of NeuN-immunolabelled cells co-localised with DAPI stained nuclei 
in the RGC layer were counted. TUNEL counting was performed in the same manner 
except the number of TUNEL-positive cells that co-localised with NeuN was assessed 
per 200μm sections. The mean NeuN-positive cells in 3x 200μm section and mean 
TUNEL-positive NeuN-labelled cells were calculated for all images before treatments 
were unmasked.  
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2.12 High Glucose Experiments  
Cell survival, expression of selected growth factors and VEGF release were 
investigated in MIO-M1 and HORCs after exposure to high glucose conditions. In 
HORCs, high glucose treatment was achieved by incubating the retinal explants in 
high glucose DMEM (Invitrogen, UK) of 25mM for 24hrs. Medium was collected for 
LDH analysis; explants were either frozen for RNA extraction or fixed for 
immunohistochemistry.  To investigate the effect of high glucose, oxidative stress and 
PKC inhibition, MIO-M1 cells were utilized as described in the following sections. 
2.12.1 In Vitro Oxidative Stress and High Glucose Treatment 
Hydrogen peroxide (H2O2) (Sigma-Aldrich, UK) was utilized to induce oxidative 
stress in MIO-M1 cells.  MIO-M1 cells were cultured in 96-well plates as described 
earlier and H2O2 was added in serum medium at a range of concentrations               
(100-2000μM).  Cell viability (MTS assay), and LDH were measured to determine the 
appropriate concentration that induces stress without loss of viability. This was done 
in low and high glucose serum free medium for up to 72hrs.  
2.12.2 Protein Kinase C beta (PKCβ) Inhibitor with High Glucose Treatment 
The PKC-𝛽 inhibitor, ruboxistaurin (LY-333531), was purchased from Sigma-Aldrich, 
UK and dissolved in sterile dimethyl sulfoxide (DMSO) (Sigma Aldrich, UK). A dose 
response for PKC-𝛽 inhibitor at a arrange of 100nM-1μM was carried out in MIO-M1 
cells cultured in serum free medium followed by MTS and LDH assays to determine 
the appropriate concentration for treatment under high glucose, oxidative stress and 
hypoxic conditions.  Medium was collected from all conditions for the measurement 
of released VEGF concentration from MIO-M1 cells.   
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2.13 Human VEGF Enzyme Linked-Immuno-Sorbent Assay (ELISA) 
A Human Vascular Endothelial Growth Factor (Hu VEGF) ELISA (Invitrogen, 
Paisley, UK), was used for the determination of VEGF concentration in culture 
medium. The assay will recognize both natural and recombinant Hu VEGF-165 
The Invitrogen human VEGF kit is a solid phase sandwich ELISA.  The assay was 
performed according to the manufacturer’s instructions. A polyclonal antibody 
specific for human VEGF has been coated onto the wells of the microtiter strips 
provided. Incubation buffer (50µl) was pipetted into all wells before adding samples 
(50 µl) or standards of known human VEGF content (100 µl). Standard diluent buffer 
(50µl) was added into all wells except the standards.  During the first incubation (30 
minutes), the VEGF antigen binds to the immobilized (capture) antibody on one site. 
After washing, a biotinylated monoclonal antibody (100 µl) specific for human VEGF 
was added. During the second incubation (30 minutes), this antibody binds to the 
immobilized VEGF captured during the first incubation. After removal of excess 
secondary antibody, Streptavidin-Peroxidase enzyme (100µl) was added. This binds 
to the biotinylated antibody to complete the four-member sandwich. After a third 
incubation (30 minutes) and washing to remove unbound enzyme, a substrate solution 
(100µl) was added, which is acted upon by the bound enzyme to produce color. A 
stop solution was added and the intensity of this color was measured at 490 nm. This 
is directly proportional to the concentration of VEGF present in the original sample. 
A plot of the absorbance of the standards against the standard concentrations (0-1500 
pg/ml) was constructed. Concentration of VEGF in the samples was presented as 
pg/ml using the plotted standard curve.  
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2.14 Data Analysis  
Data is presented as mean ± standard error of the mean (s.e.m) of at least four 
experiments. GraphPad (Prism®, version 6) was used to analyse and present data. A 
one-way analysis of variance (ANOVA) was used to establish statistical significance 
between data sets in combination with Dunnett post-hoc test. Student’s t-test was used 
to test for significance when only two variables were present.  A P value equal or less 
than 0.05 was considered statistically significant.   
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Chapter 3 
Effect of Oxygen and Glucose Deprivation on the Survival and Cytotoxicity of 
Human Müller Cells (MIO-M1) 
3.1 Introduction  
Müller cells are the principle macroglial cells in the retina, and they are radially 
oriented cells spanning the whole thickness of the retina, communicating with all type 
of neurons within the retina (Newman and Reichenbach, 1996; Reichenbach and 
Bringmann, 2013). They provide structural support and regulate neuronal cell 
metabolism. They control essential processes such as glucose metabolism, antioxidant 
production, ion and substrate exchange and vascular regulation (Bringmann et al., 
2000; Eichler et al., 2000; Bringmann and Reichenbach, 2001; Winkler et al., 2000). 
In addition, Müller cells play a major role in the retina by responding to pathological 
stimuli. This includes responses to hypoxia, ischemia, glucose deprivation and 
inflammatory conditions (Bringmann et al., 2006).  Reactivity of Müller glia during 
retinal detachment and other forms of retinal injury such as proliferative diabetic 
retinopathy (PDR), proliferative vitreoretinopathy (PVR) and glaucoma has been 
documented (Andjelic et al., 2014; Campochiaro et al., 1997; Flammer and 
Mozaffarieh, 2007; Hollborn et al., 2004).  
In PVR, uncontrolled Müller cell proliferation and hypertrophy and eventual 
formation of a glial scar are the hallmarks of the disease (Morescalchi et al., 2013). 
Activation of Müller cells in experimental retinal detachment in rats led to the 
expression of GFAP, vimentin and nestin with evidence of Müller cell proliferation 
and growth within the retina and into the subretinal space (Luna et al., 2010).   
In addition, immunochemical staining has identified Müller cells in diabetic retinal 
scars. Theses scars prevent flattening of the retina and cause macular wrinkling 
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leading to loss of vision (Lewis et al., 1991; Lewis et al., 2010).  In a mouse model of 
inherited glaucoma (DBA/2J), microglia activation was an early alteration in the 
retina and optic nerve, contributing to disease progression (Bosco et al., 2011). In a 
recent study by Bosco et al., (2015); using the DBA/2J mouse model, an early 
microgliosis at the optic nerve head was detected. The author suggested that 
monitoring microglial activation is a good indicator of future neurodegeneration 
severity (Bosco et al., 2015). In addition, in an IOP-induced glaucoma model in rats, 
evidence of glial cell proliferation at the optic head region was detected by 
upregulation of cell proliferation associated genes: Top2a plays a role in DNA 
replication, whereas Prc1 regulates the mitotic spindle midzone formation and Espl1 
regulates chromatid separation at anaphase. Interestingly, this was not associated with 
a change in the expression of GFAP (Johnson et al., 2011). 
On the other hand, different experimental stressors have been shown to decrease the 
viability of glial cells in vitro. For example in one study, high dose of hydroquinone 
decreased the viability of the human Müller cell line (MIO-M1) to 41% of control 
with a 5-fold increase in LDH levels. Death under this condition was attributed to 
oxidative, mitochondrial and autophagic pathways with no apoptosis involved 
(Ramirez et al., 2013).  Cell death in MIO-M1 cells was also induced by a high dose 
of catechol, in which viability decreased to 46% with increased caspase 3/7 activity 
(Mansoor et al., 2010). Moreover, exposure of rat C6 glioma cells to H2O2 caused a 
dose-dependent cell death (Ahn et al., 2015). Similarly, the MIO-M1 cell viability 
was decreased after exposure to H2O2 induced oxidative stress (Hu et al., 2014).  
In addition, the effects of oxygen-glucose deprivation has not previously been 
investigated in Müller cells but various studies have been carried out using cultured 
astrocytes  (Huang et al., 2013; Lee et al., 2006; Lee et al., 2009; Niu et al., 2009; Pei 
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and Cheung, 2003; Velly et al., 2009).  As oxygen and glucose deprivation (OGD) is 
part of the pathophysiology of glaucoma and could occur as a result of decreased 
ocular blood flow, the aim of the experiments presented in this chapter was to identify 
whether oxygen and/or glucose deprivation would have a direct effect on cell survival 
of human Müller cells (MIO-M1).   
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3.2 Results  
3.2.1 Effect of Oxygen–Glucose Deprivation (OGD) on the Viability and 
Cytotoxicity of Human Müller Cells (MIO-M1) 
Human MIO-M1 cells were exposed for 24hrs to full oxygen-glucose deprivation 
(OGD) or reduced levels of oxygen and glucose of 10-30% (0.56-1.67 mM glucose/ 
2-6%O2) of control levels (5.55mM glucose/20% O2).  Full OGD caused a significant 
5-fold increase (*p≤ 0.05; n=4) in released LDH compared to control while reduced 
levels to 10-30% did not change LDH release (Figure 3.1A) indicating cell death with 
total OGD only. This was confirmed by the viability test, which showed a significant 
reduction of approximately 50% in the survival rate with full OGD, but no loss of 
viability with reduced (10-30%) oxygen and glucose levels compared to control after 
24hrs (Figure 3.1B).  
Interestingly, when oxygen and glucose were reduced to 20% of control level                       
(1.11mMglucose/4%O2), MIO-M1 cell viability increased significantly (*p≤0.05; n=4) 
by approximately 20% compared to control, which indicated, possible proliferation of 
the cells under these conditions. These results indicate that MIO-M1 cells withstand 
oxygen and/or glucose deprivation levels below full deprivation but when they are 
completely depleted of both oxygen and glucose they lose viability.  Since both 
oxygen and glucose were changed together in these experiments, then it was 
important to look at them separately to determine the main substrate affecting the 
proliferation and survival. 
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 3.2.2 Effect of Oxygen Deprivation on the Survival and Cytotoxicity of Human 
Müller Cells (MIO-M1) 
Despite the reduction of oxygen concentration to the MIO-M1 cells for 24hrs, the 
LDH levels were comparable to control at all levels of oxygen deprivation including 
full deprivation (Figure 3.2A).  Furthermore, MIO-M1 cells maintained the same 
survival rate as control with reduced oxygen and even with complete deprivation. The 
viability of the MIO-M1 cells slightly, but significantly, increased (*p≤0.05; n=4) by 
13% and 21% at 2% and 4% oxygen respectively as compared to control (Figure 
3.2B). 
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Figure 3.1: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) 
of human Müller cells (MIO-M1) after 24hrs exposure to full oxygen-glucose 
deprivation (OGD) or reduced levels of glucose and O2 (0.56-1.67mM glucose/2-
6%O2 (mean ± s.e.m, * p≤0.05; n=4).  
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Figure 3.2: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) 
of human Müller cells (MIO-M1) after 24hrs exposure to full oxygen deprivation 
or reduced levels of oxygen 2-6% (mean ± s.e.m, * p≤0.05; n=4). 
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Figure 3.3: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) 
of human Müller cells (MIO-M1) after 24hrs exposure to full glucose deprivation 
or reduced levels of glucose 0.56-1.67mM (mean ± s.e.m, * p≤0.05; n=4). 
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3.2.3 Effect of Glucose Deprivation on the Survival and Cytotoxicity of Human  
Müller Cells (MIO-M1) 
Full deprivation of the MIO-M1 cells from glucose significantly for 24hrs increased                
(*p≤0.05; n=4) LDH levels by approximately 2-fold compared to control. No 
detectable alterations in the LDH levels were found when glucose was reduced to 10-
30% (0.56-1.67 mM) of the control level (5.55 mM) (Figure 3.3 A). 
Full glucose deprivation also reduced the viability by approximately 50%. On the 
other hand, viability was increased significantly with 1.11mM glucose (Figure 3.3B). 
These results were similar to those seen with reduced levels of oxygen and glucose 
deprivation (1.11mMglucose/4%O2).  
3.3 Long –term Oxygen Glucose Deprivation 
Human MIO-M1 cells showed resistance when exposed to all levels of hypoxia and 
OGD conditions below full deprivation for 24hrs. It was interesting to find that 
hypoxia, glucose deprivation, and OGD at 20% of control (1.11mMglucose/4%O2) 
caused MIO-M1 cell proliferation. This level was therefore chosen to study MIO-M1 
viability and cytotoxicity in response to long-term deprivation (48 and 72hrs).  
3.3.1 Effect of Long-term Oxygen-Glucose Deprivation on the Survival and 
Cytotoxicity of Human Müller Cells (MIO-M1) 
At 72hrs, human MIO-M1 cells incubated in 1.11mM glucose/4%O2 lost their 
integrity as evidence by 1.6-fold increase in total releasable LDH compared to control 
(*p≤0.05; n=4), while no detectable LDH release was found in 24 and 48hr 
experiments. Viability results confirmed the LDH data with a significant reduction in 
viability by 50% after 72hrs (Figure 3.4 A). MIO-M1 cells maintained at 1.11mM 
glucose/4%O2 for 24hrs showed a significant 30% increase (*p≤0.05; n=4) in 
viability compared to control suggesting that MIO-M1 cells proliferated as indicated 
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earlier. This proliferation was maintained, but at lower rate of 14% after 48hrs (Figure 
3.4B).   
3.3.2 Effect of Long-term Oxygen Deprivation on the Survival and Cytotoxicity 
of Human Müller Cells (MIO-M1) 
Cytotoxicity data showed no significant change of released LDH at any time point 
with oxygen deprivation to 4%. This was supported by viability data, which did not 
decrease with oxygen deprivation (4%) but slightly increased by approximately 10% 
at 24-48 hrs (Figure 3.5A, B).  
3.3.3 Effect of Long-term Glucose Deprivation on the Survival and Cytotoxicity 
of Human Müller Cells (MIO-M1) 
Long-term glucose deprivation to the MIO-M1 cells showed a similar pattern to OGD 
in which a significant 1.6-fold increase in LDH levels was seen at 72hrs                    
(*p≤0.05; n=4). No significant increase in LDH levels was found at earlier time points 
(Figure 3.6A). A significant 24% increase in viability was seen at 24hrs          
(*p≤0.05; n=4). The cells maintained similar viability to control at 48hrs with no 
proliferation, while a significant reduction (*p≤0.05; n=4) in viability by 40% was 
seen at 72hrs (Figure 3.6B). These results were very similar to those seen with both 
oxygen and glucose deprivation (Figure 3.4B).  
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Figure 3.4: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) 
of human Müller cells (MIO-M1) after 24hrs exposure to 20% OG level (1.11 
mM glucose/4%O2) for 24, 48 and 72hrs (mean ± s.e.m, * p≤0.05; n=4, t.test).  
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Figure 3.5: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) 
of human Müller cells (MIO-M1) after 24hrs exposure to 4% oxygen for 24, 48 
and 72hrs (mean ± s.e.m, * p≤0.05; n=4, t.test).  
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Figure 3.6: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) 
of human Müller cells (MIO-M1) after 24hrs exposure to 1.11 mM glucose for 24, 
48 and 72hrs (mean ± s.e.m, * p≤0.05; n=4, t.test).  
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The data, therefore, indicated that MIO-M1 cells were able to withstand oxygen 
deprivation for up to 72hrs with no effect on viability. In relation to glucose, 1.11mM 
caused a proliferation at 24hrs, but this proliferation was not maintained, and death 
occurred after 72hrs of glucose deprivation to this level. This loss of viability at 72hrs 
death may have been due to glucose utilization lowering the concentration in the 
bathing medium. The glucose utilization rate was therefore measured.  
MIO-M1 cells were cultured at physiological glucose level (5.55mM) and also at         
1.11mM glucose. Starting concentrations for control and treatment was measured at 
5.0±0.23mM and 1.17±0.08 mM respectively. The concentration after 24hrs was 
3.64±0.09mM and 0.14 ±0.05 mM for the control and reduced glucose respectively 
(Figure 3.7 A,B).  
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Figure 3.7 Glucose utilization by MIO-M1 under (A) control (5.55 mM) and (B) 
1.11mM glucose for 24hrs.  
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3.4 Discussion  
The human Müller cell line (MIO-M1) has been utilized to study glial cell function in 
vitro in relation to normal and diseased states. They express Müller cell markers and 
the authors also reported that the cells occasionally expressed GFAP after detachment 
from the monolayer indicating that they may be activated in vitro (Limb et al., 2002).  
Furthermore, Lawrence et al., (2007) reported that MIO-M1 cells also express stem 
cell markers, and they have been shown to differentiate into RGC precursors that 
were able to restore RGC function after in vivo transplantation (Singhal et al., 2012). 
This further demonstrates their stem cell characteristics.  
As oxygen and glucose deprivation is part of the pathophysiology of glaucoma, the 
survival of Müller cells in a model of simulated ischemia was investigated using the 
MIO-M1 cell line. In an animal model of glaucoma, elevated IOP was associated with 
early astrocytes and Müller cell responses such as increased expression of GFAP, 
vimentin, nestin and glutamine synthetase (Lam et al., 2003; Xue et al., 2006). 
Activation of Müller cells in the human glaucomatous retina has been reported with 
early responses including increased immunostaining for GFAP (Tezel et al., 2003; 
Wang et al., 2002), and also glial proliferation (Thanos et al., 1991).  In retinal stress, 
Müller cells initially respond by releasing survival factors in an attempt to rescue 
RGCs (Bringmann et al., 2009). As damage occurs to RGCs soma and the nerve fiber 
layer is affected, Müller cell processes replace the lost RGCs and form a glial scar 
(Nickells, 2007).  
In the experiments reported here, the effect of OGD on cell survival was investigated 
in the MIO-M1 cells.  They were subjected to four levels of oxygen and/or glucose 
deprivation compared to atmospheric oxygen (20%) and normal plasma glucose level 
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(5.55 mmol/L), which served as the experimental control. The deprivation levels were 
10-30% of control levels.  
3.4.1 Effect of Oxygen–Glucose Deprivation on the Survival and Cytotoxicity 
Human Müller Cells (MIO-M1) 
Initial experiments assessing viability and cell death revealed that necrotic damage 
was detected when oxygen and glucose was withdrawn completely for 24hrs leading 
to a significant 5-fold increase in LDH levels. Viability results matched the LDH 
release data, with approximately 50% survival rate compared to control with full 
OGD. Viability studies of Müller cells in general and specifically for MIO-M1 cells 
under similar levels of OGD have not been presented previously in the literature, 
although studies have reported data from other glial cells derived from non-human 
species in relation to different diseases/conditions. For example, findings by Schmid-
Brunclik et al., (2008) indicated that exposure of astrocytes to OGD caused death as 
early as 6hrs. Longer OGD treatment for 24hrs resulted in 90% of all astrocyte nuclei 
becoming TUNEL positive with obvious nuclear condensation and cell shape 
disruption (Schmid-Brunclik et al., 2008). In addition, exposure of astrocytes in 
culture to OGD caused cellular injury as measured by LDH efflux (Haun et al., 1992). 
Blocking of Ca2+ channels with nimodipine reduced astrocytes death indicating that 
influx of extracellular Ca2+ contributed to astrocyte death in ischemia (Haun et al., 
1992).  
With deprivation levels below full OGD, no change in the released LDH was 
observed which reflects that MIO-M1 cells withstand OGD at these levels with no 
loss of viability. Interestingly, exposure of MIO-M1 cells to 1.11mM glucose/4%O2 
for 24hrs caused an increase in viability indicating possible proliferation under this 
level of ischemia. The proliferation of Müller cells has previously been seen in other 
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conditions including retinal detachment (Lewis et al., 1992; Lewis et al., 1999), 
diabetic retinopathy (Guidry et al., 2009), proliferative vitreoretinopathy (Guidry, 
2005) and glaucoma (Flammer and Mozaffarieh, 2007). Activation of Müller cells is 
described as a non-specific response to either mechanical or ischemic stress (Flammer 
and Mozaffarieh, 2007). Ischemia-induced proliferation of Müller cells has been 
reported in vivo when ischemia was induced in rats by central retinal artery occlusion 
(Stefansson et al., 1988). Furthermore, Müller cells isolated from rat retina after 
transient ischemia followed by reperfusion in vivo showed gliosis characteristics 
including cellular hypertrophy, alteration in osmotic swelling and expression of 
GFAP and CRALBP (Kuhrt et al., 2008). This response by Müller cells has also been 
found in adult zebrafish after an excision of the dorsal retina in which glial cells 
proliferated and filled the lesion in the retina (Yurco and Cameron, 2005).  
With decreased oxygen-glucose levels (1.11mM glucose/4%O2) for longer periods, 
there was no loss in viability at 48hrs, but the damage was apparent by the 72hrs time 
point.  However, this most likely reflected that glucose levels had decreased due to 
glucose utilization by the cells (Figure 3.7). To assess if the changes seen were 
oxygen or glucose-dependent, each level of deprivation was repeated but the cells 
were deprived of either oxygen or glucose.  
3.4.2 Effect of Oxygen Deprivation on the Survival and Cytotoxicity Human 
Müller Cells (MIO-M1) 
Current results found that MIO-M1 cells were resistant to the absence of oxygen with 
all levels of deprivation. Even full oxygen deprivation for 72hrs did not alter viability 
or increased cell death. Interestingly, MIO-M1 cells slightly increased in number 
when they were maintained at 2 and 4% oxygen for 24hrs.  
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Wang et al., (2012) found that exposure of the of rat Müller cell line, rMC-1 to 
hypoxic conditions (2%O2) for 24hrs, followed by three days of re-oxygenation, 
significantly induced cell proliferation (2-fold increase). The experiments investigated 
the mechanism of proliferation implicating the involvement of Notch signaling in the 
induction of Müller cell proliferation under hypoxic conditions by activating positive 
cell-cycle regulators such as cyclins A and D1, as well as the neural and retinal 
progenitor markers (Wang et al., 2012). In addition, anoxia has also been found to 
induce proliferation of primary astrocytes isolated from newborn rats (Schmid-
Brunclik et al., 2008). They also reported that ATP levels dropped by 50–70% within 
the first 6–24 hrs of anoxia, but were subsequently maintained at 48hrs. However, in 
other studies exposure of a primary culture of astrocytes from newborn rat cerebral 
cortex to full oxygen deprivation for 24hrs resulted in astrocyte death with a 10-fold 
increase in LDH level (Yu et al., 1989). This was also found in primary glial culture 
from the cerebral hemispheres of newborn rats, with 24hrs hypoxia resulting in an        
80% increase in LDH efflux (Callahan et al., 1990). The mechanism of tolerance of 
MIO-M1 cells to hypoxia was not investigated in the current experiments, but may be 
explained by Yu et al., (2008) findings which showed that increase expression of two 
major forms of glucose transporters (GLUT1 and GLUT3) occurred in cultured rat 
hippocampal neurons and astrocytes exposed to hypoxia (1% O2) followed by anoxia. 
This suggests that glucose uptake is increased which helps to maintain ATP levels by 
glycolysis during hypoxic insult (Yu et al., 2008).  
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3.4.3 Effect of Glucose Deprivation on the Survival and Cytotoxicity Human 
Müller Cells (MIO-M1) 
Glucose deprivation showed a similar response to OGD, highlighting the importance 
of glucose for the survival of glial MIO-M1 cells. Full glucose deprivation for 24hrs 
reduced MIO-M1 cell viability and increased cell death.  In other studies using MIO-
M1 cells, full glucose deprivation for a very short period of one hour did not change 
the viability or intracellular ATP level (Toft-Kehler et al., 2014). In another study by 
Schmid-Brunclik et al., (2008) exposure of astrocytes to full glucose deprivation 
under the normoxic condition for 6hrs induced proliferation by approximately 40% 
compared to control. Wang et al., (2012) showed that rat Müller cells withstand full 
glucose deprivation for 12hrs but experiments conducted for 24hrs with full glucose 
deprivation have not been reported.  
Lower levels of deprivation of glucose maintained similar viability to control and 
increased proliferation was seen at 1.11mM glucose. In order to investigate this 
proliferation further, the cells were exposed to this level of glucose for a longer period 
of time. However, the proliferation was not increased but no loss in viability was 
found at 48hrs and the damage was apparent by the 72hr time point. Similarly, 
exposure of MIO-M1 cells to 2.2mM glucose for 24hrs did not alter the ATP levels 
(Emery et al., 2011). It was recognized that this is likely due to the fact that glucose 
would be being utilized over the incubation period. Therefore, glucose utilization by 
MIO-M1 cells was measured under control and 1.11mM glucose conditions over a 
24hrs period (Figure 3.7 A,B). The results showed that after 24hr there was little 
glucose left in the cells, which were incubated in 1.11mM glucose at the start of the 
experiments. The results therefore indicated that MIO-M1 cells were able to cope 
with reduced glucose for 48hrs despite the consumption of glucose in the first 24hrs, 
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which was unexpected. If we consider that the cells were proliferating as a response to 
switching them from 5.55mM glucose to the reduced level 1.11mM glucose, they 
would actually consume more glucose than usual as they were increasing in number. 
After accommodating to the new condition, no more proliferation was seen, and they 
may switch to lower rate of glucose utilization, which enabled them to survive for 
48hrs but failed to maintain them for 72hrs.  Findings by Schmid-Brunclik et al., 
(2008) indicated that in cultured astrocytes fully deprived of glucose under normoxia 
for 6hrs, a 50% decrease in ATP levels occurred, but ATP levels recovered to 70% at 
48 hrs. A study by Jelluma et al., (2006) showed that in human astrocytes, withdrawal 
of glucose enhanced mitochondrial respiratory chain activity of fatty acid oxidation 
and thus sustained ATP levels. Active production of lactate in the presence of glucose 
is a characteristic of astrocytes in culture (Pauwels et al., 1985; Swanson and 
Benington, 1996). Müller cells share similar metabolic activity as they are reported to 
depend 80–90% on glycolysis as their main pathway for energy production whether 
under aerobic and anaerobic conditions (Winkler et al., 2000), metabolizing glucose 
primarily to lactate (Poitry-Yamate et al., 1995). Blocking glycolysis by iodoacetate 
has been found to cause a decline of ATP to low levels and loss of viability in Müller 
cells indicating the importance of this pathway to survival (Poitry-Yamate and 
Tsacopoulos; 1995; Winkler et al., 2000). It has been proposed that lactate produced 
by glycolysis is then used as a source of oxidative energy metabolism for retinal 
neurons (Poitry-Yamate et al., 1995; Tsacopoulos et al., 1998; Xu et al., 2007). 
Because of this metabolic activity, Müller cells consume very low rates of oxygen 
thus preserving it for retinal neurons. This in turn, makes them more resistance to 
oxygen deprivation (Poitry-Yamate and Tsacopoulos; 1995; Winkler et al., 2000) as 
was seen in the experiments reported in this chapter.  In the absence of glucose, 
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Müller cells use other substrates such as lactate, pyruvate, glutamate or glutamine and 
generate energy by metabolizing these substrates via tricarboxylic acid cycle, a non-
dominant pathway which requires oxygen (Tsacopoulos et al., 1998; Winkler et al., 
2000). Mechanisms requiring lactate or pyruvate would not be available to the cells in 
the current experiements and glutamate or glutamine from the culture medium were 
unable to support the cells as loss of viability occurred with full glucose deprivation 
in the presence of oxygen. 
Glucose deficiency can be also compensated by the glycogen deposits in Müller cells, 
which allow them to withstand short periods of ischemia (Bringmann et al., 2006; 
Johnson, 1977), with Müller cells having abundant glycogen phosphorylase a key 
enzyme in glycogen degradation (Pfeiffer-Guglielmi et al., 2005). These mechanisms 
may have aided MIO-M1 cell survival in the early stress of glucose deprivation but in 
vivo experiments of ischemia for one hour caused depletion of the glycogen store in 
Müller cells  (Gohdo et al., 2001).        
Generally, the resistance of Müller cells to stress can be explained by several 
properties and functions that these cells can perform. These include the cells unique 
energy metabolism, glycogen deposits, ability to proliferate and release neurotrophic 
and growth factors, buffering of elevated potassium levels (Bringmann et al., 2006). 
Also, their glutathione content and ability to defend against oxidative stress (Garcia 
and Vecino, 2003) and their defense mechanism against glutamate excitotoxicity 
(Bringmann et al., 2009).  The present research has supported the notion that Müller 
cells are relatively resistant to ischemic damage.  
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The fact that viability increased when oxygen and glucose level dropped to 20% of 
control level (1.11mM glucose/4%O2) highlights that MIO-M1 cells may proliferate, 
perhaps protecting themselves by releasing growth/survival factors that could also be 
important to RGCs during ischemic insult.  In the next chapter, gene expression of 
key growth factors, specific Müller cell markers, glutamate and ATP signaling related 
genes will be investigated.    
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Chapter 4 
Effect of Oxygen and Glucose Deprivation on Gene Expression in 
Human Müller cells (MIO-M1) 
4.1 Introduction 
As previously discussed, human Müller (MIO-M1) cells were resistant to oxygen and 
glucose deprivation. Only complete withdrawal of glucose, rather than oxygen, was 
the trigger for cell loss suggesting the importance of glucose for survival of MIO-M1 
cells. Results from previous experiments have also shown that MIO-M1 cells 
proliferate in response to reduction in glucose and oxygen to 20% (1.11mM 
glucose/4%O2) of the control levels suggesting the possibility that Müller cells may 
respond to this level of ischemic stress by secreting growth/survival factors. 
Proliferation and gliosis is a cellular attempt to restore normal function and prevent 
damage (Liberto et al., 2004). In the central nervous system (CNS), astrocytes 
respond to insults by proliferation, increased production of GFAP, vimentin, nestin 
and cytokines (Liberto et al., 2004). Activated astrocytes become larger in size with 
nuclear hypertrophy and produce trophic and growth factors in an attempt to protect 
adjacent neurons and glia (Albrecht et al., 2002; Hudgins and Levison, 1998). These 
responses may result in the formation of astrogliotic scars (Norenberg, 1994; Norton 
et al. 1992). Similarly, microglial cells in the brain become activated during injury 
and release cytokines such as IL-1β, IL-3, IL-6, TNF-α, and VEGF (Stoll et al., 2002).  
In the retina, Müller cells are the main glial cells. They express numerous receptors 
and release neurotrophic and growth factors. Among these are VEGF, EGF, PDGF, 
IGF-1, bFGF, NGF, ciliary neurotrophic factor (CNTF) (Bringmann et al., 2001; Cao 
et al., 1997; Cao et al., 2001; Harada et al., 2000;Wen et al., 1995). The mitogenic 
activity of these growth factors has been examined in Müller cell cultures and in vivo 
(Ikeda and Puro, 1994; Lewis et al., 1992; Mascarelli et al., 1991; Uchihori and Puro, 
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1991). Müller cells also respond to anti-angiogenic factors such as PEDF and TGF-β 
(Eichler et al. 2004; Ikeda et al., 1998).  In the following section, key growth factors 
will be introduced in relation to retinal and Müller cell function and their role during 
injury.  
One of the Müller cell survival factors, which is released in response to hypoxia, is 
VEGF-A (Aiello et al., 1995; Eichler et al., 2000; Yafai et al., 2004).  The VEGF 
family belongs to the platelet-derived growth factor (PDGF)/VEGF supergene family 
(Dvorak, 2002). It exists in six isoforms termed VEGF-A, B, C, D, E and placental 
growth factor (PIGF) (Dvorak, 2002; Shibuya et al., 2006; Takahashi et al., 2005). 
Exon splicing of the human VEGF-A gene results in the generation of four different 
isoforms: VEGF121, VEGF165, VEGF189, and VEGF206. VEGF165, is the predominant 
isoform, with pro-angiogenic, as well as neuroprotective, properties and when the 
term “VEGF” is used, it refers to the VEGF-A/VEGF165 isoform (Houck et al., 1991). 
VEGF binds and activates VEGFR1 and VEGFR2 tyrosine kinase receptors and both 
are involved in angiogenesis (Shibuya et al., 2006). These receptors are expressed 
predominantly on vascular endothelial cells and stimulate proliferation and 
chemotaxis (Neufeld et al., 1999). Disruption of genes encoding VEGFR1 and 
VEGFR2 results in severe abnormalities of blood vessel formation and fatal 
consequences during embryogenesis (Shalaby et al., 1995) Increased oxygen in the 
retina results in decreased expression of VEGF and endothelial cell death (Yamada et 
al., 1999).  
In pathological conditions of the eye such as ischemia, VEGF is over-expressed and 
contributes to pathophysiological changes such as retinal vascular leakage and 
neovascularization. VEGF has been shown to exert neuroprotective effects, increasing 
neuronal cell survival through inhibition of apoptosis (Jin et al., 2000; Jin et al., 2001), 
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stimulation of neurogenesis and angiogenesis (Sun et al., 2003; Jin et al., 2000), 
increasing neuronal glucose uptake (Sone et al., 2000) and activation of antioxidants 
including induction of expression of heme oxygenases 1 (HO-1) (Chao et al., 2013; 
Zhu et al., 2007).  
One factor that can potentiate VEGF action is PDGF as they share a low but 
significant sequence homology of 100 amino acids (Finkenzeller et al., 1997).  The 
PDGF family consists of five isoforms: PDGF-A, B, C, and D, existing as 
homodimers (PDGF-AA, -BB, -CC, -DD) or as a heterodimer AB (Fredriksson and 
Eriksson, 2004). They act on tyrosine kinase receptors PDGFR-α and -β to induce 
angiogenesis and promote survival and proliferation of different cell types 
(Fredriksson and Eriksson, 2004). In the eye, PDGF-A is expressed by both neurons 
and astrocytes (Pringle et al., 1989). Glial cells possess PDGFR-α and a high 
expression of PDGF-A results in extensive proliferation of glial cells (Pringle et al., 
1989). High expression of PDGF-A in the retina was associated with glial cells 
proliferation and traction, causing retinal detachment without vascular cell 
involvement (Mori et al., 2002).  
Basic fibroblast growth factor (bFGF) is a potent mitogenic factor, which increases 
endothelial cell proliferation and migration, through activation of FGF receptors 
(Walsh et al., 2001). Basic FGF has been shown to regulate photoreceptor survival 
and differentiation and stimulate Müller cells proliferation (Mack and Fernald, 1993; 
Hicks and Courtois, 1990). Basic FGF stimulates angiogenesis in vivo and has been 
shown to promote neuronal survival in ischemic insult and glutamate toxicity 
(Anderson et al., 1988; Freese et al., 1992).  
Another factor important for retinal homeostasis is pigment epithelium-derived factor 
(PEDF), a secreted 50-kDa glycoprotein and a member of the serpin superfamily 
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(Bouck, 2002). It was originally identified in conditioned medium from RPE and was 
found to be an endogenous inhibitor of angiogenesis in the eye (Bouck, 2002; 
Tombran-Tink and Johnson, 1989). PEDF expression has been detected in the retinal 
ganglion cell layer (Behling et al., 2002) and in Müller cells (Eichler et al., 2004). In 
addition, PEDF receptor was identified and isolated initially from retinoblastoma 
tumour cells (Singh et al., 1998) and neural retina (Aymerich et al., 2001). PEDF 
expression is regulated by hypoxia in a reciprocal direction to that of VEGF; as 
hypoxia is a stimulatory factor for VEGF expression, it decreases PEDF release 
(Eichler et al., 2004). Besides its function as an inhibitor of angiogenesis, PEDF has 
been shown to support the development and survival of photoreceptors (Cayouette et 
al., 1999; Jablonski et al., 2000), and also protect retinal ganglion cells from 
ischemia-induced death (Pang et al., 2007; Takita et al., 2003; Unterlauft et al., 2012).  
Another important inhibitor of angiogenesis is leukaemia inhibitory factor (LIF), 
which is a member of the interleukin-6 cytokine family. The LIF receptor signals via 
glycoprotein 130, to activate the JAK (Janus kinase) tyrosine kinase family (Heinrich 
et al., 2003).  Ash et al., (2005) studied the effect of LIF, in early retinal development 
and found that LIF inhibited retinal vascular development. This inhibition was 
independent of VEGF expression in vivo. In contrast, Kubota et al., (2008) showed 
that LIF-deficient mice exhibited increased microvessel density and upregulated 
VEGF in vivo. In a rat IOP-induced glaucoma model, increased expression of LIF 
mRNA was found (Johnson et al., 2011) and endogenous LIF produced by Müller 
cells, has been found to support survival of photoreceptors during light-induced injury 
(Bürgi et al., 2009; Joly et al., 2008). 
As previously discussed, glutamate excitotoxicity plays a prominent role in hypoxic-
ischemic insult in the retina. Major pathways of glutamate metabolism consist of 
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glutamate uptake by the glial glutamate transporter (GLAST) followed by enzymatic 
conversion to glutamine by glutamine synthetase (GS) (Ishikawa et al., 2013). In 
addition, the purinergic signaling system has been shown to be involved in 
pathogenesis of hypoxic-ischemic injury (Montero and Orellana, 2015; Niyadurupola 
et al., 2013).  Pannexins are newly discovered channels expressed in a variety of 
tissues with multiple functions and have been implicated as ATP conduits in many 
cells (Bruzzone et al., 2003; Panchin et al., 2000; Phelan et al., 1998). These channels 
can be activated by membrane potential changes or by independent voltage stimuli 
such as low oxygen environment, mechanical stress or increased cytoplasmic calcium 
ions (Bao et al., 2004; Bruzzone et al., 2003). Reigada et al., (2009) has shown that 
ATP is released as a result of elevated pressure and pannexin hemichannels contribute 
to at least some of the ATP release. Sridharan et al., (2010) demonstrated that reduced 
oxygen tension causes ATP release from erythrocytes, which can be prevented by the 
pannexin-1 inhibitor. A recent study by Voigt et al., (2015) demonstrated that rat 
Müller cells expressed mRNAs for pannexin-1 and -2 and that glutamate induce ATP 
release from Müller cells occurs via these channels. 
After ATP release and signaling, nucleotide needs to be inactivated to adenosine. This 
is achieved by the action of various enzymes including ectonucleotide 
pyrophosphatase/phosphodiesterase 2 (ENPP2; Autotaxin), which possess ATPase 
activity to produce ADP and Pi (Goding et al., 2003; Stefan et al., 2006). In addition, 
it has an ATP pyrophosphatase activity and thus produces AMP and PPi (Clair et al., 
1997). NTPDase2 is the dominant ectonucleotidase expressed by rat astrocytes in the 
CNS and retinal Müller cells (Iandiev et al., 2007; Wink et al., 2006). In addition, 
ENPP2 expression has been found in ciliary, iris pigment, and retinal pigment 
epithelial cells (Fuss et al., 1997; Narita et al., 1994) and it is secreted by 
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oligodendrocytes (Stefan et al., 2006). ENPP2 protein with was found in human 
aqueous humour from normal eyes (Iyer et al., 2012; Tokumura et al., 2002), but it 
was found to be significantly elevated in aqueous humour from POAG patients (Iyer 
et al., 2012). Increased levels of ENPP2 were also found in the aqueous humour in an 
ocular hypertensive mice model (Wang et al., 2015). Animal studies have also shown 
that lysophospholipase D present in aqueous humour of porcine, rabbit and mouse 
(Iyer et al., 2012) and also released from healthy and injured corneal tissues and/or 
ciliary body into the aqueous humour in rabbits (Tokumura et al., 2012). Moreover, 
ENPP2 also catalyses the hydrolysis of lysophosphatidylcholine (LPC) to generate 
lysophosphatidic acid (LPA), which is referred to as lipophospholipase D activity.  
LPA acts on G protein-coupled receptors named LPA1-6 (Houben and Moolenaar, 
2011; Moolenaar, 2002). LPA receptors have been found to be expressed in astrocytes, 
microglia, and oligodendrocytes (Rao et al., 2003; Tabuchi et al., 2000; Yu et al., 
2003). LPA has been implicated in mediating cell proliferation, migration, apoptosis, 
inflammation, tumor metastasis, angiogenesis, fibrosis and secretion of matrix 
metalloproteinases (MMPs), cytokines and chemokines (Houben and Moolenaar, 
2011; Nakanaga et al., 2010; Okudaira et al., 2010). Furthermore, LPA receptors have 
been found in the trabecular meshwork and Schlemm's canal and influence the 
aqueous humour outflow and potentially IOP in enucleated porcine eyes (Mettu et al., 
2004). Therefore, expression of glutamate markers and purinergic related genes by 
Müller cells under conditions of OGD will be also investigated.   
Finally, the expression of heat shock proteins (HSPs) under hypoxic-ischemic injury 
in Müller cells will be also investigated.  HSPs are ubiquitous and highly conserved 
proteins whose expression is induced by different stressors (Garrido et al., 2001). 
They are divided into four major families according to their molecular size: HSP90, 
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HSP70, HSP60 and the small HSPs (Garrido et al., 2001). The HSP70 family 
constitutes the most conserved and best-studied class of HSPs functioning as ATP-
dependant molecular chaperones (Lee et al., 2001). They assist in the folding of 
newly synthetized polypeptides, assembly and the transport of protein across cell 
membranes (Beckmann et al., 1990; Shi and Thomas; 1992). In pathological 
conditions, HSP70 enhances the ability of injured cells to overcome the increase in 
unfolded or denatured proteins (Nollen et al., 1999).  Furthermore, HSP70 prevents 
stress-induced apoptosis by inhibition of stress-activated protein kinase SAPK/JNK 
(c-Jun N-terminal kinase) (Mosser et al., 1997) and inhibition of Bax activation, 
thereby preventing the release of proapoptotic factors from mitochondria 
(Stankiewicz et al., 2005).  
As hypoxic-ischemic insult underlies retinal neuron degeneration in glaucoma, Müller 
cells are first responders to retinal insult, therefore, it is of great interest to identify the 
survival factors expressed by the human glial cell line, MIO-M1 cells in our in vitro 
model of oxygen and glucose deprivation.  
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4.2 Results 
To investigate the effect of oxygen and/or glucose deprivation on gene expression in 
vitro, cultured MIO-M1 cells were exposed to control (5.55mMglucose/20%O2), 
hypoxia (5.55mMglucose/0-4%O2) and/or glucose deprivation (0-1.11mM/20% O2), 
for 24hrs.  
4.2.1 Effect of Oxygen and Glucose Deprivation on the Expression of Angiogenic 
Growth Factors 
4.2.1.1 Effect of Oxygen and Glucose Deprivation on the Expression of VEGF 
mRNA  
Deprivation of oxygen and glucose to the 20% oxygen-glucose level (1.11mM 
glucose/4%O2) caused no significant changes in VEGF expression at 24hrs, although 
there was an indication of a small increase as a result of low glucose (Figure 4.1). In 
full OGD, VEGF mRNA was significantly (*p≤ 0.05; n=4) increased at each time-
point (3,6,12 and 24hrs) with a 20-fold increase at the 24hrs time-point (Figure 42A). 
A significant increase in VEGF mRNA (*p≤ 0.05; n=4) was obtained when cells were   
totally deprived from oxygen at each time-point with 7-fold increase at the 24hrs 
(Figure 4.2B).  Full glucose deprivation caused significant increase by 2 fold (*p≤ 
0.05; n=4) in VEGF mRNA compared to control at 24hrs (Figure 4.2C). In full OGD, 
hypoxia and glucose deprivation, the increase in VEGF mRNA was observed as early 
as 3hrs and remained elevated over 24hrs experiment interval. In each case, VEGF 
mRNA level was highest at 12hrs. Comparing the levels of VEGF mRNA in oxygen 
deprivation versus glucose alone indicate that hypoxia was the key contributor to 
increasing levels seen in OGD; although it is notable that the absence of glucose did 
cause a significant increase in the VEGF expression.  
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Figure 4.1: Expression of VEGF mRNA in human Müller cells (MIO-M1) after 
24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.2: Expression of VEGF mRNA in human Müller cells (MIO-M1) after 
3, 6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) oxygen 
deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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4.2.1.2 Effect of Oxygen and Glucose Deprivation on the Expression of PDGF 
mRNA  
As shown in Figure 4.3, PDGF mRNA did not change with different conditions of 
oxygen (4%O2) glucose deprivation (1.11mM) or with a combination of both 
(1.11mM glucose/4%O2). Complete withdrawal of oxygen and glucose deprivation 
did not result in an increase in PDGF expression in cultured MIO-M1 cells at any of 
the time-points measured (Figure 4.4 A, B & C) although, a significant decrease was 
seen with full OGD at the 24hrs time-point. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Expression of PDGF mRNA in human Müller cells (MIO-M1) after 
24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.4: Expression of PDGF mRNA in human Müller cells (MIO-M1) after 
3, 6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) oxygen 
deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
 
3h
rs
6h
rs
12
hr
s
24
hr
s
0
50
100
150
N
o
rm
a
liz
e
d
 m
R
N
A
 E
x
p
re
s
s
io
n
 
(%
 o
f 
c
o
n
tr
o
l)
Control
OGD
*
3h
rs
6h
rs
12
hr
s
24
hr
s
0
50
100
150
N
o
rm
a
li
z
e
d
 m
R
N
A
 E
x
p
re
s
s
io
n
 
(%
 o
f 
c
o
n
tr
o
l)
Control
No glucose
(A) 
(B) 
(C) 
3h
rs
6h
rs
12
hr
s
24
hr
s
0
50
100
150
N
o
rm
a
li
z
e
d
 m
R
N
A
 E
x
p
re
s
s
io
n
 
(%
 o
f 
c
o
n
tr
o
l)
Control
Hypoxia
   
 101 
4.2.1.3 Effect of Oxygen and Glucose Deprivation on the Expression of basic 
FGF mRNA  
Similar to PDGF, bFGF mRNA proved to be unchanged after 24hrs exposure to           
(1.11mM glucose/ 4%O2), oxygen deprivation (4%O2) and glucose (1.11 mM) as 
compared control (Figure 4.5). Full OGD showed little overall change in bFGF 
mRNA expression, although there was a slight but significant reduction (*p≤ 0.05; 
n=4) in the level observed at 12hr time-point. Oxygen deprivation caused no 
significant changes. Glucose deprivation alone caused a significant 42% increase    
(*p≤ 0.05; n=4) in bFGF mRNA after 24hrs (Figure 4.6C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Expression of bFGF (FGF2) mRNA in human Müller cells (MIO-M1) 
after 24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.6: Expression of bFGF mRNA in human Müller cells (MIO-M1) after 3, 
6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) oxygen 
deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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4.2.2 Effect of Oxygen and Glucose Deprivation on the Expression of Anti-
angiogenic Growth Factors 
4.2.2.1 Effect of Oxygen and Glucose Deprivation on the Expression of PEDF 
Exposure of MIO-M1 cells to reduced level of glucose and oxygen (1.11mM/4%O2), 
hypoxia (4%O2) and 1.11 mM glucose resulted in significant down-regulation          
(*p≤ 0.05; n=4) of PEDF mRNA by 36, 15 and 26% respectively as shown in Figure 
4.7. Full OGD caused a significant reduction (*p≤ 0.05; n=4) in PEDF mRNA by 25% 
compared to control at 24hrs with no change in the expression at earlier time points 
(Figure 4.8A). Similarly, hypoxia caused a significant 20% reduction (*p≤ 0.05; n=4) 
in PEDF mRNA at 24hrs as compared to control that was proceeded by slight but 
significant (*p≤0.05; n=4) increase at 12hrs (Figure 4.8B). Complete deprivation of 
glucose resulted in no change in PEDF mRNA at any time point (Figure 4.8 C).  
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Expression of PEDF mRNA in human Müller cells (MIO-M1) after 
24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.8: Expression of PEDF mRNA in human Müller cells (MIO-M1) after 3, 
6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) oxygen 
deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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4.2.2.2 Effect of Oxygen and Glucose Deprivation on the Expression of LIF 
As shown in Figure 4.9, the expression of LIF mRNA with reduced glucose and 
oxygen level (1.11mM glucose/4%O2), hypoxia (4%O2) and 1.11mM glucose alone 
did not change significantly. Full OGD significantly (*p≤ 0.05; n=4) upregulated LIF 
mRNA peaking at 3hrs (7-fold) decreasing to 2.5- and 1.48- fold (*p≤ 0.05; n=4) at 6 
and 12hrs to reach the control level after 24hrs (Figure 4.10A). Hypoxia (0%O2) 
increased LIF mRNA with an approximate 1.7-fold increase at 12hrs only (Figure 
4.10B).  A similar pattern to full OGD was seen in glucose deprivation alone (Figure 
4.10C) with a large significant increase (6.4-fold) seen at the earliest time-point (3hrs).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Expression of LIF mRNA in human Müller cells (MIO-M1) after 
24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.10: Expression of LIF mRNA in human Müller cells (MIO-M1) after 3, 
6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) oxygen 
deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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4.2.3 Effect of Oxygen and Glucose Deprivation on the Expression of Glutamate 
Markers 
4.2.3.1 Effect of Oxygen and Glucose Deprivation on the Expression of 
Glutamine Synthetase (GLUL) 
Reduced levels of glucose (1.11mM) and/or oxygen (4%) did not result in any 
significant change in GLUL mRNA levels (Figure 4.11). Full OGD significantly       
(*p≤ 0.05; n=4) down-regulated the levels by 20% at 3hrs followed by up-regulation 
by 49% at 24hrs as compared to control (Figure 4.12A). Complete deprivation of 
oxygen resulted in significant upregulation (*p≤ 0.05; n=4) of GLUL mRNA levels at 
12 and 24hrs by 2- and 1.30- fold respectively as compared to control (Figure 4.12 B). 
No change in the expression of GLUL mRNA was found with full glucose deprivation 
alone (Figure 4.12 C). 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Expression of GLUL mRNA in human Müller cells (MIO-M1) after 
24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.12: Expression of GLUL mRNA in human Müller cells (MIO-M1) after 
3, 6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) oxygen 
deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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4.2.3.2 Effect of Oxygen and Glucose Deprivation on the Expression of the 
Glutamate-Aspartate Transporter, GLAST (SLC1A3) 
Expression of SLC1A3 mRNA in MIO-M1 cells under reduced levels of glucose and 
oxygen (1.11mM glucose/4% O2), hypoxia alone (4%O2) and 1.11mM glucose did 
not exert a significant change on SLC1A3 expression at 24hrs (Figure 4.13). 
Full OGD resulted in a significant increase in SLC1A3 expression at 12hrs by 
approximately 2-fold and continued to be strongly expressed (5-fold) at 24hrs           
(*p≤ 0.05; n=4) as compared to control (Figure 4.14A).   
Full hypoxia reduced the levels at 3hrs by 40% as compared to control. This was 
followed by significant upregulation (*p≤ 0.05; n=4) at 24hrs by 1.5-fold (Figure 
4.14B). Full glucose withdrawal significantly (*p≤ 0.05; n=4) reduced SLC1A3 
mRNA expression at 3hrs and although there was a trend of increasing levels with 
time, no significant changes were seen (Figure 4.14C). 
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Figure 4.13: Expression of SLC1A3 mRNA in human Müller cells (MIO-M1) 
after 24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.14: Expression of SLC1A3 mRNA in human Müller cells (MIO-M1) 
after 3, 6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) 
oxygen deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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4.2.3.3 Effect of Oxygen and Glucose Deprivation on the Expression of 
Glutamate Decarboxylase (GAD1) 
As shown in Figure 4.14A, reduced levels of glucose and oxygen 
(1.11mMglucose/4%O2), hypoxia (4%O2) and 1.11mM glucose did not result in 
significant changes in GAD1 mRNA expression. Full OGD significantly (*p≤0.05; 
n=4) upregulated the levels by 1.45-fold after 24hrs as compared to control (Figure 
4.14B).  
 
  
 
Figure 4.15: Expression of GAD mRNA in human Müller cells (MIO-M1) after 
24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2) and (B) control, no glucose (0mM/20% O2), 
hypoxia (5.55mM/0% O2) and full OGD. Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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4.2.4 Effect of Oxygen and Glucose Deprivation on the Expression of Purinergic 
Signaling Related Genes 
4.2.4.1 Effect of Oxygen and Glucose Deprivation on the Expression of 
Pannexin1 (PANX1) 
Reduced levels of glucose and oxygen (1.11mM glucose/4%O2) resulted in significant 
(*p≤0.05; n=4) upregulation of PANX1 by 1.5-fold as compared to control (Figure 
4.16A). Similarly, Full OGD significantly (*p≤ 0.05; n=4) upregulated the expression 
by approximately 2-fold (Figure 4.16B).  
 
 
Figure 4.16: Expression of PANX1 mRNA in human Müller cells (MIO-M1) 
after 24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2) and (B) control, no glucose (0mM/20% O2), 
hypoxia (5.55mM/0% O2) and full OGD. Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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4.2.4.2 Effect of Oxygen and Glucose Deprivation on the Expression of 
Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENNP2) 
Expression of ENNP2 mRNA did not change after 24hrs exposure to                         
1.11mM glucose/4%O2, hypoxia (4%O2), and 1.11 mM glucose (Figure 4.17).  
Exposure of MIO-M1 cells to full OGD significantly upregulated (*p≤0.05; n=4) 
ENNP2 mRNA by 1.5-fold as compared to control at 24hrs (Figure 4.18A).  
Significant upregulation (*p≤0.05; n=4) was obtained with full hypoxia at 12 and 
24hrs by 57 and 46% respectively (Figure 4.18B) while complete glucose deprivation 
significantly (*p≤0.05; n=4) upregulated ENNP2 mRNA by 57% at 24hrs compared 
to control (Figure 4.18C).  
 
 
 
 
 
 
 
 
 
Figure 4.17: Expression of ENNP2 mRNA in human Müller cells (MIO-M1) 
after 24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.18: Expression of ENNP2 mRNA in human Müller cells (MIO-M1) 
after 3, 6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) 
oxygen deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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4.2.5 Effect of Oxygen and Glucose Deprivation on the Expression of Glial 
Müller Cells Markers 
4.2.5.1 Effect of Oxygen and Glucose Deprivation on the Expression of GFAP 
Reduction of oxygen level to 4% significantly upregulated GFAP mRNA by 1.5-fold 
(*p≤ 0.05; n=4) (Figure 4.19A,B&C). No change was detected with other levels of 
oxygen and/or glucose deprivation at all time points (Figure 4.19B&C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Expression of GFAP mRNA in human Müller cells (MIO-M1) after 
24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.20: Expression of GFAP mRNA in human Müller cells (MIO-M1) after 
3, 6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) oxygen 
deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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4.2.6 Effect of Oxygen and Glucose Deprivation on the Expression of Heat-Shock 
Protein (HSPA1B) 
Exposure of MIO-M1 cells to 1.11mM glucose/4%O2, 4%O2 and 1.11mM glucose 
did not alter the expression of HSPA1B mRNA (Figure 4.21). The upregulation of 
HSPA1B mRNA with full OGD did not follow an increasing pattern over time. 
Instead, it increased at 3hrs by 7-fold (*p≤0.05; n=4) and by 11-fold at 12 and 6–fold 
24hrs respectively (*p≤ 0.05; n=4) (Figure 4.21A).  Full hypoxia did not cause any 
change in HSPA1B mRNA levels at any time intervals (Figure 4.24B) while full 
glucose deprivation significantly upregulated the expression by 5.5–fold (*p≤ 0.05; 
n=4) at 3hrs as compared to control (Figure 4.21C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Expression of HSPA1B mRNA in human Müller cells (MIO-M1) 
after 24hrs exposure to control conditions (5.55mM glucose/ 20%O2), glucose 
deprivation (1.11 mM glucose/20%O2), hypoxia (5.55mM glucose/4%O2) and 
OGD (1.11mM glucose/4%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; ANOVA).  
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Figure 4.21: Expression of HSPA1B mRNA in human Müller cells (MIO-M1) 
after 3, 6, 12 and 24 hrs exposure to (A) full OGD (0mM glucose/0%O2), (B) 
oxygen deprivation (5.55 mM glucose/0%O2) and (C) glucose deprivation (0mM 
glucose/20%O2). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4; t-test). 
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 MIO-M1 cell exposed to 24hrs to oxygen and glucose deprivation  
Full OGD 1.11mM glucose/4%O2 
Gene 
Name 
OGD Hypoxia Glucose OGD Hypoxi
a 
Glucose 
VEGF *↑ 3,6,12,24 *↑ 3,6,12,24 *↑ 24 ↑ 24 ↔ ↑ 24 
PDGF *↓24 *↓24 ↓24 ↔ ↔ ↔ 
FGF  *↓12,  
↑ 24 
*↓12,  
↑ 24 
*↑ 24 ↔ 
PEDF *↓24 *↓24 ↔ *↓24 *↓24 *↓24 
GFAP ↓24 ↓24 ↔ ↑ 24 *↑ 24 ↓24 
GS *↑ 24h *↑ 24h ↔ ↔ ↓24 ↑ 24 
SLC1A3 *↑12, 24 *↑12, 24 ↑ 6,12,24 ↑ 24 ↔ ↔ 
ENNP2 *↑ 24h *↑ 24h *↑ 24h ↔ ↔ ↔ 
LIF *↑ 3,6,12 
↓24 
*↑ 3,6,12 
↓24 
*↑ 3h ↓24 ↔ ↓24 
HSPA1B *↑3,12, 24 *↑3,12, 24 
 
*↑3hr ↔ ↔ ↔ 
GAD *↑ 24 *↑ 24 ↔ *↓24 ↓24 ↓24 
PANX-1 *↑ 24 *↑ 24 ↑ 24 *↑ 24 ↓24 ↑ 24 
 
Table 4.1: Summary of gene expression changes in MIO-M1 under oxygen 
and/or glucose deprivation for 24hrs (* indicate statistical significant change). 
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4.3 Discussion 
Müller cells are the major macroglial cells in the retina, which respond to every 
pathological condition in the eye including light-induced damage, ischemia, retinal 
detachment, glaucoma and diabetic retinopathy (Bringmann and Reichenbach, 2001; 
Bringmann et al., 2006). Müller cell responses involve the production of neurotrophic 
factors, growth factors and cytokines, which may contribute to Müller cell 
proliferation and gliosis in an attempt to protect the retinal neurons (Bringmann et al., 
2009). However, uncontrolled proliferation of Müller cells can lead to the formation 
of a gliotic scar, which is detrimental to retinal function (Bringmann et al., 2009). A 
balance between angiogenic and antiangiogenic factors in the eye is also essential to 
maintain a healthy status in the retina and pathological conditions can lead to an 
imbalance which may result in neovascularization in the retina.  In the current study, 
the expression of important regulators of angiogenesis, excitotoxicity, and stress 
indicators were studied in the MIO-M1 cell line under conditions of simulated 
ischemia.  
4.3.1 Effect of Oxygen and Glucose Deprivation on the Expression of Angiogenic 
Growth Factors 
Vascular endothelial growth factor (VEGF) is a hypoxia-inducible angiogenic growth 
factor (Neufeld et al., 1999; Shibuya, 2008).  Glial cells are the major source of 
VEGF in the retina (Pierce et al., 1995; Famiglietti et al., 2003; Kim et al., 1999). 
VEGF is also expressed by cultured MIO-M1 in vitro (Eichler et al., 2004; Holborn et 
al., 2004 a, b; Yafai et al., 2004) and studies have shown that MIO-M1 cells produce 
VEGF under normoxic conditions (Eichler et al., 2004; Yafai et al., 2004). In addition, 
hypoxia has been shown to increase VEGF production by rat Müller cells (Brook et 
al., 1998) and hypoxia (5%O2) stimulates VEGF release from cultured rat and rabbit 
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retinal explants as well as guinea pig Müller cells and rMC-1 cell lines (Eichler et al., 
2000). Furthermore, exposure of MIO-M1 cells to hypoxia (0.5%O2) for 24hrs caused 
a 5-fold increase in VEGF level (Yafai et al., 2004). This is in agreement with Eichler 
et al., (2004) who demonstrated that exposure of MIO-M1 cells and guinea pig Müller 
cells to hypoxic condition (0.5% O2) produced approximately 6- and a 25-fold 
increase in VEGF levels respectively. Results from the current research showed that 
MIO-M1 cells significantly increased the expression of VEGF mRNA when deprived 
fully of both oxygen and glucose (OGD) and hypoxia (0%O2) for 24hrs by 20- and 7-
fold respectively (Figure 4.1 & 4.2). 
Further studies looking at interactions between Müller cells and other retinal cells in 
relation to VEGF have been carried out. For example, the released VEGF by MIO-M1 
cells could be responsible for protecting the bovine retinal endothelial cells (BRECs) 
cells from apoptosis in co-culture (Yafai et al., 2004). Inhibition of VEGF expression 
in MIO-M1 cells under serum-free normoxic conditions led to an increase in the 
number of TUNEL-positive BRECs cells (Saint-Geniez et al., 2008). In a study by 
Kurihara et al., (2012) it has been found that knocking out VEGF in adult mouse RPE 
cells, caused rapid dysfunction of cone photoreceptors and led to vision loss. Indeed, 
low doses of VEGF (10ng/ml) were found to be a survival factor for isolated 
photoreceptor cells, decreasing apoptotic cell death (Saint-Geniez et al., 2008). VEGF 
may also be responsible for glial cell proliferation as reported by Schmid-Brunclik et 
al. (2008) who have shown that astrocytes proliferate in cultures deprived of both 
oxygen and glucose (OGD), and this was associated with an increase in the 
expression of HIF-1α and VEGF.  In addition, exposure of guinea pig Müller cells to 
hypoxia increased the release of VEGF, which was thought to increase proliferation 
of endothelial cells when cultured in Müller cells derived hypoxic-medium  (Eichler 
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et al., 2001). Others have reported that in normoxic glucose deficiency conditions, 
VEGF expression was upregulated in glioma cells in vitro (Shweiki et al., 1995). In a 
clonal glial cell line (C6 cells), total deprivation of glucose or oxygen for 12 hours 
resulted in 13-fold induction of VEGF mRNA as well as upregulation of the glucose 
transporter, GLUT1 (Stein et al., 1995). It has been also reported that glucose 
deprivation increased expression and stabilization of VEGF mRNA and prolong its 
half-life (Satake et al., 1998; Stein et al., 1995; Yun et al., 2005). In contrast, Brooks 
et al., (1998) reported that hypoxia increased VEGF production in rat retinal Müller 
cells after 48hrs, and it increased further by high glucose concentration. Findings by 
Eichler et al., (2004) disagree with Brooks et al., (1998) and reported that high 
glucose concentration (10-25mM) blocked the stimulatory effect of hypoxia on VEGF 
mRNA expression and protein release, both in retinal culture and Müller cell culture. 
The results presented here are in agreement with previous research showing that 
oxygen deprivation caused large increase in VEGF expression but also that full 
glucose deprivation alone significantly increased VEGF mRNA. These data suggest 
that oxygen is the main regulator of VEGF expression in MIO-M1 cells, but glucose 
also contributes to its regulation.  
Platelet-derived growth factor (PDGF) is a known mitogenic growth factor for Müller 
cells (Milenkovic et al., 2003; Yamada et al., 2000). Several studies have reported 
that Müller cells express PDGF-α and β subunits (Cox et al., 2003; Cui et al., 2009; 
Milenkovic et al., 2003; Mudhar et al., 1993; Robbins et al., 1994). An early study by 
Uchihori and Puro, (1991) indicated that PDGF has both mitogenic and chemotactic 
effects on cultured human retinal glial cells from post-mortem eyes and that the 
calcium-channel blocker, nifedipine, inhibited these effects. In addition, 
transactivation of PDGF tyrosine kinase receptor has been found to cause P2Y-
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receptor-induced mitogenic signaling in Müller cells (Milenkovic et al., 2003). Velez 
et al., (2012) has reported that MIO-M1 cells express the PDGF-α receptor, and that 
interaction between Müller cells and RPE can lead to upregulation of PDGF-α 
receptor and increased Müller cell pathogenicity in proliferative vitreoretinopathy 
(PVR).  In a study by Moon et al., (2009), PDGF (10ng/ml) induced proliferation of 
rat Müller cells and increased phosphorylation of the PDGF receptor that could be 
blocked by PDGF receptor-selective tyrosine kinase inhibitor. In addition, impairing 
the expression of PDGF-β in retinal glial cells was found effective in the reversing 
retinal gliosis during experimental ischemic retinopathy (DeNiro et al., 2011). The 
evidence that PDGF is a mitogenic factor for Müller cells is therefore strong. Results 
from this study, however, did not find any regulation of PDGF mRNA under two 
levels of oxygen and glucose deprivation in MIO-M1 cells, suggesting that the 
autocrine release of PDGF is not responsible for the proliferation seen at             
1.11mM glucose/4%O2. PDGF was, however, down regulated by OGD, which may 
have an influence survival.   
In the injured retina, Müller cells are the major source of bFGF (Morimoto et al., 
1993; Walsh et al., 2001). It has been shown to stimulate the proliferation of cultured 
Müller cells (Cao et al., 1997; Geller et al., 2001; Walsh et al., 2001). In a study by 
Holborn et al., (2004), bFGF was found to increase the proliferation of cultured 
human MIO-M1 cells, as well as increase the secretion of VEGF. In cultured glial 
cells derived from adult post-mortem retina, bFGF increases calcium currents through 
L-type voltage-gated channels and nifedipine inhibits both the calcium current and the 
bFGF-induced proliferation (Puro and Mano, 1991). Immunoreactivity of bFGF was 
remarkably high in human retinal tissue from patients with ischemic PDR and also in 
transient retinal ischemia in rats (Yafai et al., 2013). bFGF has also been found to 
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rescue photoreceptors in retinal degeneration (Cao et al., 1997; Harada et al., 2000) 
and excitotoxic insults can also stimulate of bFGF expression and release (Nakamichi 
et al., 2003).  Its release was strongly stimulated by the pro-inflammatory cytokines, 
IL-1β and TNF-α (Yafai et al., 2013; Yoshida et al., 2004) indicating its role in retinal 
neovascularization during ischemia. Current results show that                             
(1.11mM glucose/4%O2) and full OGD did not cause up-regulation of bFGF mRNA 
while complete glucose deprivation alone significantly upregulated bFGF expression. 
Hypoxic conditions (0.2%O2) have previously been found to increase the release and 
expression of bFGF mRNA from Müller cells (Yafai et al., 2013) which is in 
accordance with the present data. It has been shown that bFGF could enhance release 
of VEGF from Müller cells and vascular endothelial cells during hypoxia (Stavri et al., 
1995). Although bFGF is a well documented growth factor for Müller cells, the 
current data do not suggest that bFGF is playing a role in MIO-M1 cell proliferation 
under reduced levels of oxygen and glucose (1.11mM glucose/4%O2).  
4.3.2 Effect of Oxygen and Glucose Deprivation on the Expression of                
Anti-angiogenic Growth Factors 
PEDF is an antiangiogenic factor, regulated in a reciprocal relation to VEGF. It has 
also been reported to exert a neuroprotective effect in cultured cerebellar granule cells 
and cultured RPE cells derived from rat (Malchiodi-Albedi et al., 1998; Taniwaki et 
al., 1995). Unterlauft et al., (2012) has shown PEDF is a glia-secreted factor that 
protects cultured adult mouse RGC during hypoxic insult (0.2%O2) and found to be 
neuroprotective against glutamate-induced toxicity in the CNS, mediating its 
protective effect through restoring calcium homeostasis and blocking the activation of 
NMDA receptors (Taniwaki et al., 1997). In addition, Cao et al., (1999) found that 
PEDF protects retinal neurons against H2O2-induced cell death in a dose-dependent 
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manner.  A balance in VEGF/PEDF ratio was found to be important in decreasing 
retinal oedema following ischemia/reperfusion injury (Tong et al., 2013) and to 
prevent retinal neovascularization (Eichler et al., 2004 a, b). It has also been reported 
that hypoxia and ischemia are associated with upregulation of VEGF mRNA and 
down regulation of PEDF mRNA in MIO-M1 cells (Eichler et al., 2004 a, b). This is 
in agreement with current data, which indicate that exposure of MIO-M1 cells to two 
levels of hypoxia (0 and 4%O2) as well as low glucose levels (1.11mM) for 24hrs 
significantly down-regulated PEDF mRNA expression (Figure 4.7 and 4.8A,B).               
In agreement with current results, findings by Eichler et al., (2004) also demonstrated 
that MIO-M1 cells produce and secrete PEDF, and hypoxia was associated with 
down-regulation of PEDF mRNA. Increasing the severity of hypoxia (0.5-5% O2) 
resulted in more down-regulation of PEDF release. These data suggest that MIO-M1 
cell proliferation could be increased under the examined conditions, by the reduction 
in the PEDF, which then allows increased activity of the secreted VEGF.  
Another inhibitor of angiogenesis is the Leukemia inhibitory factor (LIF), a member 
of the IL-6 family of cytokines, which has neuroprotective properties in the CNS 
promoting neuronal survival, neurogenesis and regeneration (Azari et al. 2006; Covey 
and Levison 2007; Heinrich et al., 2003; Ishibashi et al. 2009).  Current result shows 
that LIF expression increased as early as 3hrs in MIO-M1 cells treated with full OGD 
and full glucose deprivation and decreased over time to reach control level by 24hrs, 
which indicates a reverse pattern to that showed for VEGF expression. Interestingly, 
hypoxia led to an increase in expression with time, which was similar to VEGF 
expression. In primary cultures of astrocyte from rats, exposed to OGD (glucose-free 
culture medium subjected to 6hrs of hypoxia, 1%O2) treated with low dose of LIF 
inhibited astrocyte proliferation induced by OGD. The mechanism of the inhibitory 
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effect of LIF was attributed to down-regulation of HIF-1α and VEGF mRNA (Fan et 
al., 2013). Kubota et al., (2008) has also shown that LIF inhibited hypoxia-induced 
VEGF expression and proliferation in cultured astrocytes.  
4.3.3 Effect of Oxygen and Glucose Deprivation on the Expression of Glutamate 
Markers  
Glutamate clearance by Müller cells is mediated by the uptake and degradation by 
GLAST and GS respectively (Derouiche and Rauen, 1995). An increase in 
extracellular glutamate upregulates the expression of GLAST in Müller cells and has 
been found to protect retinal neurons from glutamate toxicity (Imasawa et al., 2005; 
Taylor et al., 2003). It was, therefore, interesting to look at the expression of GLAST 
in MIO-M1 cells under conditions of oxygen and/or glucose deprivation. The human 
Müller cell line (MIO-M1) used in this study has previously been shown to express 
GLAST (SLC1A3) (Hollborn et al., 2011). In the current experiments, MIO-M1 cells 
exposed to 24hrs-simulated ischemia caused a significant 5-fold increase of GLAST 
in full OGD. In agreement with the current results, in vivo retinal ischemia for 48hrs 
in rats caused a marked increase in GLAST mRNA in the INL with more than 90% of 
cells expressing GFAP, suggesting that Müller cells play a major role in the 
regulation of glutamate under ischemic conditions (Otori et al., 1994). This may 
contribute to the protection of ganglion cells when co-cultured with Müller cells, 
which were protected from glutamate toxicity and hypoxia damage (Kitano et al., 
1996).  Current results also showed that hypoxia (0%O2) caused significant up-
regulation of GLAST in cultured MIO-M1 cells and 4% oxygen did not significantly 
alter GLAST expression. This is in agreement with Imasawa et al., (2005) study who 
reported that exposure of cultured rat retinal glial cells to hypoxia (5%O2) did not 
alter GLAST expression. To the contrary, more severe hypoxic conditions 2.5 and 1% 
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O2 exposure for 24hrs, caused a significant reduction in GLAST protein and mRNA 
expression in astrocytes (Dallas et al., 2007), full hypoxia, however was not studied. 
Both hypoxia and glutamate treatment have been found to reduce the survival rate of 
cultured rat RGCs in vitro (Kitano et al., 1996). Damage from these stressors was 
reduced after treatment with a glutamate blocker and co-culture with cortical 
astrocytes and retina-derived Müller cells. These results suggest that glutamate is 
increased in hypoxic conditions, and that glial cells are playing a major role in retinal 
detoxification of glutamate (Kitano et al., 1996). In addition, Toft-Kehler et al., (2014) 
reported increased GLAST protein and mRNA expression following glucose 
deprivation for one hour in MIO-M1 cells. The results presented here did not show 
significant up-regulation of GLAST but increasing trend was seen with time in MIO-
M1 cells.   
Glutamine synthetase (GS) is the key glutamate-metabolizing enzyme expressed by 
Müller cells that convert glutamate to the non-excitotoxic amino acid glutamine 
(Riepe and Norenburg, 1977). The released glutamine is taken up by neurons where it 
is hydrolyzed by glutaminase to form glutamate again to be used in neurotransmission 
(Thoreson and Witkovsky, 1999). MIO-M1 cells express glial glutamine synthase 
(GLUL) as indicated by RT-PCR, protein and immunohistochemistry analysis 
(Holborn et al., 2011). Results from this study showed that MIO-M1 cells cultured in 
full OGD conditions significantly upregulated GLUL mRNA. Similarly, full oxygen 
deprivation alone significantly increased GLUL expression at 12 and 24hrs. Glucose 
deprivation (0mM) failed to regulate GLUL levels indicating that the increased levels 
seen in OGD are originating from the effect of oxygen rather than glucose. No 
expression change was found at lower levels of deprivation. It has been proposed that 
the function of GS is impaired in ischemia due to lack of intracellular ATP (Oliver et 
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al., 1990). In astrocytes cultured in glucose-deprived condition, the specific activity of 
GS decreased, and enzyme turnover increased (Rosier et al., 1996). In addition, in 
primary cultured cortical astrocytes exposed to OGD for 6 hours, decreased GS 
expression and increased the extracellular glutamate level were detected (Wang et al., 
2013). Interestingly, there was a reduction in expression in full OGD at 3hrs, but after 
this time there was an increase in GS expression, which would contribute towards 
detoxification of glutamate.  
Glutamate can be also converted to GABA by glutamic acid decarboxylase (GAD), 
and then GABA is converted to succinate semialdehyde by GABA transaminase 
(GABA-T) activity (Kobayashi et al., 1999). Although GAD has been reported to 
exist in cultured Müller cells (Kubrusly et al., 2005), other studies indicated that GAD 
is expressed in the neuronal retina, but not in Müller cells (Agardh et al., 1987; 
Nishimura et al., 1983). Expression of GAD mRNA under full OGD was significantly 
upregulated indicating that these cells express the enzyme and that it can be regulated 
by ischemia. No similar data has been found in other studies about the regulation of 
GAD expression under these conditions in the retina and this is the first study 
examining the effect of oxygen and/or glucose on the expression of GAD in MIO-M1 
cells. 
 4.3.4 Effect of Oxygen and Glucose Deprivation on the Expression of Purinergic 
Signaling Molecules 
Pannexin1, encoded by the PANX1 gene, is a mammalian hemichannel expressed in 
the brain and the ocular tissues (Kurtenbach et al., 2014). It is activated by changes in 
membrane potential, ATP, an increase in intracellular calcium, glutamate, reduced 
oxygen, ischemia and following purinergic receptor activation (Kurtenbach et al., 
2014) which mediates release of ATP from the cell, increasing extracellular ATP 
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concentration and stimulating purinergic signaling and possibly excitotoxicity 
(Kurtenbach et al., 2014).  
Several studies have suggested that activation of purinergic signaling is involved in 
the proliferation of Müller cells. Human Müller cells isolated from donor retinas and 
activated by external ATP evoked the release of intracellular Ca2+ and increased 
density of P2X7 receptor channels. This resulted in subsequent activation of big 
conductance K+ channels (IBK), which may contribute to the induction of proliferative 
activity in gliotic Müller cells during PVR (Bringmann et al., 2001). Similar findings 
were reported by Francke et al., (2002) who suggested that ATP evoked Ca2+ 
responses might support the proliferation of Müller cells during PVR in rabbit retina. 
Furthermore, extracellular ATP has been found to evoke the release of mitogenic 
growth factor, PDGF from Müller cells (Milenkovic et al., 2003). The current results 
show that exposure of MIO-M1 cells to full OGD and reduced levels 1.11mM 
glucose/4%O2 significantly upregulated PANX1 mRNA after 24hrs. Dvoriantchikova 
et al., (2012) found that PANX1 deficiency protects RGCs from death induced by 
OGD in Panx1−/− mice thought to be mediated by inhibiting caspase-1 and the 
production of interleukin-1β as well as suppressing permeation of RGC plasma 
membranes (Dvoriantchikova et al., 2012). In addition, purinergic receptor-mediated 
Ca2+ responses in activated retinal glial cells have also been found in retinal 
detachment and retinopathy model in rabbits (Francke et al., 2003; Francke et al., 
2005; Uckermann et al., 2003; Uhlmann et al., 2003). On the other hand, Newman 
(2003) demonstrated that activated glial cells might protect neurons in the retina by 
releasing ATP that is converted to adenosine and subsequently activating neuronal 
adenosine receptors. Similar findings were reported in vivo experiments by Hu et al., 
(2010) implicating that a balance between extracellular ATP and its protective 
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metabolite adenosine is essential to the survival of RGCs. In the current study, the 
expression of PANX1 mRNA increased in ischemia suggesting that ATP may be 
released from MIO-M1 cells during through pannexin hemichannels but more 
experiments are needed to prove the ATP release and its role in MIO-M1 cell 
proliferation.  
Autotaxin encoded by the gene ENNP2, possess lysophospholipase D activity as well 
as ATPase-like activity, converting lysophospholipids such as 
lysophosphatidylcholine to lysophosphatidic acid (LPA) (Clair et al., 1997; Tokumura 
et al., 2002). Results from the current study show that full OGD, hypoxia and glucose 
deprivation significantly increased ENNP2 mRNA expression indicating that 
activation of this enzyme is taking place in MIO-M1 cells in response to stressors. 
This would facilitate degradation of ATP to ADP, which may indicate that ATP 
release is a significant event in ischemia.  Under normal culture condition, human 
ARPE-19 were shown to express ENNP1-3 mRNA and were able to degrade externally 
added ATP while ecto-ATPase inhibitors blocked ATP degradation (Reigada et al., 
2005). More experiments are needed to investigate the ATP release from MIO-M1 
cells and the involvement of LPA-mediated effect in survival and proliferation.  
4.3.5 Effect of Oxygen and Glucose Deprivation on the Expression of Glial Cell 
Markers 
GFAP is widely used as a stress marker expressed by reactive retinal glia in several 
pathological conditions in the retina. These include retinal ischemia (Kim et al., 1998), 
age-related macular degeneration (Diloreto et al. 1995), oxygen-induced retinopathy 
(Prentice et al., 2011; Smith et al., 1994), and diabetic retinopathy (Lieth et al. 1998).  
Hypoxia has been reported to cause upregulation of GFAP mRNA and protein as 
early as 3hrs (Kaur et al., 2007). MIO-M1 cells transfected with a GFAP promoter 
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and exposed to 40hrs hypoxia (1%O2) resulted in a 16-fold induction of luciferase 
activity (Prentice et al., 2011) and cultured rat Müller cells showed 3-fold increases in 
GFAP mRNA after 72hrs of hypoxia (Tan et al., 2015). The results reported here 
indicate that human MIO-M1 cells showed no evidence of GFAP regulation in full 
OGD, hypoxia (0%O2) or full glucose deprivation. However, oxygen deprivation to 
4%O2 showed a significant increase in GFAP mRNA at 24hrs as compared to control. 
Studies suggest that neuronal loss does not appear to be a prerequisite for GFAP 
induction (Fitzgerald et al., 1990; Osborne et al., 1991). Interestingly, it has been 
found that GFAP mRNA is transcribed for a limited time, and the gene is 
subsequently turned off (Sarthy and Egal, 1995). This could explain why GFAP 
expression did not change with full OGD.  
4.3.6 Effect of Oxygen and Glucose Deprivation on the Expression of Heat-shock 
Protein HSPA1B (HSP70) 
Heat-shock proteins are highly conserved proteins expressed in response to various 
insults to increase cell survival (Parcellier et al., 2003). Findings by Papadopoulos et 
al., (1996) showed that expression of HSP-70 enhances the survival of astrocytes 
challenged with heat or oxygen-glucose deprivation. Similarly, in primary culture of 
astrocytes pre-treated with heat followed by exposure to full OGD for 6 hours and 
reperfused with glucose at a concentration of 5.5 mmol/L at normoxia for 24hrs 
resulted in over-expression of HSP70. This expression protected against OGD by 
interrupting phosphorylation of the inhibitor of IκB, c-Jun N-terminal kinases (JNK) 
and p38 (Kim et al. 2015). Culture of rat retinal ganglion cells and Müller cells 
exposed to hyperthermia (42ºC) followed by hypoxia (9% oxygen) for 6 hrs or a sub-
lethal dose of glutamate showed detectable level of HSP72 in control retinal cultures 
and significant increase was found in culture pre-treated with heat shock as evidence 
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by immunoreactivity (Caprioli et al., 1996).  The survival rate of cells pre-treated with 
heat was significantly greater compared to cells that had no pre-treatment. This 
protection was abolished with inhibition of heat shock protein synthesis (Caprioli et 
al., 1996). The expression of the human inducible HSP70 in astrocytes protected them 
from glucose deprivation and oxidative stress with a well-preserved level of 
glutathione (Xu and Giffard, 1997). In the current experiments, exposure of cultured 
MIO-M1 cells to full OGD increased the expression of HSPA1B mRNA as early as 
3hrs and continued to be raised over the 24hrs of the experiment. Oxygen deprivation, 
however, did not alter in HSPA1B expression, whilst glucose deprivation caused a 
large increase in expression, but only at the early time point (3hrs). Overall. it does 
appear that ischemia insult increases HSPA1B expression in MIO-M1 cells and this 
may be part of the mechanism that protect the cells from ischemic damage.  
In conclusion, current experiments were conducted in an attempt to understand 
mechanisms that may be involved in the survival and proliferative state of MIO-M1 
cells under conditions of simulated ischemia.  More prominent changes in gene 
expression were found with complete deprivation of both oxygen and glucose rather 
than at the reduced levels (1.11mM glucose/4%O2). In the next chapter it will be 
investigated whether such changes occur in the intact human retina, using human 
organotypic retinal culture (HORCs). Survival of RGCs under these conditions will 
also be investigated.  
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Chapter 5 
Effects of Oxygen and Glucose Deprivation on the Survival and Gene 
Expression in Human Organotypic Retinal Cultures (HORCs) 
5.1 Introduction 
As previously discussed vascular dysregulation induced-reduction in blood flow is 
one proposed mechanism of retinal ganglion cell (RGC) loss, which occurs in 
glaucoma (Arnold, 1995; Harju and Vesti, 2001; Michelson et al., 1996; Michelson et 
al., 1998; Schwartz et al., 1977; Schwartz, 1994; Sugiyama et al., 2000; Tanaka, 1995; 
Yamazaki et al., 1996). Ischemic insult deprives the cells of oxygen and vital 
nutrients such as glucose and decreases waste removal.  This deprivation will disturb 
tissue homeostasis and eventually leads to injury and death (Osborne et al., 2004). 
Retinal cells depend on glucose as a source of energy, and retinal Müller cells are the 
primary users, converting glucose into monocarboxylic acids, lactate, and pyruvate 
that are supplied to neurons and photoreceptors to meet their energy requirements 
(Poitry-Yamate, and Tsacopoulos; 1992; Poitry-Yamate et al., 1995).  Deprivation of 
both oxygen and glucose deprives the retinal neurons of energy and induces 
deleterious effects on the tissue including ion and neurotransmitter disturbances, 
excitotoxicity, and angiogenesis (Osborn et al., 2004). For example, during retinal 
ischemia there is an accumulation of extracellular glutamate, which plays a role in 
excitotoxic neuronal death (Barnett et al., 2001; Boris-Moller and Wieloch, 1998).   
The mechanism of glutamate release has been attributed to ischemia-induced 
depolarization and activation of voltage-dependent Ca2+ channels resulting in the 
exocytotic release of glutamate (Wahl et al., 1994). Also, Nishizawa, (2001) has 
suggested that in ischemia-induced energy failure, the glutamate release can also be 
independent of Ca2+ ions mediated by the glutamate transporter working in a reverse 
direction due to the imbalance of sodium ions across the neuronal membrane. As 
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discussed previously, glutamate is taken up by glial by glutamate transporters, and 
detoxified by glutamine synthetase and the activity of each these may increase to 
enhance the clearance of extracellular glutamate (Shaked et al., 2002). In addition, 
ATP-mediated excitotoxicity and overstimulation of purinergic P2X7 receptors has 
been shown to increase RGC death during retinal ischemia in mechanisms similar to 
these occurring with glutamate toxicity (Niyadurupola et al., 2013). Ischemia-induced 
angiogenesis is a complex process characterized by vasodilation, increased vascular 
permeability and proliferation of endothelial cells (Witmer et al., 2003).  
Angiogenesis is controlled by growth factors such as VEGF and bFGF.   
Furthermore, PDGF is responsible for recruitment of pericytes and smooth muscle 
cells for the developing vessels (Mignatti and Rifkin, 1996). With decreased blood 
supply, angiogenesis is a specific homeostasis response. However, upregulation of 
growth factors may also be part of the cytoprotective response (Bouck, 2002; Witmer 
et al., 2003). In the present experiments, human organotypic retinal cultures (HORCs) 
were used to assess the loss of RGCs as a result of simulated ischemic insult in vitro. 
This model was developed by Niyadurupola et al., (2010) and is a tool to investigate 
RGC loss in the human retina. The explants were taken from macular, para-macular 
and peripheral regions and assessed for the distribution of retinal RGCs using THY-1 
mRNA and counting RGCs using immunohistochemistry with another RGC marker, 
NeuN. The distribution of these markers was consistent with the proposed allocation 
of RGCs in the retina indicating that explants can be used to compare the loss of 
RGCs as a result of various insults. Furthermore, there were equivalent numbers of 
RGCs in the paramacular explants. Exposure of HORCs to glutamate or simulated 
ischemia (OGD) caused a reduction in both THY-1 mRNA and the numbers of NeuN-
labelled neurons (Niyadurupola et al., 2010).  In this chapter, the effects of two levels 
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of OGD were investigated in vitro using HORCs to determine the survival of RGCs. 
Expression of angiogenic and antiangiogenic growth factors, excitotoxicity related 
genes and glial cell markers were also assessed.  
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5.2 Results 
5.2.1 Effect of Graded Levels of Glucose Deprivation on the LDH Release and 
RGCs Death in HORCs  
HORCs were incubated in glucose-deprived medium, ranging from 0-4.99mM under 
normoxic condition for 24hrs and LDH was measured from medium to assess overall 
of cell viability. The control condition was the physiological glucose level of 5.55mM 
and levels ranged from 10% deprivation to complete absence of glucose. Figure 5.1 
shows glucose-dependent survival in HORCs, in which there was gradual increase in 
LDH release as the deprivation level increased. Significant levels of LDH release 
(2.5-fold) were found when the deprivation level reached 80% (1.11 mM). Maximum 
LDH release was seen with full glucose deprivation (3.67-fold).    
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Effect of graded levels of glucose deprivation on LDH release from 
HORCs in medium after 24hrs (*p≤0.05; n=4. ANOVA) 
 
5.
55
4.
99
5
4.
44
3.
85
3.
33
2.
77
5
2.
22
1.
66
5
1.
11
0.
55
5
N
o 
gl
uc
os
e
0
100
200
300
400
500
Glucose concentration mmol/L
L
D
H
 R
e
le
a
s
e
(%
 o
f 
C
o
n
tr
o
l)
*
*
*
C
o
n
tr
o
l
   
 138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Representative immunofluorescence photomicrographs showing NeuN 
and TUNEL-labelling in HORCs with control and 20-60% glucose deprivation (4.44-
2.22 mM). DAPI = blue, NeuN = red, TUNEL = green.  
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Figure 5.3: Effect of glucose deprivation on RGC death (A) Average number of 
NeuN-labelled cells from three intact 200μm from 8 sections per sample expressed as 
percentage of control and (B) Percentage of TUNEL-positive ganglion cells exposed 
for 24hr to glucose deprivation (0-555 mM) (*p≤0.05; n=4, ANOVA).  
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the mean numbers of NeuN-labelled was detected when the glucose deprivation was 
80% of the control (1.11 mM) and full glucose deprivation (0mM) respectively.  The 
number of NeuN-labelled neurons did not change in lower glucose levels (2.22-
4.44mM) (Figure 5.3A). The percentage of TUNEL-positive RGCs was 
approximately 80% to 90% in HORCs exposed to 1.11mM and full glucose 
deprivation respectively (Figure 5.3B).   
5.2.2 Effect of Oxygen Glucose Deprivation (OGD) on the LDH Release and 
RGCs Death in HORCs 
Full deprivation of oxygen and glucose (OGD) and glucose deprivation alone resulted 
in significant 3- and 4-fold increases (*p≤0.05; n=4) in LDH release respectively 
compared to control (Figure 5.4). Although, oxygen deprivation alone for 24hrs did 
not cause LDH release there was an additive effect when both oxygen and glucose 
were deprived together.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Effect of full glucose, oxygen deprivation and both (OGD) on LDH 
release from   HORCs after 24hrs (*p≤0.05; n=4, ANOVA).  
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Figure 5.5: Representative immunofluorescence photomicrographs showing TUNEL-
labelling in HORCs with control (5.55 mM glucose), glucose deprivation (0mM), 
oxygen deprivation (0%O2), and full OGD. DAPI= blue, NeuN= red, TUNEL=green. 
GCL= ganglion cell layer, INL= inner nuclear layer, ONL= outer nuclear layer 
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decreased after exposure to glucose deprivation (0 mM) and full OGD (0mM/0%O2) 
(*p≤0.05; n=4) (Figure 5.5B). Oxygen deprivation showed similar number of NeuN-
labelled RGCs to control with no apoptotic nuclei.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Effect of OGD on RGC death (A) Average number of NeuN-labelled 
cells from three intact 200μm from 8 sections per sample expressed as percentage of 
control and (B) Percentage of TUNEL-positive ganglion cells exposed for 24hr to 
control, full hypoxia, full glucose deprivation and full OGD (*p≤0.05; n=4, ANOVA).  
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5.2.3 Effect of Reduced Glucose and Oxygen Levels (1.11mM/4%O2) on the LDH 
Release and RGCs Death in HORCs 
In another set of experiments, HORCs were incubated in reduced levels of oxygen 
and/or glucose to 80% of the control level. In other words, oxygen was reduced to 4%, 
while glucose was reduced to 1.11mM. Results show that exposure of HORCs to 
reduced levels of glucose and oxygen (1.11mM glucose/4%O2) and 1.11mM glucose 
resulted in a significant increase in the released LDH by 1.6- and 1.7-fold respectively 
(*p≤0.05; n=4) as compared to control. Oxygen deprivation alone (4%O2) did not 
result in detectable LDH release (Figure 5.7).  
 
 
 
 
 
 
 
Figure 5.7: Effect of (A) control (5.55 mM glucose/20%O2), 1.11 mM glucose,            
4% oxygen and both (1.11mM glucose/4%O2) on LDH release from HORCs after 
24hrs (*p≤0.05; n=4, ANOVA).   
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Figure 5.8: Representative immunofluorescence photomicrographs showing TUNEL-
labelling in HORCs with control (5.55mMglucose/20%O2), hypoxia (4%), glucose 
deprivation (1.11 mM) and 20% OG (1.11 mM glucose/4% O2) for 24hrs. DAPI= 
blue, NeuN= red, TUNEL=green. GCL= ganglion cell layer, INL= inner nuclear layer, 
ONL= outer nuclear layer 
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Figure 5.9: Effect of 1.11mM glucose/4%O2 on RGC death (A) Average number of 
NeuN-labelled cells from three intact 200μm from 8 sections per sample expressed as 
percentage of control and (B) Percentage of TUNEL-positive ganglion cells exposed 
for 24hr to control (5.55mMglucose/20%O2), glucose deprivation (1.11mM), hypoxia 
(4%O2) and both (*p≤0.05; n=4, ANOVA).  
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The survival of RGCs under 1.11 mM glucose, 4% oxygen and a combination of both 
was investigated (Figure 5.8). Validation of RGC loss by immunohistochemistry 
showed that the mean numbers of NeuN-labelled neurones in the retinal ganglion cell 
layer were significantly decreased after 24hrs of glucose deprivation (1.11 mM) and 
20% OG (1.11 mM glucose/4%O2) compared with control (*p≤0.05; n=4) (Figure 
5.9A).  A significant 3.5- and 3- fold increase (*p≤0.05; n=4) in the TUNEL-positive 
neurons in glucose-deprived and oxygen and glucose deprived HORCs respectively 
were detected (Figure 5.9B).  This was associated with TUNEL-positive nuclei found 
in the INL and ONL in addition to the RGC layer (Figure 5.8). 
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5.2.4 Effect of Oxygen and Glucose Deprivation on the Expression of Angiogenic 
Factors in HORCs 
5.2.4.1 Effect of Oxygen and Glucose Deprivation on the Expression of VEGF 
mRNA  
Expression of VEGF mRNA was significantly increased under full OGD by 2.5-fold 
(*p≤0.05; n=4) compared to control (Figure 5.10A).  To determine whether this 
expression is oxygen or glucose dependent, VEGF mRNA was also determine under 
each nutrient deprivation alone. Exposure of HORCs to hypoxia (0%O2) caused a 
significant (*p≤0.05; n=4) 2.59-fold increase the expression as compared to control, 
while full glucose deprivation (0mM) did not result in significant alteration in the 
expression. Changes seen under reduced levels of oxygen and/or glucose were not 
significant (Figure 5.10B) 
 5.2.4.2 Effect of Oxygen and Glucose Deprivation on the Expression of PDGF 
mRNA  
Expression levels in HORCs were found to be upregulated significantly in full 
deprivation. Full OGD resulted in 2.6 fold up-regulation of PDGF mRNA expression 
compared to control (Figure 5.11A). Full oxygen deprivation alone caused 2-fold up-
regulation in the PDGF mRNA expression (*p≤0.05; n=4). Glucose deprivation alone 
has less effect on the expression of PDGF compared to oxygen. Under reduced levels 
of oxygen and/or glucose, no significant changes were found (Figure 5.11B) 
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Figure 5.10:  Expression of VEGF mRNA in HORCs after 24hrs exposure to: (A) 
full glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA) 
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Figure 5.11:  Expression of PDGF mRNA in HORCs after 24hrs exposure to: (A) full 
glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA) 
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5.2.4.3 Effect of Oxygen and Glucose Deprivation on the Expression of bFGF 
mRNA  
Exposure of HORCs to 1.11mM glucose caused a significant down-regulated bFGF 
mRNA expression by approximately 50% compared to control (Figure 5.12B). The 
changes seen under other deprivation conditions were not statistically significant.    
5.2.5 Effect of Oxygen and Glucose Deprivation on the Expression of                
Anti-angiogenic Factors 
5.2.5.1 Effect of Oxygen and Glucose Deprivation on the Expression of PEDF 
The expression of PEDF mRNA levels did not change at any level of oxygen and 
glucose deprivation (Figure 5.13A, B).  
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Figure 5.12:  Expression of bFGF mRNA in HORCs after 24hrs exposure to: (A) full 
glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA). 
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Figure 5.13:  Expression of PEDF mRNA in HORCs after 24hrs exposure to: (A) full 
glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA). 
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5.2.5.2 Effect of Oxygen and Glucose Deprivation on the Expression of LIF 
Full OGD and glucose deprivation resulted in a significant reduction in LIF mRNA to 
approximately 16 and 36% of control (Figure 5.14A). Although reduced levels of 
oxygen and/or glucose to 20% (1.11mM glucose/4%O2) showed a similar reduction 
pattern in expression of LIF, it was statistically non-significant (Figure 5.14B).  
5.2.6 Effect of Oxygen and Glucose Deprivation on the Expression of Glutamate 
Markers 
5.2.6.1 Effect of Oxygen and Glucose Deprivation on the Expression of 
Glutamine Synthetase (GLUL) 
Exposure of HORCs to full glucose deprivation significantly (*p≤0.05; n=4) 
increased GLUL mRNA by approximately 3-fold compared to control. Full hypoxia 
and OGD did not result in any significant regulation (Figure 5.15A).  A similar 
pattern of expression was found with reduced levels of 1.11mM glucose, 4% oxygen 
and both (1.11mM glucose/4%O2) but was statistically non-significant (Figure 5.15B).  
5.2.6.2 Effect of Oxygen and Glucose Deprivation on the Expression of the 
Glutamate-Aspartate Transporter, GLAST (SLC1A3) 
The expression of glutamate transporter, GLAST in HORCs was not significantly 
altered under any of the treatments (Figure 5.16A,B). Although a trend towards an 
increased expression in glucose deprivation and OGD was evident.  
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Figure 5.14:  Expression of LIF mRNA in HORCs after 24hrs exposure to: (A) full 
glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA) 
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Figure 5.15:  Expression of GS (GLUL) mRNA in HORCs after 24hrs exposure to: 
(A) full glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM 
glucose/0%O2) and full OGD (0mM glucose/0%O2) and (B) glucose deprivation 
(1.11mM glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both 
oxygen and glucose (1.11mMglucose/4%O2), All conditions were compared to 
control (5.55mM/20%O2). Gene expression was normalized to the housekeeping 
genes TOP1 and CYC1 (n=4; *p≤0.05; ANOVA) 
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Figure 5.16:  Expression of SLC1A3 mRNA in HORCs after 24hrs exposure to: (A) 
full glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA). 
 
C
on
tr
ol
 (5
.5
5m
M
 / 
20
%
)
1.
11
m
M
 g
lu
co
se
4%
O
xy
ge
n
1.
11
 m
M
/4
%
 
0
50
100
150
200
N
o
rm
a
liz
e
d
 m
R
N
A
 E
x
p
re
s
s
io
n
 
(%
 o
f 
c
o
n
tr
o
l)
C
on
tr
ol
 (5
.5
5m
M
 / 
20
%
)
(-
) g
lu
co
se
H
yp
ox
ia
Fu
ll 
O
G
D
0
100
200
300
N
o
rm
a
liz
e
d
 m
R
N
A
 E
x
p
re
s
s
io
n
 
(%
 o
f 
c
o
n
tr
o
l)
(A) 
(B) 
   
 157 
5.2.6.3 Effect of Oxygen and Glucose Deprivation on the Expression of 
Glutamate Decarboxylase (GAD1) 
Exposure of HORCs to full OGD caused a significant 2-fold upregulation (*p≤0.05; 
n=4) in GAD1 mRNA. Full glucose deprivation and hypoxia (0%O2) did not alter the 
levels significantly (Figure 5.17A). Lower deprivation conditions showed a similar 
pattern to full deprivation, but the levels were not significant (Figure 5.17B).  
5.2.7 Effect of Oxygen and Glucose Deprivation on the Expression of Purinergic 
Signaling Related Genes 
5.2.7.1 Effect of Oxygen and Glucose Deprivation on the Expression of 
Pannexin1 (PANX1)  
No significant changes were seen in expression of PANX1 mRNA under any of the 
conditions investigated. Although a trend towards an increase in full OGD and 
glucose deprivation was apparent (Figure 5.18).  
5.2.7.2 Effect of Oxygen and Glucose Deprivation on the Expression of Autotaxin 
(ENNP2) 
Expressions of ENNP2 mRNA did not significantly change under any of the 
conditions investigated (Figure 5.19).  
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Figure 5.17:  Expression of GAD mRNA in HORCs after 24hrs exposure to: (A) full 
glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA). 
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Figure 5.18:  Expression of PANX1 mRNA in HORCs after 24hrs exposure to: (A) 
full glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA). 
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Figure 5.19:  Expression of ENNP2 mRNA in HORCs after 24hrs exposure to: (A) 
full glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA). 
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5.2.8 Effect of Oxygen and Glucose Deprivation on the Expression of Glial 
Müller Cells Markers 
5.2.8.1 Effect of Oxygen and Glucose Deprivation on the Expression of GFAP 
No significant changes to the levels of GFAP mRNA levels were seen under the 
conditions of these experiments (Figure 5.20 A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20:  Expression of GFAP mRNA in HORCs after 24hrs exposure to: in 
HORCs after 24hrs exposure to: (A) full glucose deprivation (0mM glucose/20%O2), 
full hypoxia (5.55mM glucose/0%O2) and full OGD (0mM glucose/0%O2) and (B) 
glucose deprivation (1.11mM glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and 
deprivation of both oxygen and glucose (1.11mMglucose/4%O2), All conditions were 
compared to control (5.55mM/20%O2). Gene expression was normalized to the 
housekeeping genes TOP1 and CYC1 (n=4; *p≤0.05; ANOVA). 
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5.2.9 Effect of Oxygen and Glucose Deprivation on the Expression of Heat-Shock 
Protein (HSPA1B) 
No significant changes to the levels of heat-Shock Protein (HSPA1B) were found at 
any level of oxygen and/or glucose deprivation (Figure 5.24A,B). Although a trend 
towards an increase in low glucose and OGD was apparent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21:  Expression of HSPA1B mRNA in HORCs after 24hrs exposure to: (A) 
full glucose deprivation (0mM glucose/20%O2), full hypoxia (5.55mM glucose/0%O2) 
and full OGD (0mM glucose/0%O2) and (B) glucose deprivation (1.11mM 
glucose/20%O2), hypoxia (5.55mMglucose/4%O2) and deprivation of both oxygen 
and glucose (1.11mMglucose/4%O2), All conditions were compared to control 
(5.55mM/20%O2). Gene expression was normalized to the housekeeping genes TOP1 
and CYC1 (n=4; *p≤0.05; ANOVA). 
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 HORCs exposed to 24hrs to oxygen and glucose deprivation  
 Full OGD 1.11mM glucose/4%O2 
Gene OGD Hypoxia Glucose OGD Hypoxia Glucose 
VEGF *↑ 24 *↑ 24 ↑ 24 ↑ 24 ↑ 24 ↑ 24 
PDGF *↑ 24 *↑ 24 ↑ 24 ↑ 24 ↑ 24 ↑ 24 
FGF  ↔ ↑ 24 ↔ *↓24 ↔ ↔ 
PEDF ↑ 24 ↔ ↔ ↔ ↔ ↔ 
GFAP ↑ 24 ↑ 24 ↑ 24 ↑ 24 ↔ ↑ 24 
GS ↑ 24 ↑ 24 *↑ 24 ↑ 24 ↔ ↑ 24 
SLC1A3 ↑ 24 ↔ ↑ 24 ↔ ↔ ↔ 
Autotaxin ↑ 24 ↑ 24 ↑ 24 ↑ 24 ↔ ↔ 
LIF *↓24 ↓24 *↓24 ↓24 ↓24 ↓24 
Heat shock ↑ 24 ↑ 24 ↑ 24 ↑ 24 ↑ 24 ↑ 24 
GAD *↑ 24 ↓24 ↑ 24 ↑ 24 ↔ ↑ 24 
PANX-1 ↑ 24 ↓24 ↑ 24 ↑ 24 ↓24 ↑ 24 
 
Table 5.1: Summary of gene expression changes in HORCs under oxygen and/or 
glucose deprivation for 24hrs (* indicate statistical significant change). 
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5.3 Discussion 
5.3.1 Effect of Oxygen and Glucose Deprivation on the Survival of Retinal 
Ganglion Cells 
The current experiments assessed LDH release, as an indicator of necrotic retinal 
damage in HORCs and apoptosis was assessed by using TUNEL assay. Deprivation 
of glucose only under the normoxic condition for 24hrs led to increasing in the release 
of LDH. The greater the deprivation, the greater the release of LDH highlighting the 
importance of glucose for retinal cells survival. A significant release of LDH was 
obtained with 1.11mM and 0.555mM glucose and full glucose deprivation indicating 
necrotic damage. Although there was no significant increase in the released LDH at 
lower levels of glucose deprivation, the LDH release started at a 10% level of 
deprivation highlighting that small decreases in glucose are detrimental to retinal cell 
survival. Retinal explants treated with graded levels of glucose showed TUNEL-
positive cells in the ganglion cell layer at higher levels of deprivation. The number of 
TUNEL-positive cells was increased in the INL and ONL as the glucose deprivation 
increased correlating with LDH data. This data in human retina is supported by 
numerous experiments in animal models. Chronic hypoglycaemia, induced by a 
mutation in the glycogen receptor gene in mice resulted in losses of visual activity by 
the age of 10 months and increased TUNEL-positive cells in the INL of the retina 
(Umino et al., 2006). In addition, isolated retina from mice after exposure to 
hyperinsulinemic/hypoglycemic clamp to induce five-hour hypoglycemia (2.2 mM 
glucose) showed significant TUNEL-positive cells in the retina compared to fewer 
cells in control (6mM glucose) (Emery et al., 2011). Cleaved caspase-3 positive cells, 
together with TUNEL-positive cells, were found in the ONL and GCL (Emery et al., 
2011).  
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Based on LDH and TUNEL data from glucose deprivation experiments, two levels of 
oxygen and glucose deprivation were chosen to examine apoptotic RGCs death. 
Several animal studies have reported a loss of inner retinal cells as a result of 
simulated ischemia. A loss of RGC was evident after IOP-induced ischemia (Osborne 
et al., 1999b; Wang et al., 2002) and ligation of ophthalmic vessels (Lafuente et al., 
2002).  Loss of photoreceptors was also reported in a carotid artery occlusion model 
(Osborne et al., 1999b). In the present experiments, complete withdrawal of oxygen 
and glucose (OGD) for 24hrs caused a significant 4-fold increase in released LDH. 
Reduced levels of oxygen and glucose (1.11mM glucose/4%O2) resulted in a 1.6-fold 
increase in LDH release. In IOP-induced ischemia in rats, TUNEL-positive cells 
appeared in the INL and GCL within one day of initiation of the ischemia, marked by 
cell body shrinkage, aggregation, condensation of nuclear chromatin and expression 
of p53 mRNA, the tumor suppressor gene known to induce apoptosis (Loo et al., 
1999). Current results show that full OGD and reduced levels (1.11mM glucose/4%O2) 
for 24hrs caused 90% and 60% TUNEL-positive RGCs respectively. This was 
associated with a reduction in the number of NeuN-labelled neurons in both 
treatments. Apoptotic death in a rat model of retinal ischemia-reperfusion injury was 
detected in RGC and INL layers (Lam et al., 1999). TUNEL-positive cells also 
appeared in the INL and ONL.  Moreover, in post-mortem eyes of patients with 
primary open-angle glaucoma and secondary glaucoma, positive TUNEL cells were 
observed in the GCL (Kerrigan et al., 1997; Okisaka et al., 1997). Similar results were 
obtained with experimental glaucoma in monkeys (Quigley et al., 1995). In the 
present study, oxygen deprivation (full and 4%O2) did not alter the LDH release as 
compared to control and did not cause RGCs death as evidenced by RGC counting 
and TUNEL staining.  This is in contrast to other reports, where, in vitro hypoxia-
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induced RGCs death has been shown to occur. Short period (2 hours) of hypoxia 
(5%O2) in rats followed by re-oxygenation caused RGCs death by caspase-3–
mediated apoptosis (Rathnasamy et al., 2014). In addition, Sivakumar et al., (2013) 
found that following exposure of neonatal rats to 2hrs hypoxia (5%O2) an increased 
amount of glutamate accumulates in the retina. This caused RGC damage through 
activation of AMPA receptors, increased Ca2+ accumulation, and ROS generation. It 
should however, be noted that experiments. As shown previously, human Müller cells 
(MIO-M1) resisted oxygen deprivation (4%O2) and/or 1.11mM glucose. They also 
survived full hypoxia whereas loss of viability only occurs when the cells were 
deprived fully of glucose or oxygen and glucose.   
5.3.2 Effect of Oxygen and Glucose Deprivation on the Expression of Angiogenic 
Growth Factors 
In the retina, VEGF is expressed by endothelial cells (Aiello et al., 1995), Müller cells 
(Pierce et al., 1995), astrocytes (Stone et al., 1995), ganglion cells (Stone et al., 1996) 
and the retinal pigment epithelium (Miller et al., 1997). Moreover, VEGF is 
upregulated in several ocular pathologies including age-related macular degeneration 
(AMD) (Ferrara et al., 2007), and proliferative diabetic retinopathy (PDR) (Duh et al., 
2004). Findings by Bai et al., (2009) suggest that retinal Müller cell-derived VEGF is 
a major contributor to ischemia-induced retinal vascular leakage and pre-retinal and 
intraretinal neovascularization. Following induction of ischemia by vein occlusion, 
VEGF mRNA was upregulated in the retina and increased in the aqueous fluid (Miller 
et al., 1994) and oxygen-induced retinopathy in rats increased VEGF 
immunoreactivity was seen in the ganglion cell layer (Vinores et al., 1997). Current 
results show that retinal explants significantly up-regulate VEGF mRNA under 
conditions of hypoxia (0%O2) and full OGD. Such upregulation might be expected to 
   
 167 
lead to pathogenic vascular changes although they could be considered as an attempt 
by the retinal cells to survive during the severe insult. In the previous chapter, MIO-
M1 cells showed an increase expression of VEGF mRNA when exposed to complete 
oxygen, glucose deprivation and oxygen-glucose deprivation. The retinal explants 
increased expression under total deprivation conditions; therefore it is possible that 
Müller cells are playing a role in this regulation.  
Another important angiogenic factor in the eye is PDGF. Under physiological states, 
PDGF is expressed at a low level in perivascular cells, ganglion cells, and in the RPE 
(Campochiaro et al., 1994; Mudhar et al., 1993) in addition to retinal glia (Uchihori 
and Puro 1991).  PDGF has been implicated in the pathogenesis of different retinal 
conditions including retinal detachment (Seo et al., 2000), proliferative 
vitreoretinopathy (Campochiaro, 1997) and ischemic retinopathy (DeNiro et al., 
2011). In the current in vitro model of ischemia, expression of PDGF mRNA in 
HORCs increased with hypoxia (0%O2) and full OGD.  As with VEGF, it is possible 
that the retinal cells increased expression of PDGF in an attempt to survive the insult. 
Previous experiments in this work showed that MIO-M1 cells did not alter the 
expression of PDGF under similar conditions, which may indicate that the source of 
PDGF in retinal explants is derived from other retinal cells. Although the response to 
ischemia may be an attempt at survival, there was no evidence of cell survival in 
HORCs exposed to full OGD. Therefore, the expression of PDGF and VEGF could 
exacerbate death rather than survival and blocking of these growth factors could be a 
strategy to reduce RGC loss and this require further investigation. It may be, however, 
that blocking these factors leads to increased degeneration. These would be 
interesting experiments to perform in the HORC model. 
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Expression of bFGF was also measured in the HORC simulated ischemia model. In 
addition to Müller cells as an important source of bFGF in the retina, it is also present 
in astrocytes, ganglion cells and pigment epithelium cells (Walsh et al., 2001). The 
release of bFGF from Müller cells increases in the retina after detachment as indicated 
by activation of extracellular signal-regulated kinase (ERK) (Geller et al., 2001) and it 
has been found that bFGF mRNA is upregulated and released after retinal stress. In 
the retinas of cats and rabbits, intravitreal injection of bFGF resulted in a significant 
elevation in the number of Müller cells four days after injection and continued to 
increase after four weeks (Lewis et al., 1992). Despite the number of findings of the 
neuroprotective effect of bFGF, there have also been reports to the contrary, for 
example that exacerbation of glutamate-mediated neurotoxicity was mediated by the 
endogenous release of bFGF through a down-regulation of glutamine synthetase 
(Kruchkova et al., 2001).  Results show that both levels of simulated ischemia and 
glucose deprivation reduced bFGF mRNA levels compared to control. This may 
indicate that reduction of bFGF expression and release is detrimental to retinal cell 
survival.  
5.3.3 Effect of Oxygen and Glucose Deprivation on the Expression of                
Anti-angiogenic Growth Factors 
Pigment epithelium derived growth factor (PEDF) is a known potent angiogenesis 
inhibitor (Eichler et al., 2004) secreted from retinal pigment epithelial cells, and 
Müller cells in the retina (Gettins et al., 2002; Ogata et al., 2002). Studies have shown 
that PEDF protects RGCs from ischemia-induced neuronal apoptotic death (Takita et 
al., 2003), reduces RGC loss and vision decline in an animal model of human 
inherited glaucoma (Zhou et al., 2009). However, current results showed that 
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expression of PEDF mRNA in HORCs did not change as a response to experimental 
conditions.  
Leukemia inhibitory factor (LIF) is another inhibitor of angiogenesis and a member of 
the interleukin-6 family of cytokines (Heinrich et al., 2003).  It can be induced in the 
brain by ischemia-reperfusion injury in neurons and astrocytes (Suzuki et al., 2000) 
and has been reported as a survival factor in cultured neurons and astrocytes (Gadient 
et al., 1998). In the present experiments, LIF mRNA was significantly reduced with 
full OGD and glucose deprivation indicating that LIF down-regulation may 
exacerbate RGCs loss under these conditions. In cultured MIO-M1 cells, initial 
upregulation was found as early as 3hrs, but the levels decreased by 24hrs, which may 
reflect the importance of LIF in mediating cell survival. It would have been 
interesting to look at earlier time points in HORCs to see if there was an increase in 
the expression prior to the decrease seen at 24hrs and in situ hybridization techniques 
could have been used to determine which retinal cells were expressing LIF.   
5.3.4 Effect of Oxygen and Glucose Deprivation on the Expression of Glutamate 
Markers 
Glutamate is the main retinal excitatory amino acid released by Müller cells, 
astrocytes, photoreceptors, bipolar cells and ganglion cells (Heidinger et al., 1998; 
Hernandez et al., 2000). Increased glutamate levels are associated with excitotoxicity 
and neurodegenerations in human and animal models of glaucoma (Brooks et al., 
1997; Honkanen et al., 2003; Levkovitch-Verbin et al., 2002; Källberg et al., 2007; 
Kim et al., 2000). In order to try to protect against elevated glutamate, its 
detoxification systems GLAST, and GS may be upregulated in an attempt to maintain 
glutamate at low concentration at the extracellular space. In HORCs exposed to 
simulated ischemia (full OGD) and complete glucose deprivation, but not oxygen 
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deprivation alone there was a trend of increasing expression of GLAST mRNA. 
Whether this indicates that glutamate is elevated, it remains a question that need to be 
confirmed, because measuring glutamate level was not attempted in this study. Data 
presented here showed that reduced levels of glucose and oxygen (1.11mM 
glucose/4%O2) did not alter the expression of GLAST regardless the fact that at this 
level, RGCs death was noticed.  
It is possible that reduced levels of glutamate and/or glutamate transporter could also 
occur due to loss of the retinal cells in that glutamate and glutamate transporters 
reside (Lehre et al., 1997; Martin et al., 2002). The authors further explained that 
glutamate levels could increase by released from dying neurons or decrease as the 
synaptic transmission declines as ganglion cells disappeared. A reduction in the level 
could also reflect Müller cell injury (Martin et al., 2002). These explanations show the 
complexities of the system, but could be an explanation for the unchanged expression 
seen under reduced levels of glucose and oxygen.   
Another method of glutamate detoxification in the retina after the up take by glia is 
the conversion of glutamate by glutamine synthetase (GS) into glutamine (Thoreson 
and Witkovsky, 1999). It has been reported that ischemia-induced ATP depletion 
inhibits GS activity, because ATP is required to convert glutamate to glutamine 
(Oliver et al., 1990). Decreased GS activity has been seen in IOP-induced glaucoma 
in rats (Moreno et al., 2005). Current results indicate that GS mRNA is upregulated 
with both levels of ischemia, hypoxia and glucose deprivation.  In agreement with the 
findings presented here, Shaked et al., (2002) reported an increase in GS activity in 
retinal explants isolated from chicken embryos exposed to glutamate, and this 
enhanced the clearance of extracellular glutamate (Shaked et al., 2002).  
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A final pathway of glutamate metabolism is the conversion to GABA by GAD. In 
normal retina, GAD immunoreactivity was found in the inner plexiform layer, inner 
nuclear layer and ganglion cell layer (Lin et al., 1983; Pusateri et al., 1984; Schnitzer 
and Rusoff, 1984; Tyler et al., 1995).  Similar studies indicated the presence of GAD 
immunoreactivity in horizontal, amacrine and bipolar cells (Agardh et al., 1987; 
Mosinger et al., 1987; Yang, 1997; Mariani and Caserta, 1986), but not in the 
ganglion cell layer (Tyler et al., 1995). It was shown here that GAD mRNA followed 
the pattern of GLAST and GS expression, specifically an increase in the expression 
was found in simulated ischemia and glucose deprivation while hypoxia did not alter 
the expression levels.  
5.3.5 Effect of Oxygen and Glucose Deprivation on the Expression of Purinergic 
Related Signaling Markers 
Stimulation of the P2X7 receptor kills retinal ganglion cells in several in vitro and in 
vivo models (Niyadurupola et al., 2013; Resta et al., 2005, 2007; Zhang et al., 2005, 
2007). The expression of the P2X7 receptor is found in Müller cells and ganglion cells 
in the retina (Brändle et al., 1998; Ishii et al., 2003). In addition, stimulation of the 
P2X7 receptors as well as simulated ischemia, mediated RGC death in human 
organotypic retinal cultures (HORCs) (Niyadurupola et al., 2013). It has also been 
found that stimulation of the P2X7 receptor opens the pannexin-1 (PANX1) 
hemichannel and activate the caspase-1 cascade (Pelegrin and Surprenant, 2006). In a 
study by Thompson et al., (2006), oxygen-glucose deprivation resulted in 
hemichannel-like activity in hippocampal neurons and in experimental retinal 
ischemia followed by reperfusion in PANX1 knockout mice, RGCs were protected 
from death with reduced Ca2+ accumulation, inflammation and apoptosis in the 
absence of pannexin 1 activity (Dvoriantchikova et al., 2012). Current results showed 
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that simulated ischemia and glucose deprivation rather than hypoxia upregulated 
PANX1 mRNA expression in HORCs indicating that glucose rather than oxygen is 
responsible for this regulation. Upregulation of PANX1 could lead to enhanced ATP 
release and activation of P2X7-mediated cell death.   
Another gene involved in purinergic signaling is ENNP2, codes for the enzyme 
autotaxin, which has ecto-ATPDase activity. No literature was found related to the 
expression of this gene in the retina under normal and ischemic conditions. Current 
results showed full OGD, hypoxia and glucose deprivation all upregulated ENNP2 
mRNA. It is possible that the function of autotaxin in production of LPA may be 
more important in relation to survival mechanisms than its activity to remove 
extracellular ATP. 
5.3.6 Effect of Oxygen and Glucose Deprivation on the Expression of Müller 
Cells Marker Expression 
In retinal disease, astrocytes, and Müller cells react to injury by increasing GFAP 
protein expression (Bringmann et al., 2006; Fernandez et al., 2009; Lewis and Fisher, 
2003). In IOP-induced ischemic insult in rats, reperfusion caused increased GFAP 
immunoreactivity in Müller cells as early as one hour and lasted for two weeks (Kim 
et al., 1998). Similarly, retinal ischemia induced by elevated IOP in mice increased 
GFAP expression 24hrs after the injury (Ji et al., 2014). GFAP upregulation in 
ischemia-reperfusion has been linked to glial cells stiffening, the formation of glial 
scar and exacerbation of injury (Lu et al., 2011).  In experimental glaucomatous eyes 
in rats, GFAP increased in the first two months post-operation and decreased at three 
and four months (Wang et al., 2000). Similar findings were reported in experimental 
glaucoma in rats (Xue et al., 2006), after laser-induced elevated IOP (Woldemussie et 
al., 2004) and in an optic nerve crush rat model (Chen et al., 2002). GFAP has also 
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been observed to increase in retinal tissue from glaucomatous human eyes (Wang et 
al., 2002). It might therefore be expected that GFAP would be upregulated in the 
HORC model with simulated ischemia. However, results from the current study 
showed that exposure of HORCs to full OGD, hypoxia, and glucose deprivation, as 
well as reduced levels, did not significantly alter the expression. 
5.3.7 Effect of Oxygen and Glucose Deprivation on the Expression of Heat-Shock 
Protein 1B (HSPA1B) 
Heat-shock proteins are complex proteins of different molecular weights, which are 
expressed under stress including ischemia (Dillmann, 1999). Ischemic injury results 
in rapid HSP-70 mRNA expression of the retina (Lewden et al., 1998). Induction of 
heat shock proteins in RGCs was found to be protective under conditions of chronic 
ocular hypertension (Ishii et al., 2003; Ostling et al., 2007) and NMDA-induced 
excitotoxicity (Ahn et al., 2008; Marcuccilli et al., 1996; Rordorf et al., 1991). In the 
present study, HSPA1B mRNA expression was upregulated under all conditions of 
oxygen and/or glucose deprivation but the induction seen was not sufficient to fully 
protect RGCs since OGD was found to cause RGC death. 
Overall, the data presented here has indicated that HORCs can be used to investigate 
RGC death and gene expression following 24hrs insults of oxygen glucose 
deprivation. It was shown that glucose rather oxygen is a critical factor for retinal 
survival as evidence by TUNEL staining primarily in RGCs in HORCs. Changes in 
gene expression have been found such as VEGF, PDGF, LIF, and PEDF.  It is 
possible that some growth factors might be neuroprotective to retinal RGCs and 
secreted by Müller cells. Therefore, it is interesting to investigate the potential 
protective effect of these cells when co-cultured with HORCs under stress condition 
of glucose deprivation.  
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Chapter 6 
Effect of VEGF-A Treatment or Müller cells Co-culture on the 
Survival of Retinal Ganglion Cells Under Glucose Deprived 
Conditions 
6.1 Introduction  
Müller cells span all the retinal layers composing columnar units, a position that 
enables them to communicate with all retinal neurons and influence their activities 
(Bringmann et al., 2006; Newman, and Reichenbach, 1996). As previously discussed, 
neuroprotective effects of Müller cells can be mediated by protection against 
excitotoxicity as well as the release of neurotrophic factors, growth factors and 
cytokines (Bringmann et al., 2001, 2009).   
Several studies have indicated that VEGF is expressed and released under conditions 
of glucose deprivation in different cell types (Iida et al., 2002; Satake et al., 1998; 
Schmid-Brunclik et al., 2008; Shweiki et al., 1995; Stein et al., 1995; Yun et al., 
2005).  In addition, VEGF-derived from activated Müller cell is one of the growth 
factors that possess both protective and damaging effects on the survival of retinal 
neurons (Eichler et al., 2000, 2004; Yafai et al., 2004; Hollborn et al., 2002; Gora-
Kupilas and Josko, 2005). It is also important for the retinal and choroidal circulation 
(Stalmans et al., 2002; Marneros et al., 2005). VEGF has been also found to be a 
survival factor for MIO-M1 cells and inhibition of VEGF increased apoptosis in these 
cells (Saint-Geniez et al., 2008). On the other hand, retinal Müller cell-derived VEGF 
is a major contributor to ischemia-induced neovascularization (Bai et al., 2009). It is 
involved in the pathogenesis of eye disorders such as diabetic retinopathy (Miller et 
al., 1997), age-related macular degeneration (Ferrara et al., 2007), retinal ischemia 
(Bai et al., 2009) and neovascular glaucoma (Horsley and Kahook, 2010). 
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In chapter 3, it was reported that MIO-M1 cells proliferate in response to oxygen 
deprivation (4%O2), glucose deprivation (1.11mM) and reduced levels of both 
(1.11mM glucose/4%O2). This proliferation may be as a result of increased 
production of mediators acting as growth factors. They have also been shown to have 
effects on neuronal survival (Bringmann et al., 2009). A significant upregulation of 
VEGF mRNA was seen with complete deprivation of oxygen and/or glucose, and 
increases were seen with reduced oxygen and glucose, although these were not found 
to be statistically significant. Investigating VEGF protein secretion from MIO-M1 
cells and its involvement in survival and proliferation under conditions of glucose 
deprivation (1.11mM) was therefore of interest.  
The interaction between Müller cells and other cells can be simulated in vitro by the 
co-culture technique. Several studies have shown that glial cells in co-culture release 
stimulatory or inhibitory factors, which are important for the proliferation or survival 
of other cells as well as protecting against different stresses. For example, co-culture 
of astrocytes with cerebellar neurons enabled uptake of glutamate by astrocytes 
(Brown, 1999; Amin and Pearce, 1997) and protected neurons against oxidative 
stress-induced damage (Drukarch et al., 1998). Similarly, co-culture of rat RGCs with 
Müller glia has also been found to safeguard the RGCs against glutamate and NO 
toxicity (Kitano et al., 1996; Kawasaki et al., 2000). In addition, co-culture of 
neonatal rat RGCs with rat Müller glia or in Müller cells derived conditioned medium 
enhanced the survival of RGCs (Raju and Bennett, 1986).  It was also found to 
enhance survival of RGCs in co-culture in different species (García et al., 2002; 
García et al., 2003; Unterlauft et al., 2014).  
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The specific aims of the present experiments were to investigate the VEGF release 
from MIO-M1 under conditions of oxygen and glucose deprivation. In addition, to 
investigate the possible neuroprotective effects of exogenous VEGF (50ng/ml) 
treatment on the survival of RGC in in HORCs under conditions of glucose 
deprivation for 24hrs. Finally, to investigate the effects of co-culture of MIO-M1  
cells with HORCs under reduced glucose (1.11mM), a level of glucose deprivation 
that had been found to cause MIO-M1 cell proliferation; to see if this interaction 
between MIO-M1 cells and the retinal explants in culture may protect RGCs from 
death under glucose-deprived condition.  
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6.2 Results  
6.2.1 Effect of Reduced Glucose and Oxygen Levels on VEGFA Release From 
Human Müller Cells (MIO-M1) 
Under control conditions (5.55mM glucose/20%O2), MIO-M1 cells secreted VEGF 
and it seems that VEGF accumulated with time (Figure 6.1A). With reduced glucose 
and oxygen (1.11mM glucose/4%O2), the rate of increase was greater (Figure 6.1A). 
Similar trends were seen with oxygen deprivation and glucose deprivation alone 
(Figure 6.1 B&C).  
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Figure 6.1: Release of VEGF-A (pg/ml) by human Müller cells (MIO-M1) after 24, 
48, and 72hrs exposure to (A) reduced levels of glucose and oxygen 
(1.11mMglucose/4%O2), (B) oxygen deprivation (5.55mMglucose/4%O2) and 
glucose deprivation (1.11mMglucose/20%O2) compared to control (5.55mM 
glucose/20% O2)  (mean ± s.e.m, n=4, t-test).  
 
(A) 
(B) 
(C) 
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6.2.2 Effect of Exogenous VEGF-A Treatment (50ng/ml) on the LDH Release 
and RGCs Survival in HORCs 
Human Müller cells (MIO-M1) released VEGF under the examined conditions and 
this could potentially play a role in neuronal survival. The effect of exogenous VEGF 
(50ng/ml) on the survival of RGCs in HORCs was therefore examined under 1.11mM 
glucose.  
Retinal injury was initially evaluated by LDH release in VEGF-treated HORCs 
exposed to glucose deprivation (1.11mM) for 24hrs. HORCs treated with normal 
glucose level (5.55mM) and VEGF caused no alteration in LDH release compared to 
control. Glucose deprivation of HORCs resulted in a significant (*p≤0.05; n=4) 
increase (3-fold) in LDH release. Treatment with VEGF (50ng/ml) did not reduce the 
increase in LDH release caused by glucose deprivation with no significant difference 
between 1.11mM glucose-VEGF and 1.11mM glucose alone (Figure 6.2).   
Immunohistochemistry of NeuN and TUNEL staining from HORCs treated under 
control and glucose deprivation (1.11mM) condition with and without VEGF 
(50ng/ml) are shown in Figure 6.4.  
The number of NeuN-positive RGCs was significantly reduced by approximately 25% 
in glucose-deprived HORCs treated with VEGF (50ng/ml) (*p≤0.05; n=4) compared 
to control.  Although the NeuN count was not significantly reduced with 1.11mM 
glucose (Figure 6.4A), a significant 3-fold increase (*p≤0.05; n=4) in the number of 
TUNEL-positive cells was observed (Figure 6.4B). In glucose- deprived HORCs 
treated with VEGF, there appeared to be a decrease in TUNEL-positive RGCs, but 
this difference was not significant. Likewise, under control conditions VEGF 
appeared to reduce apoptotic RGCs but significant again was not gained.   
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Figure 6.2: Effect of VEGF-A treatment (50ng/ml) on the release of LDH by HORCs 
under control (5.55mM glucose/20%O2) and glucose deprivation 
(1.11mMglucose/20%O2) for 24hrs  (mean ± s.e.m, * p≤0.05; n=4, ANOVA).  
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Figure 6.3: Representative immunofluorescence photomicrographs of NeuN and 
TUNEL-labelling in HORCs labelling after 24hrs exposure to control, control 
+VEGFA, 1.11mM glucose, 1.11mM glucose +VEGF-A. DAPI = blue, GCL = 
ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer. 
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Figure 6.4: Effect of VEGF-A (50 ng/ml) RGCs death under glucose deprivation on 
(A) Average number of NeuN-labelled cells from three intact 200μm from 8 sections 
per sample expressed as percentage of control and (B) Percentage of TUNEL-positive 
ganglion cells, exposed for 24hr to glucose deprivation (1.11mM) (*p≤0.05; n=4, 
ANOVA).  
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6.2.3 Effect of Glucose Deprivation and MIO-M1 Co-culture on LDH Release 
and Survival of Retinal Ganglion Cell in HORCs   
Initially, LDH measurement was used to assess the overall effect of co-culture with 
MIO-M1 cells on HORC integrity with 1.11mM glucose. From previous experiments, 
it would be expected that 1.11mM glucose have no effect on the cytotoxicity of MIO-
M1 cells. Data presented here show similar results in which the LDH release from 
MIO-M1 cells was similar under control and 1.11mM glucose conditions. Culturing 
HORCs with MIO-M1 cells at normal glucose levels (5.55mM) for 24hrs did not 
increase the releasable LDH significantly compared to control (HORCs only).  As 
shown previously, exposure of HORCs to 1.11mM glucose for the same time period 
resulted in a significant increase (*p≤0.05; n=4) in LDH levels compared to control 
HORCs. When HORCs were cultured with MIO-M1 cells, a significant increase 
(*p≤0.05; n=4) in LDH was found compared to control alone (Figure 6.5). With no 
significant difference between HORCs cultured in the presence or absence of         
MIO-M1 cells 
 
 
 
 
 
 
 
 
Figure 6.5:  Effects of co-culture of MIO-M1 cells with HORCs on LDH release 
(U/L) when exposed to control (5.55mM glucose/20%O2) or glucose deprivation 
(1.11mMglucose/20%O2) conditions for 24hrs (mean ± s.e.m, *p≤0.05; n=4, 
ANOVA). 
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RGCs loss was assessed by immunohistochemistry where the numbers of NeuN-
labelled neurons in the retinal ganglion cell layer were counted in combination with 
TUNEL staining. Representative images are shown in Figure 6.6 and quantification in 
Figure 6.8.  
Control HORCs cultured alone under normal glucose level (5.55mM) for 24hrs did 
not affect the retinal layer integrity or increased TUNEL staining. Increased TUNEL 
staining was however noted in control HORCs in co-culture. In HORCs-treated with 
1.11mM glucose, TUNEL staining was also found in all layers which appeared more 
intense in the RGCs layer, inner nuclear layer, outer nuclear layer in HORCs with 
MIO-M1 co-culture under glucose deprivation compared to controls indicating that          
MIO-M1 cells increased retinal damage (Figure 6.5). A significant reduction in the 
mean number of NeuN-labelled by approximately 25% (*p≤0.05; n=4) was detected 
when HORCs were co-cultured with 1.11mM glucose-treated in co-culture with MIO-
M1 cells (Figure 6.7A).  The number of NeuN-labelled neurons was not reduced 
significantly different to control in HORCs treated with 1.11mM glucose or 5.55mM 
in combination with MIO-M1 cells (Figure 6.7A). A similar percentage of TUNEL-
positive cells in the RGCs layer was found in HORCs co-cultured under control 
conditions and 1.11mM glucose. Control HORCs co-cultured with MIO-M1 cells in 
1.11mM glucose has however more TUNEL detected in other layers (Figure 6.7B).   
 
 
   
 185 
 
 
Figure 6.6: Representative immunofluorescence photomicrographs of NeuN and 
TUNEL-labelling in HORCs labelling after 24hrs exposure to control, control co-
cultured with MIO-M1, 1.11mM glucose, 1.11mM glucose co-cultured with MIO-M1. 
DAPI = blue, GCL = ganglion cell layer, INL = inner nuclear layer, ONL = outer 
nuclear layer. 
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Figure 6.7: Effect of co-cultured MIO-M1 and HORCs under control (5.55mM) and 
glucose deprivation (1.11mM) for 24hrs on the survival of RGCs (A) Average 
number of NeuN-labelled cells from three intact 200μm from 8 sections per sample 
expressed as percentage of control and (B) Percentage of TUNEL-positive ganglion 
cells, exposed for 24hr to glucose deprivation (1.11 mM) (*p≤0.05; n=4, ANOVA).  
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6.2.4 Effect of Glucose Deprivation and MIO-M1 Co-culture on the VEGF-A 
Release from HORCs  
In earlier experiments, the regulation of VEGF under different glucose deprivation 
was investigated and it was found that VEGF mRNA in cultured primary Müller cells 
and HORCs is upregulated when glucose deprivation conditions were applied for 
24hrs. Secretion of VEGF protein therefore was also investigated in the co-culture 
experiments.  
Under 1.11mM glucose, VEGF released by MIO-M1 cells increased by 
approximately 2-fold (41.85±16.24 pg/ml) after 24hrs compared to control 
(16.85±4.87) while retinal explants cultured alone under control condition (5.55mM 
glucose/20%O2) resulted in VEGF level of 23.17±7.98 pg/ml. Control HORCs in co-
culture caused 3-fold increase in VEGF concentration of approximately 60.1± 15.37 
pg/ml. Further increase was detected in HORCs treated with 1.11mM glucose alone 
of approximately 4-fold (80.67±18.14 pg/ml) compared to control. When HORCs 
were cocultured with MIO-M1 cells under similar level of glucose deprivation this 
caused approximately 10-fold increase in VEGF (251.76±196 pg/ml) compared to 
HORC control (Figure 6.8).  This suggests that both cultured MIO-M1 cells and 
HORCs release VEGF under condition of glucose deprivation. It is worth mentioning 
that there was variation in the released protein between retinal explants under same 
condition indicating donor variability.  
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Figure 6.8: VEGF-A release from MIO-M1 and HORCs under control condition and 
glucose deprivation (1.11mM) when cultured alone and together (*p≤0.05; n=4, 
ANOVA). 
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6.3 Discussion 
Retinal glial cells can exert both neuroprotective and neurotoxic effects through 
releasing different factors (Bringmann et al., 2006; Heidinger et al., 1999; Kawasaki 
et al., 2000; Tezel and Wax, 2000).  Müller glia activation has been reported to occur 
in different retinal injuries and conditions such as ischemia-reperfusion (Pannicke et 
al., 2005), axotomy of the optic nerve (Chun et al., 2000), glutamate excitotoxicity 
(Honjo et al., 2000; Kawasaki et al., 2000) and experimental glaucoma (Carter-
Dawson et al., 1998). In Chapter 3, it was reported that MIO-M1 cells proliferate in 
response to glucose deprivation (1.11mM), hypoxia (4%O2) and glucose/oxygen 
deprivation (1.11mM glucose/4%O2). This proliferation may be associated with 
increased production of protective mediators such as growth factors. In an attempt to 
protect RGCs against glucose deprivation-induced loss, retinal explants were treated 
with VEGF and in other experiments, co-cultured with MIO-M1 cells under the 
condition of glucose deprivation (1.11mM).  
It has been shown in different cell lines that glucose deprivation increased VEGF 
expression and release (Brooks et al., 1998; Eichler et al., 2000; Iida et al.2002; 
Satake et al., 1998; Stein et al., 1995; Shweiki et al., 1995; Yun et al., 2005). The 
VEGF concentration in astrocytes after exposure to hypoxia for 24hrs was 
approximately 10pg/ml in cytoplasmic fraction, and 350pg/ml in the medium and 
higher levels of VEGF were found after exposure to anoxia (Schmid-Brunclik et al., 
2008).  Current data show that MIO-M1 cells release VEGF after exposure to oxygen 
deprivation (4%O2), glucose deprivation (1.11mM) and reduced levels of both 
(1.11mMglucose/4%O2) at different time points. Interestingly, MIO-M1 cells also 
showed increasing levels of VEGF over time at normal glucose and oxygen 
conditions (control conditions). Although, it is well known that hypoxia is the most 
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powerful stimulant to VEGF release (Witmer et al., 2003), the level of protein 
production by MIO-M1 cells was found in the present study to increase as a result of 
glucose deprivation alone as well as by reduced levels of both glucose and oxygen 
(1.11mM glucose/4%O2).  The increase in VGEF proteins by MIO-M1 cells under 
1.11mM glucose is thought to be one factor responsible for cell proliferation and 
survival and thus it is also possible that the released growth factor may protect RGCs 
in HORCs.  
In vitro studies have shown that VEGF could protect neurons against hypoxia, 
glutamate excitotoxicity and deprivation of oxygen, or glucose (Jin et al., 2000; 
Tolosa et al., 2008). In addition, VEGF was found effective in protecting primary 
cultures of rat cerebral cortical neurons from hypoxia and glucose deprivation (Jin et 
al., 2000) while a higher dose of VEGF (100ng/ml) reduced apoptosis in neuronal 
cultures exposed to hypoxia (Ding et al., 2005; Jin et al., 2001). Another isoform of 
VEGF (VEGF120; 100ng/ml) inhibited apoptosis of retinal explant cultures in an 
ischemia-reperfusion model in rats (Nishijima et al., 2007). Therefore, we sought to 
explore the neuroprotective effect of VEGF (50ng/ml) on HORCs exposed to 
1.11mM glucose. Similar elevated levels of LDH were released from HORCs exposed 
to 1.11mM glucose with and without VEGF indicating that addition of the growth 
factor did not protect against glucose deprivation-induced damage. Although RGC 
numbers significantly reduced with VEGF treatment under glucose deprivation, a 
slight reduction in apoptosis was seen in both control and glucose deprivation in 
VEGF-treated HORCs. It is therefore not possible to say that protection was found, 
but it is worth considering that the current concentration of VEGF used would not be 
effective in overcoming the damage induced by glucose deprivation, and further 
experiments would be needed to determine the appropriate and neuroprotective dose. 
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On the other hand, VEGF cannot be excluded as a cause of damage rather than a 
protective agent as the low glucose and VEGF together had less RGC.  
Another approach used here to investigate the effects of secreted factors from the 
MIO-M1 cells on RGCs survival was the co-culture of MIO-M1 cells with retinal 
explants. Co-culture of HORCs with MIO-M1 did not result in RGCs protection, but 
rather an increase in cell death even in control HORC was observed. It therefore 
appears that there are factors secreted into the medium by MIO-M1 cells that diffuse 
into the retinal explant to activate apoptotic death pathways as evidence by TUNEL 
data presented here.  VEGF released by activated Müller cells has been shown to have 
both neuroprotective and detrimental effects (Bringmann et al., 2006). Glial activation 
has been reported to exacerbate disease progression, increasing vascular permeability, 
and causing neovascularization by releasing VEGF (Penn et al., 2008). Schmid-
Brunclik et al., (2008) have also shown that glucose-free astrocyte-conditioned media 
contained an elevated concentration of VEGF, which increased retinal injury. VEGF 
causes endothelial cell hyperplasia resulting in capillary non-perfusion, and more 
damage follows by inducing vessel dilation and leakage, focal hemorrhages, 
microaneurysms, and retinal neovascularization (Tolentino et al., 2002). 
In the present study, VEGF protein was detected in HORCs exposed to glucose 
deprivation alone and when co-cultured with MIO-M1 cells. Previous results (Chapter 
5) also showed that VEGF mRNA is upregulated in HORCs exposed to 1.11mM 
glucose.  The source of VEGF in current experiments originates from both retinal 
explants and MIO-M1 cells with some evidence of synergistic effects. Also there was    
a large variation in the VEGF level between retinal explants suggesting donor 
variability in response to the experimental condition. It is possible that the released 
VEGF by MIO-M1 cells and HORCs contributed to more damage to retinal explants 
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and caused RGCs loss. In co-culture experiments under different conditions (rat 
Müller cells with RGC under hypoxic condition 0.2%O2) RGC protection was not 
seen but viability was increased in normoxic condition. The author explained that 
reduced neuroprotection of Müller glial cells might be linked to changes in the level 
of released survival factors and/or to the deleterious effect of other factors secreted by 
reactive glial cell (Unterlauft et al., 2012). This may explain in part the increase in 
apoptotic cell death in control HORCs co-cultured with MIO-M1 cells. The exposure 
of MIO-M1 cells to HORC in co-culture may release different factors from both 
which led to activation of the cells and enhanced RGCs death even in control 
conditions. Therefore, anti-VEGF treatment may be considered as a potential 
protective agents as favorable visual outcome was obtained in different conditions 
including age-related macular degeneration (Campochiaro, 2007), angiomatous 
proliferation (Cho et al., 2015), proliferative diabetic retinopathy (Avery et al., 2006), 
ischemic central retinal vein occlusion (Brown et al., 2014), neovascular glaucoma 
(Horsley and Kahook, 2010; Park et al., 2012) and for the treatment of glioblastoma 
(Gerstner et al., 2009). More experiments are needed to investigate the role of anti-
VEGF for protection against glucose deprivation induced damage as well as retinal 
ischemia. Experiments using the inhibitor would help determine the role of VEGF in 
either protecting the cells mediating neuronal cell death.  
Other mechanisms should also be considered for mediation of neurotoxic effects by 
glial cells in culture. Chronic activation of Müller cells leads to inflammatory 
processes by the production of cytokines such as TNF-α and interleukin (IL)-1β and 
these mediate RGC death (Tezel and Wax, 2000; Kitaoka et al., 2007; Tezel et al., 
2012). Excess production of NO increases oxidative stress and contributes to toxic 
damage in neurons and photoreceptors (de Kozak et al., 1997; Kashiwagi et al., 2001).  
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Kashiwagi et al., (2001) suggested that when glial cells proliferate, they may express 
fewer receptors and possess limited enzyme activity, which may exert neurotoxic 
effects on retinal RGCs.  This may explain the current results as MIO-M1 cells 
usually undergo proliferation when exposed to 1.11mM glucose and, therefore, were 
unable to eliminate toxins such as glutamate or ROS derived from HORCs and MIO-
M1 cells if any in the medium.  
Further studies are needed to clarify if pro-inflammatory cytokines are released in the 
current model under a condition of glucose deprivation (1.11mM) and thus contribute 
to RGCs death in HORCs when co-cultured with MIO-M1 cells.  
In conclusion, alterations in the cellular functions of glial cells when exposed to 
glucose deprivation that led to proliferation as well as co-culture with HORCs can 
result in toxic rather than beneficial effects on the RGCs. VEGF is released from 
MIO-M1 cells and possibly by retinal explants when exposed to 1.11mM glucose and 
it may contribute to apoptotic RGCs death. Anti-VEGF may provide therapy for the 
management of RGC degeneration in retinal ischemia. Although the relationship 
between neurodegeneration and neuroprotection would need further investigation. 
Pro-inflammatory cytokines may play a role, and further investigation is needed to 
reveal the secreted factors by MIO-M1 cells, which led to more damage to retinal 
explants in the current model.      
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Chapter 7 
Effect of High Glucose on the Gene Expression and Survival of 
Human Müller Cells (MIO-M1) and RGCs in HORCs 
 
7.1 Introduction 
As shown previously, VEGF is not only regulated by hypoxia. VEGF mRNA was 
also found to be upregulated under full glucose deprivation and reduced glucose 
(1.11mM) both in MIO-M1 cells and HORCs. Furthermore, the influence of VEGF in 
retinal diseases is not limited to conditions where the oxygen and glucose are 
deprived; it has been implicated in other retinal conditions such as diabetic 
retinopathy (DR) in which glucose levels are raised and responsible for vascular 
complications (Antonetti et al., 2012) as well as loss of neuronal cells in the retina 
(Martin et al., 2004; Park et al., 2003). In common with glaucoma, several studies 
have provided evidence suggesting diabetes-induced degeneration of RGCs in 
humans showing that RGCs undergo apoptosis and that there was increased 
expression of Bax, caspase-3 and caspase-9 in RGCs from diabetic patients (Abu-El-
Asrar et al. 2004; Abu El-Asrar et al. 2007; Barber et al. 1998; Oshitari et al., 2008). 
Moreover, neovascularization is a serious complication of several retinal diseases 
including DR and neovascular glaucoma (Gao et al., 2001; Hamanaka et al., 2001; 
Lim et al., 2009; Mason et al., 2015; Miller et al., 1997; Tripathi et al., 1998).  VEGF 
is part of the pathophysiological changes and anti-VEGF therapy is suggested as a 
potential therapy in treatment of these diseases (Dong et al., 2014; Horsley and 
Kahook, 2010; Jo et al., 2006; Park et al., 2012; Simo and Hernandez, 2008).  The 
data presented so far in this thesis has related to deprivation of glucose.  In this final 
chapter, the effects of high glucose are investigated in research relating predominantly 
to diabetic retinopathy. 
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DR is a microvascular complication of diabetes mellitus (Liew et al., 2014). In the 
UK, 3.3 million people were suffering from diabetes in 2014 (Quality and Outcomes 
Framework 2012/3), and this number is expected to reach 5 million by 2025 (AHPO 
diabetes prevalence model). DR affects almost three-quarters of patients who have 
had diabetes for more than 15 years (Klein et al., 1984) and it is the leading cause of 
vision loss in adults of working age (Liew et al., 2014). Elevated blood glucose is the 
main pathogenic factor contributing to the development of biochemical and cellular 
alterations in DR and leads to two major complications, macular oedema, and 
neovascularization (The Diabetes Control and Complications Trial Research Group, 
1993). The initial alteration of DR leading to macular oedema is termed 
microangiopathy (Mohamed et al., 2007), in which vascular permeability increases 
causing a passive influx of plasma into the retina (Aiello et al., 1998). The term 
“proliferative diabetic retinopathy” or PDR describes the advanced stage of 
retinopathy in which signs of neovascularization or abnormal, newly present blood 
vessels are formed in the retina and can spread into the vitreous. These vessels may 
bleed into the vitreous, and as they are attached to the retina with fibrous tissue, they 
can pull and detach the retina (Antonetti et al., 2012; Crawford et al., 2009; Fong et 
al., 2004). High glucose has been shown to cause a direct deleterious effect to both 
pericytes and endothelial cells leading to damage of vessel walls, and occlusion of 
some vessels can occur (Nehls and Drenckhahn, 1991). Blockage of retinal capillaries 
can then cause hypoxia-ischemia, which stimulates signalling pathways and further 
increases vascular permeability that exacerbates damage (Hamanaka et al., 2001; 
Linsenmeier et al., 1998; Schroder et al., 1991).  
Beyond the vascular abnormalities, neurodegenerative changes occur as a 
consequence of chronic high glucose in DR; increased apoptosis of ganglion cells, 
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glial cell reactivity, and altered glutamate metabolism have all been reported (Barber 
et al., 1998; Lieth et al., 1998; Mizutani et al., 1998). Studies have shown that 
glutamate concentration in the retina can increase as a result of blood-retinal barrier 
impairment in which an increase as little as 5μM glutamate can be lethal to neurons 
(Castillo et al., 1997; Do carmo et al., 1998; Gowda et al., 2011; Lieth et a., 1998). 
Furthermore, Müller cell dysfunction has been reported in diabetes in which the 
ability to convert glutamate into glutamine is reduced which also would increase 
retinal glutamate concentration (Lieth et al., 1998). A study by Yu et al., (2009) 
revealed that GS mRNA expression and activity progressively decreased over a 
period of 12 months after induction of diabetes in rats.  It has also been found that 
GLAST activity is reduced in diabetes, compromising the ability of Müller cells to 
regulate glutamate (Li et al., 2002). Investigators have found that GLAST has redox-
sensing sites and oxidation reduces GLAST function, which may contribute to the 
changes were seen in the diabetic retina (Lieth et al., 2000; Kowluru et al., 2001; 
Trotti et al., 1998).  
Activation of Müller cells has been shown to occur in human and rat diabetic retina 
(Mizutani et al., 1998; Lieth et al., 1998; Rungger-Brandle et al., 2000; Barber et al., 
2000; Zhao et al., 2015). Rungger-Brandle et al., (2000) suggested that glial activation 
is an early feature of retinopathy that follows leakage of the blood-retinal barrier. In 
an animal model of diabetes, overexpression of GFAP was observed three months 
after induction of diabetes in rats (Lieth et al., 1998, Rungger-Brandle, Barber et al., 
2000, Mizutani et al., 1998). Müller cell activation in diabetes, as in other retinal 
injuries, results in release of growth and neurotrophic factors including VEGF 
(Eichler et al., 2000), PEDF (Eichler et al., 2004), TGFβ (Ikeda et al., 1998), brain-
derived neurotrophic factor (BDNF), and nerve growth factor (NGF) (Ali et al., 2011). 
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Much research has focused on VEGF as the main growth factor participating in the 
pathogenesis of DR because of its potent angiogenic activity, and its role in the 
control of vascular permeability and endothelial cell proliferation (Aiello et al., 1994; 
Simo et al., 2002). VEGF was detected in the vitreous fluids from patients with 
diabetic retinopathy (Aiello et al., 1994), proliferative diabetic retinopathy (Shinoda et 
al., 2000; Hernandez et al., 2001; Simo et al., 2002) and ischemic occlusion of the 
central retinal vein in diabetes (Aiello et al., 1994).  In chronic diabetes in rats, VEGF 
expression increased in the GCL, INL, and ONL, with an increase in the number of 
capillaries and VEGF protein, detected in vascular and perivascular structures 
(Hammes et al., 1998). Also, expression of VEGF receptors was found to increase in 
retinas of diabetic rats (Gilbert et al., 1998). In post-mortem human eyes of 
individuals with diabetes, those without microvascular leakage, as well as controls, 
were negative for VEGF staining (Hofman et al., 2001) while VEGF receptors were 
expressed in the presence of leaky microvessels (Witmer et al., 2002). In addition, the 
number of VEGF-stained vessels in human diabetic retinas was higher than non-
diabetics (Mathews et al., 1997). This may indicate that VEGF expression and release 
is linked to vascular changes. Furthermore, Amin et al., (1997) found that VEGF 
expression precedes retinal neovascularization in post-mortem human retinas and 
optic nerves of humans with diabetes without proliferative retinopathy. Multiple 
retinal cells express PEDF to counterbalance the angiogenic effect of VEGF 
(Barnstable and Tombran-Tink, 2004). In patients with DR, decreased levels of PEDF 
in ocular fluids and vitrectomy specimens suggest that the loss of PEDF contributes to 
diabetes-induced neovascularization and neuronal loss (Ogata et al., 2002; Barnstable 
and Tombran-Tink, 2004). Down-regulation of PEDF in DR also contributes to 
inflammation and vascular leakage that increases VEGF and TNF-α secretion by 
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retinal Müller cells (Zhang et al., 2006) and over-expression of PEDF inhibits retinal 
inflammation and neovascularization (Park et al., 2011). The imbalance between 
VEGF and PEDF is proposed to lead to active proliferative DR (Ogata et al., 2002).   
In addition to VEGF and PEDF, other growth factors or cytokines are also involved in 
regulating angiogenesis including PDGF A/B and bFGF (Praidou et al., 2010; Simo et 
al., 2006). PDGF has been implicated in retinal neovascularization in different 
pathologies including age-related macular degeneration and proliferative diabetic 
retinopathy (Bo et al., 2014; Cox et al., 2003; Mori et al., 2002; Velez et al., 2012).  
The levels of PDGF isoforms, -AA, -AB, and -BB were elevated in serum and 
vitreous of patients with PDR (Praidou et al., 2009) and in a study by Gong et al., 
(2014), serum levels of PDGFA/B and bFGF were increased significantly in diabetic 
compared to non-diabetic rats. Studies have shown that a combination of anti-VEGF 
and anti-PDGF-BB is more effective than blocking VEGF-A alone for the treatment 
of ocular neovascularization in experimental mice (Dong et al., 2014; Jo et al., 2006) 
and similar results were reported in human trials in which co-administration of anti-
VEGF and an anti-PDGF agent together was very effective for the management of 
AMD (Mones et al., 2011).  
One of the pathways associated with hyperglycemia-induced vascular injury is the 
production of reactive oxygen species (ROS). Several studies have indicated that ROS 
formation increases retinal vascular damage, which can be reduced with antioxidants 
(Du et al., 2003; Kowluru et al., 2000). The increase in ROS occurs by multiple 
pathways including glucose auto-oxidation; the polyol pathway and increased 
advanced glycation end products (AGEs) (Brownlee, 2001 and Brownlee, 2005; 
Inoguchi and Sonta et al., 2003; Jain, 2006). Several studies have found that oxidative 
stress contributed to increased production of VEGF under in vitro conditions and 
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therefore it has been proposed to be involved in upregulation of VEGF expression in 
diabetes (Ellis et al., 1998; Ellis et al., 2000; Kuroki et al., 1996; Lu et al., 1998) and 
several studies also demonstrate a role for PKC activation in this process (Kowluru et 
al., 1997; Kowluru et al., 1999; Lee et al., 1989). Furthermore, Siflinger-Birnboim et 
al., (1992) found that non-toxic concentration of H2O2 increased permeability of 
cultured endothelial cells by activation of PKC and similar findings were reported by 
Konishi et al., (1997).  
Protein kinase C is a group of enzyme members of the serine/threonine-related protein 
kinase family. Isoforms α, βI, βII and γ are the conventional PKCs and are widely 
distributed in various tissues. Their activity is dependant on Ca2+, phosphatidylserine 
(PS) and diacylglycerol (DAG) (Geraldes and King, 2010). Another subclass is the 
novel PKCs (δ, ε, η, and θ), which are regulated by PS and DAG, but are Ca2+-
independent. The last subclass is the atypical PKCs (ζ and λ) in which activity is 
regulated by PS, but is independent of Ca2+ and DAG (Parekh et al., 2000).  
Hyperglycemia has been found to activate several PKC isoforms in retinal tissues, 
including PKC-α, -β- δ and ε (Idris et al., 2001; Ishii et al., 1996) and PKC isoforms 
have been shown to play a key role in processes such as endothelial dysfunction, 
vascular permeability, angiogenesis, cell growth and apoptosis (Geraldes and King, 
2010; Newton, 2003).  
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Figure 7.1: Hyperglycemia-induced activation pathways that can lead to production of vascular 
endothelial growth factor (VEGF) causing retinal complications (see text for details). PKCß activation 
can be inhibited using inhibitors for example LY33531 (Ruboxistaurine) 
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Pathways involved in hyperglycemia induced VEGF activation via PKC are 
summarized in Figure 7.1. Hyperglycemia-induced vascular damage and PKC 
activation is proposed to occur via increased flux of glucose through the polyol and 
hexosamine pathways and intracellular formation of AGEs, all of which cause an 
increase in the glycolytic intermediate dihydroxyacetone phosphate that is responsible 
for elevated DAG levels. In the polyol pathway, glucose is converted to sorbitol by 
the enzyme aldose reductase, using NADPH as a cofactor. NADPH is also required to 
regenerate reduced glutathione. Depletion of NADPH by the polyol pathway is 
proposed as a mechanism of increased intracellular oxidative stress (Lee and Chung, 
1999). The AGEs modify protein function, interacting with AGE receptors (RAGE) 
on vascular endothelial cells, which leads to ROS production (Giacco and Brownlee, 
2010; Kowluru and Chan, 2007). 
Each of these (DAG, oxidative stress and AGE/RAGE) have been shown to activate 
PKC and activation of PKC, in turn, can activate expression of VEGF (Geraldes and 
King, 2010; Giacco and Brownlee, 2010). Expression of VEGF is responsible for 
diabetic retinopathy complications such as macular oedema and neovascularization. 
Blocking of PKC could be a useful strategy to reduce VEGF secretion and may 
improve retinal condition. The PKC-β isoform has been suggested as a specific target 
in DR (Aiello, 2002). 
PKC-β inhibitors have been used in several experimental systems to investigate the 
role of PKC-β in DR. For example, treatment with the PKC-β inhibitor LY379196 
reduced NADPH oxidase (Quagliaro et al., 2003). Another PKC-β inhibitor, 
LY333531 (Ruboxistaurin), reduced VEGF-induced vascular permeability and 
neovascularization in bovine aortic endothelial cells (Xia et al., 1996). In the retina, 
LY333531 also attenuated leukocyte entrapment in the retinal microcirculation 
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(Nonaka et al., 2000) and intravitreal administration of LY333531 decreased retinal 
PKC-β activation and improved retinal blood flow (Bursell et al., 1997). Oral 
administration of LY333531 has also been shown to reduce VEGF-induced retinal 
and optic nerve neovascularization in a pig model of branch retinal vein occlusion 
(Danis et al., 1998) and improved retinal blood flow in diabetic rats (Ishii et al., 1996).  
High glucose, oxidative stress and hypoxia all occur in diabetes and have been shown 
to induce expression and release of VEGF.  Due to the detrimental vascular effects of 
VEGF in DR, the use of anti-VEGF therapy may have beneficial effects (Simo and 
Hernandez, 2008). Therefore, the aim of the present experiments was to explore the 
effect of long-term high glucose treatment on survival, growth factor expression and 
VEGF release in MIO-M1 cells. In addition, high glucose treatment was combined 
with hypoxia and/or H2O2 to induce oxidative stress to examine if they work 
synergistically to further induce VEGF release. In the later experiments, a PKC-β 
inhibitor LY333531 was used to examine its ability to reduce VEGF levels. 
Experiments were also performed in HORCs to study the effect of high glucose as on 
the survival of RGCs. 
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7.2 Results 
High glucose experiments in this chapter were carried out using commercially 
available high glucose medium with the highest concentration of 25mM. This 
concentration is approximately five times higher than the physiological glucose levels 
of 5.55mM. It should be noted that some cells in cultures are routinely grown in high 
glucose concentration of 25mM (Russell et al., 1999; Vincent et al., 2005) but as 
MIO-M1 cells are routinely cultured in 5.55mM glucose then the higher level of 
25mM was considered the best concentration to produce a hyperglycemic insult 
without causing death. 
7.2.1 Effect of High Glucose (HG) on the Cytotoxicity and Viability of Human 
Müller Cells (MIO-M1) and RGC Survival in HORCs 
As shown in Figure 7.2A, exposure of MIO-M1 cells to raised glucose levels (10-
25mM) for 24hrs did not alter the release of LDH compared to physiological levels of 
glucose (5.55 mM). The viability of MIO-M1 cells (Figure 7.1B) was also 
comparable to control indicating that HG treatment at these concentrations and for 
this time period does not affect the survival of MIO-M1 cells.  
Exposure of HORCs to HG levels (10-25mM) did not cause any elevation of LDH 
release (Figure 7.2A).  Assessment of RGC numbers in retinal explants exposed to the 
highest level of glucose (25mM) showed a similar number of NeuN-positive cells to 
control (5.55mM). This indicates that exposure of HORCs to this level of glucose for 
24hrs does not affect the survival of RGCs (Figure 7.2B). Immunohistochemistry 
revealed normal structure of the retina treated with high glucose (Figure 7.2C).  
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Figure 7.2: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) of 
human Müller cells (MIO-M1) after 24hrs exposure to control (5.55mM glucose) or 
raised levels of glucose (10-25 mM) (mean ± s.e.m, * p≤0.05; n=4).  
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Figure 7.3: (A) Cytotoxicity (total releasable LDH) in HORCs after 24hrs exposure 
to control (5.55mM glucose) or raised levels of glucose (10-25 mM) and (B) NeuN 
counting in HORCs after 24hrs exposure to control and high glucose (25mM) under 
normoxia (mean ± s.e.m, * p≤0.05; n=4).  
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Figure 7.3C: Representative immunofluorescence photomicrographs of NeuN 
labelling in HORCs after 24hrs exposure to control or high glucose (25mM). DAPI = 
blue, GCL = ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer. 
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7.2.2 Effect of High Glucose (HG) on Genes Expression in Müller cells (MIO-M1) 
and HORCs 
7.2.2.1 Effect of High Glucose (HG) on the Expression of VEGF mRNA in 
Human Müller cells (MIO-M1) and HORCs 
Exposure of MIO-M1 cells to 25mM glucose for 24hrs significantly (*p<0.05, n=4) 
increased VEGF mRNA expression by 4-fold as compared to normal glucose 
(5.55mM). Glucose levels of 10-20mM did not alter VEGF expression (Figure 7.3A). 
In HORCs, no significant increases in VEGF mRNA expression were seen in 25mM 
glucose compared to control (5.55mM) (Figure 7.3B).  
7.2.2.2 Effect of High Glucose (HG) on the Expression of PDGF mRNA in 
Human Müller cells (MIO-M1) and HORCs 
In MIO-M1 cells, a similar pattern of change to VEGF was found with PDGF in 
which the highest glucose level of 25mM caused a significant 2.6-fold (*p<0.05, n=4) 
upregulation in PDGF mRNA expression compared to control (Figure 7.4A). No 
regulation of PDGF mRNA was seen under high glucose concentrations in HORCs 
(Figure 7.4B).  
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Figure 7.4: Expression of VEGF mRNA in (A) human Müller cells (MIO-M1) and 
(B) HORCs after 24hrs exposure to control (5.55mM glucose) or raised levels of 
glucose (10-25mM). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4).  
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Figure 7.5: Expression of PDGF mRNA in (A) human Müller cells (MIO-M1) and 
(B) HORCs after 24hrs exposure to control (5.55mM glucose) or raised levels of 
glucose (10-25 mM). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4).  
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7.2.2.3 Effect of High Glucose (HG) on the Expression of bFGF and PEDF 
mRNA in Human Müller Cells (MIO-M1) 
The expression of bFGF mRNA showed a trend towards an increase at 25mM glucose 
but a decrease at 10-20mM, however, no changes were found to be significant (Figure 
7.5A). In addition, the expression of the anti-angiogenic factor, PEDF, did not change 
under raised glucose concentration (10-25mM) compared to control (Figure 7.5B).   
7.2.2.4 Effect of High Glucose (HG) on the Expression of Glutamine Synthetase 
(GLUL) and Glutamate Transporter (SCL1A3) mRNA in Human Müller Cells 
(MIO-M1) and HORCs 
Expression of glutamine synthetase (GLUL) mRNA in MIO-M1 cells showed no 
significant changes with increasing levels of glucose (Figure 7.6A). GLUL and 
GLAST (SCL1A3) expression in HORCs showed trend towards increasing, but no 
significant changes were found (Figure 7.6B&C).  
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Figure 7.6: Expression of (A) bFGF mRNA and (B) PEDF in human Müller cells           
(MIO-M1) after 24hrs exposure to control (5.55mM glucose) or raised levels of 
glucose (10-25 mM). Gene expression was normalized to the housekeeping genes 
TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4).  
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Figure 7.7: Expression of GLUL mRNA in (A) human Müller cells (MIO-M1) and 
(B) HORCs. (C) Expression of the glutamate transporter GLAST (SCL1A3) in 
HORCs after 24hrs exposure to control (5.55mM glucose) or raised levels of glucose 
(10-25 mM) in MIO-M1 or 25mM glucose in HORCs. Gene expression was 
normalized to the housekeeping genes TOP1 and CYC1 (mean ± s.e.m, *p≤0.05; n=4).  
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7.2.3 Effect of HG on the Release of VEGF from Human Müller Cells (MIO-M1) 
and HORCs 
VEGF is the main growth factor involved in the pathology of diabetic retinopathy 
therefore levels of VEGF protein were measured using ELISA in both MIO-M1 cells 
and HORCs treated with high glucose.  
In MIO-M1 cells, the release of VEGF was studied over a period of 72hrs both under 
normal glucose (5.55mM) as a control and high glucose (25mM) conditions. A 
significant increase in VEGF (*p<0.05, n=4) of approximately 2.6-fold was seen with 
HG after 72hrs compared to its control. In HORCs, the levels were measured only at 
24hrs. They showed concentration dependant increase in VEGF release. A significant 
increase (*p<0.05, n=4) of approximately 4.5-fold was seen with 20mM glucose 
(Figure 7.7B).  
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Figure 7.8: Release of VEGF from (A) human Müller cells (MIO-M1) after 24, 48, 
and 72hrs exposure to control low glucose (5.55mM) and high glucose (25mM) and 
(B) HORCs after 24hrs exposure to control low glucose (5.55mM) and raised levels 
of glucose (10-25 mM) (mean ± s.e.m, *p≤0.05; n=4).   
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7.2.4 Effect of Oxygen Deprivation on VEGF Release Human Müller Cells 
(MIO-M1) Under Normal and High Glucose Condition.  
In DR, raised glucose is often combined with decreased oxygen. The effects of 
hypoxia and high glucose were therefore investigated on VEGF secretion from       
MIO-M1 cells.  
Significant stimulation of VEGF release was found under full hypoxia in both low 
(5.55mM) and high glucose (25mM) (*p<0.05, n=4) at all time points (Figure 7.8).  In 
the first 24hrs, VEGF level was 67.1±20.7pg/ml under hypoxia-low glucose 
compared to 148.5±41.9 pg/ml with the combination of hypoxia high glucose 
although this difference was not significant.  The levels of VEGF release with 
hypoxia and hypoxia/HG continued to increase up to 72hrs, but no synergism was 
apparent.  
 
 
 
 
 
 
 
 
 
Figure 7.9: Release of VEGF by human Müller cells (MIO-M1) after 24, 48, and 
72hrs exposure to (A) 5.55mMglucose and (B) high glucose (25mM) under normoxia 
(20%O2) and full hypoxia (0%O2) and (C) combination of both (mean ± s.e.m, * 
p≤0.05; n=4). Comparison made to respective control.  
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7.2.5 Effect of Hydrogen Peroxide (H2O2) on the Cytotoxicity and Viability of 
Human Müller Cells (MIO-M1) Under Normal and High Glucose 
The mechanism of VEGF upregulation in high glucose has been proposed to be via 
generation of ROS. The effects of oxidative stress on VEGF release was therefore of 
interest. Initial experiments assessed the survival of MIO-M1 cells in H2O2 at 24hrs in 
order to determine a concentration that caused oxidative stress without causing cell 
death.  
Treatment of MIO-M1 cells with H2O2 (100μM- 1mM) at control (5.55mM) glucose 
levels caused no change in LDH release (Figure 7.9A) or viability (Figure 7.9B) at 
24hrs. Increase in LDH release and reduction in viability was seen with 2mM H2O2 
(Figure 7.10A). Interestingly, MIO-M1 cells under high glucose (25mM) were more 
sensitive to the oxidative stress induced by H2O2.  Under those conditions, 500μM and 
1mM H2O2 showed elevated levels of LDH (Figure 7.10A) and significant loss of 
viability (Figure 7.10B) at the 24hrs time point.  
From these experiments, lower doses of H2O2 (50 and 100 μM) for 24hrs were chosen 
and to induce oxidative stress without loss of viability at either level of glucose.  
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Figure 7.10: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) 
of human Müller cells (MIO-M1) after 24hrs exposure to H2O2 (100-2000nM) under 
5.55mM glucose and normoxia (mean ± s.e.m, * p≤0.05; n=4). 
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Figure 7.11: (A) Cytotoxicity (total releasable LDH) and (B) viability (MTS assay) 
of human Müller cells (MIO-M1) after 24hrs exposure to H2O2 (100-1000nM) under 
25mM glucose and normoxia (mean ± s.e.m, * p≤0.05; n=4).  
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7.2.6 Effect of Hydrogen Peroxide (H2O2) and Glucose on VEGF Release Under 
Normoxic Condition in Human Müller cells (MIO-M1) 
Exposure of MIO-M1 cells to H2O2 (50 and 100 μM) for 24hrs showed an increasing 
trend in VEGF secretion both under normal (5.55mM) and HG (25mM) conditions, 
but no significant increases were seen at this time point (Figure 7.11).  
  
 
Figure 7.12: Release of VEGF by human Müller cells (MIO-M1) after 24hrs 
exposure to low glucose (5.55mM glucose/20%O2) and high glucose (25mM/ 20%O2) 
either alone or in combination with 50μM or 100μM H2O2, under normoxia (mean ± 
s.e.m, * p≤0.05; n=4, t.test).  
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7.2.7 Effect of Hydrogen Peroxide (H2O2) and Glucose on VEGF Release Under 
Hypoxic Condition in Human Müller cells (MIO-M1) 
Exposure of MIO-M1 cells to hypoxia under normal glucose and HG increased VEGF 
secretion compared to normoxia (Figure 7.12).  The highest level of H2O2 (100μM) 
significantly increased (*p<0.05, n=4) VEGF secretion from a control level of           
8.17± 3.00 pg/ml to 99.3±25.43 pg/ml under hypoxic conditions (Figure 7.12A). HG 
conditions, hypoxia and oxidative stress significantly increased (*p<0.05, n=4) the 
VEGF secretion with low dose H2O2 (50μM) from a control level of 20.52±5.35 pg/ml 
to 84.9±24.5 pg/ml and to 74.5±8.34 pg/ml with the highest level of H2O2 (100μM). 
The higher concentration of H2O2 did not appear to increase VEGF secretion 
compared to the lower concentration (Figure 7.12B). Hypoxia and oxidative stress 
(100μM H2O2) significantly increased VEGF secretion from 34.35± 6.38 pg/ml 
compared to 74.5± 8.34 pg/ml with high glucose and oxidative stress, alone.   
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Figure 7.13: Release of VEGF by human Müller cells (MIO-M1) after 24hrs 
exposure to (A) low glucose (5.55mM) and (B) high glucose (25mM) under normoxia 
and full hypoxia either alone or in combination with 50μM or 100μM H2O2 (mean ± 
s.e.m, *, # p≤0.05; n=4, t.test). * Compared to respective control (no H2O2), # 
compared to HG+100μM H2O2.  
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7.2.8 Effect of PKC-β Inhibitor (LY333531) on VEGF Release Under High 
Glucose Condition in Human Müller Cells (MIO-M1) 
Initially, MIO-M1 cells were treated with PKC-β inhibitor (LY333531) in a range of 
100nM-1μM under control low glucose conditions. Viability and cytotoxicity tests 
were carried out for these experiments.  As shown in Figure 7.13A, the LDH level 
was similar to control with all concentrations of LY333531. The viability of MIO-M1 
cells was not affected with any of the concentrations used (Figure 7.13B). Therefore, 
the highest dose (1μM) and a lower concentration (500nM) were chosen for the next 
experiments.    
Treatment of MIO-M1 cells under control conditions with LY333531 showed a dose-
dependent trend of reduced VEGF secretion from the initial level of 10.2±5.3 pg/ml to 
2.96±1.73 pg/ml with 500nM and 1.25±0.44 pg/ml with 1μM LY333531 at 24hrs 
(Figure 7.14A).  However, no reduction in VEGF secretion was significant.  Under 
high glucose conditions (25mM), no significant changes were seen with either 
concentration or at any time point (Figure 7.14B).  
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Figure 7.14: Effect of the PKCβ inhibitor (LY333531) on the survival of human 
Müller cells (MIO-M1) under control conditions (A) Cytotoxicity (total releasable 
LDH) and (B) Viability (MTS assay) after 24hrs (mean ± s.e.m, *p≤0.05; n=4).  
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Figure 7.15: Release of VEGF by human Müller cells (MIO-M1) after 24, 48, and 
72hrs exposure to (A) 5.55mMglucose/20%O2 and  (B) 25mMglucose/20%O2 either 
alone or in combination with 500nM or 1μM PKCβ inhibitor (LY333531)  (mean ± 
s.e.m, * p≤0.05; n=4).  
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7.2.9 Effect of PKC-β Inhibitor (LY333531) on VEGF Release Under Hypoxia in          
Human Müller Cells (MIO-M1) 
Exposure of MIO-M1 cells to LY333531 (500nM and 1μM) did not reduce VEGF 
secretion as a result of full hypoxia (0%O2) at 24hrs (Figure 7.15A). At 48 and 72hrs 
there were trends towards a dose-dependant decrease in VEGF secretion as a result of 
PKC-β inhibition, but no significant reduction were found. Under HG and hypoxia, a 
significant reduction in VEGF was obtained with 1μM LY333531 at 24hrs (Figure 
7.15B).  A dose dependent decrease could be seen at later time points, but these were 
not found to be significant. 
7.2.10 Effect of Hydrogen Peroxide (H2O2) and Hypoxia with and without PKC-β 
Inhibitor (LY333531) on VEGF Release in Human Müller Cells (MIO-M1) 
Under control conditions, treating MIO-M1 cells with H2O2 and 1μM LY333531 did 
not reduce the VEGF levels (Figure 7.16A). Actually, an increase in VEGF secretion 
was apparent with 50μM H2O2 although this was not found to be significant. Under 
conditions of high glucose, no effect of PKC inhibition was seen in the presence of 
H2O2 (Figure 7.16B). Likewise, with hypoxia and HG in the presence of H2O2, no 
significant inhibition was seen (Figure 7.17). 
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Figure 7.16: Release of VEGF by human Müller cells (MIO-M1) after 24, 48, and 
72hrs exposure to (A) 5.55mMglucose/0%O2 and  (B) 25mM/0%O2 either alone or in 
combination with 500nM or 1μM PKCβ inhibitor (LY333531)  (mean ± s.e.m, * 
p≤0.05; n=4). *Comparison to respective control, ∍ comparison to hypoxia. 
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Figure 7.17: Release of VEGF by human Müller cells (MIO-M1) after 24hrs 
exposure to (A) low glucose (5.55mM) and (B) high glucose (25mM) under normoxia 
either alone or in combination with 50μM or 100μM H2O2 in addition to 1μM PKCβ 
inhibitor (LY333531)   (mean ± s.e.m, * p≤0.05; n=4, t.test).  
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Figure 7.18: Release of VEGF by human Müller cells (MIO-M1) after 24hrs 
exposure to (A) low glucose (5.55mM) and (B) high glucose (25mM) under hypoxia 
either alone or in combination with 50μM or 100μM H2O2 in addition to 1μM PKCβ 
inhibitor (LY333531) (mean ± s.e.m, * p≤0.05; n=4, t.test).  
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7.3 Discussion 
Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause 
of blindness (Aiello et al., 1998). It is worth mentioning that diabetes is a metabolic 
disease, and its complications are developed over years. It is difficult to simulate and 
match all the clinical course of DR using experimental models but using cell culture 
models can be useful to study the cellular mechanisms underlying diabetic retinopathy 
(Matteucci et al., 2014). Proteomics studies on vitreous humour samples from patients 
with diabetic retinopathy identified many proteins responsible for biological processes 
and could be considered clinical biomarkers (Kim et al., 2007). These proteins are 
responsible for biological or pathological functions including but not limited to: cell 
growth and transport, metabolism and, immune response (Kim et al., 2007). It is also 
important to note that hyperglycemia accelerates different pathological pathways such 
as advanced glycation end products (AGEs), which formed by the non-enzymatic 
reaction of glucose and other glycating compounds derived both from glucose and 
from fatty acids (Giacco and Brownlee, 2010; Kowluru and Chan, 2007). Production 
of AGEs increases oxidative stress and disturbs protein function through modifying of 
the extracellular matrix component and causes the interaction between the modified 
proteins and AGE receptors (RAGE), which induced ROS production and mediate 
deleterious effects of hyperglycemia (Giacco and Brownlee, 2010; Kowluru and Chan, 
2007). Most knowledge about the pathophysiology and therapeutic strategies were 
derived from in vivo experimental models of DR (Matteucci et al., 2014). However, 
retinal culture can have a significant contribution to the understanding of mechanisms 
of toxicity and treatment (Matteucci et al., 2014).  Müller cells are the first responders 
in retinal diseases including diabetic retinopathy (Barber et al., 2000; Barber et al., 
2003).  In addition to vascular abnormalities, activation of Müller cells occurs in DR 
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and both lead to increased VEGF expression and exacerbation of the condition 
(Barber et al., 2003). Oxidative stress also plays an important role in exacerbating the 
condition (Kowluru and Chan, 2007). In the present study, the human Müller cell line 
MIO-M1 and HORCs were used to investigate cell survival under conditions of high 
glucose and also expression changes in key genes. In addition, MIO-M1 cells were 
used to determine the influence of glucose, hypoxia and oxidative stress on VEGF 
release and the role of PKCβ in the process was investigated.  
7.3.1 Effect of High Glucose on the Cytotoxicity and Viability Human Müller 
Cells (MIO-M1) and RGCs Survival in HORCs 
In the present study, elevated glucose levels (10-25mM) for 24hrs did not affect 
viability or increase LDH levels in MIO-M1 cells compared to the culture at normal 
glucose levels (5.55mM). Shin et al., (2014) reported similar results in mouse retinal 
astrocytes, where exposure to high glucose (40mM) had no effect on apoptosis of 
retinal astrocytes, although it did enhance their proliferation. On the other hand, 
several studies have reported reduced viability with equal or higher level of glucose in 
different Müller cell lines. For example, exposure of transformed rat retinal Müller 
cells (the rMC-1 cell line) to high glucose (25mM) resulted in decreased viability with 
a 1.5-fold increase apoptotic cells compared to control (Du et al., 2003), a finding 
confirmed by other investigators (Muto et al. 2014; Trueblood et al., 2011). Other 
researchers have used a higher level of glucose (Han et al., 2015) showing that the 
exposure of primary rat Müller cells to 55mM glucose resulted in a 50% reduction in 
viability with significant increases in LDH release compared to the control (25mM).  
Another study by Zhao et al., (2015), in which exposure of primary rat Müller cells to 
high glucose (15-55mM) for 24, 48, and 72hrs, revealed that exposure to 35mM for 
48hrs caused an approximate 40% reduction in viability. It is possible that 
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transformed or primary rat Müller cells respond to high glucose stress differently than 
human Müller cells. Also if MIO-M1 cells were exposed to a higher glucose 
concentration of more than 25mM cell death may occur.  However, whether these 
levels would be considered to be relevant to levels seen in diabetes would have to be 
considered. Exposure of HORCs to high glucose for 24hrs did not cause any death as 
evidence by a comparable level of LDH release and RGC number.  
Other researchers have found that hyperglycemia-induced apoptosis in neuronal and 
Müller cells in rat and human retinas as well as Müller cell activation (Hammes et al., 
1995; Kerrigan et al., 1997). Furthermore, GFAP staining presented along the entire 
length of the Müller cell processes in retinas obtained from post-mortem diabetic 
patients as well as streptozotocin-induced diabetic rats (Mizutani et al., 1998; Zeng et 
al., 2000). Reduction in the NeuN-positive retinal ganglion cells with increases in 
TUNEL staining was also observed in streptozotocin-diabetic rats (Barber et al., 1998; 
Zeng et al., 2000) and human diabetes (Barber et al., 1998).  A significant reduction 
in Brn3a has been found after three months of inducing diabetes in rats (Zhao et al., 
2015). In patients with DR, a thinning of the RGC layer was found with type 1 
diabetes indicating an early neurodegenerative effect of high glucose on the retina 
(van Dijk et al., 2010). In the current study, high glucose stress in HORCs was 
induced over a very short time of 24hrs.  This may not be enough to induce death 
compared to animal studies. More sensitive measures may be required to see initial 
changes using the human retinal culture. 
7.3.2 Effect of High Glucose on the Expression of Growth Factors in Human 
Müller Cells (MIO-M1) and HORCs 
Müller cells are considered one of the major sources of VEGF in the retina (Bandello 
et al., 2013; Reichenbach and Bringmann, 2013; Wang et al., 2010). As mentioned 
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earlier, several studies have shown increased expression of VEGF mRNA and protein 
under the condition of HG (Bai et al., 2009; Dong et al., 2014; Hofman et al., 2001; 
Ke et al., 2012; Mu et al., 2009). Expression of VEGF mRNA and release by rat 
Müller cells increased after exposure to HG (20mM) (Ke et al., 2012). Others 
reported that HG (25mM) causes VEGF secretion with a peak at 24hrs (Ye et al., 
2012). In primary cultures of rat Müller cells exposed to HG (30mM), VEGF 
secretion increased at 48 and 72hrs compared to control (5.55mM) (Jiang et al., 2012). 
Similarly, expression of HIF-1α and VEGF mRNA in cultured rat retinal Müller cells 
increased after 24hrs exposure to 30mM HG (Li et al., 2012). In the present study, a 
significant 4-fold increase of VEGF mRNA in MIO-M1 cells was obtained under the 
highest glucose level of (25mM). Current results also showed that VEGF expression 
was increased in MIO-M1 cells under HG with no evidence of death or damage in 
contrast to other studies that reported high glucose-induced cell death. Findings by 
Sueishi et al., (1996) also showed that VEGF was expressed by RGCs under hypoxia 
and diabetic condition in rats and has been found that vitreous VEGF level is 
significantly higher in patients with PDR compared to non-diabetic patients (Ambati 
et al., 1997). In HORCs, expression of VEGF mRNA was upregulated by increasing 
the glucose levels and was found to be significantly elevated at 20mM. From 
literature searches this appears to be the first time that glucose has been shown to 
regulate VEGF secretion in the human retina. 
In addition to changes in VEGF, MIO-M1 cells exposed to HG for 24hrs, showed an 
increase in expression of PDGF-A mRNA by 2.6-fold, highlighting the involvement 
of PDGF in Müller cells response in diabetic injury. No alteration in PDGF 
expression was found under HG treatment in HORCs. Other studies have reported 
that cultured human vascular endothelial cells increase production of PDGF in 
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response to high glucose (Mizutani et al., 1992; Mizutani et al., 1995; Okuda et al., 
1996). Elevated PDGF levels have also been found retinas from diabetic patients 
(Gong et al., 2014; Praidou et al., 2009). This is the first time that changes in PDGF 
have been investigated in Müller cells. It may be therefore that the use of anti-PDGF 
in combination with anti-VEGF could exert a beneficial effect for the management of 
DR (Dong et al., 2014; Jo et al., 2006).  
In addition, anti-angiogenic factors should be considered. The levels of VEGF mRNA 
and protein increased, and the levels of PEDF mRNA and protein decreased in rat 
Müller cells cultured under HG (10-30mM). This suggests that the balance of these 
factors is disturbed under hyperglycemia that may contribute to neovascularization 
(Mu et al., 2009; Xie et al., 2012). In addition, gliotic Müller cells from diabetic 
patients displayed decreased PEDF immunoreactivity (Lange et al., 2008). However, 
this reciprocal regulation between VEGF and PEDF in high glucose was not seen by 
Zhang et al., (2006) using rat retinal Müller cells. Current results show that no 
alteration to the expression of PEDF was found MIO-M1 cells under HG conditions.  
The expression of bFGF under HG (25mM) in cultured MIO-M1 cells was found to 
follow a similar pattern to VEGF and PDGF in this study. Current results support the 
view that VEGF, PDGF, and bFGF produced by human Müller cells might be 
involved in the development and the progression of diabetic retinopathy. 
7.3.3 Effect of High Glucose on Expression of Glutamate Markers in Human 
Müller Cells (MIO-M1) and HORCs 
In vitro and in vivo studies indicated that glial dysfunction occurs in DR, and the 
activity of GS and glutamate transporters is reduced.  Shen and Xu, (2009) suggested 
that an increase in IL-1β in rat Müller cells decreased the expression of GS under HG 
condition. In Müller cells isolated from diabetic rats, GLAST activity was reduced, 
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and this decrease was attributed to hyperglycemia–induced oxidative stress (Li and 
Puro, 2002). Furthermore, in rat Müller cells cultured under HG (25mM), GLAST 
expression decreased significantly suggesting a consequent reduction in glutamate 
uptake (Xie et al., 2012). Lieth et al., (1998, 2000) reported that GS activity was 
reduced in diabetic rat retinas with increased in GFAP expression and glutamate 
levels indicating that glutamate metabolism is impaired in activated Müller cells in 
diabetes. Moreover, in a study by Ambati et al., (1997), the vitreous concentration of 
glutamate was higher in patients with PDR than non-diabetic patients. Data presented 
here showed that the expression of glutamine synthetase (GLUL) did not change in 
MIO-M1 cells under HG treatment. In HORCs, the expression of GLUL and GLAST 
(SLC1A3) tended to increase under 25mM glucose compared to control HORC 
cultured under physiological glucose level (5.55mM). Although this was not found to 
be significant, it would be interesting to investigate the expression of these genes at 
different time periods in HORCs as maximal changes may not occure at 24hrs.  
7.3.4 Effect of High Glucose, Oxidative Stress and Hypoxia on the Release of 
VEGF in Human Müller cells (MIO-M1) 
Initial experiments suggested that MIO-M1 cells released VEGF under hyperglycemic 
conditions.  As hypoxia also occurs in the advanced stages of diabetic retinopathy 
(DR) (Arden and Sivaprasad, 2011; Hamanaka et al., 2001), MIO-M1 cells were also 
exposed to hypoxic conditions, which is a known potent stimulant of VEGF 
expression and release. Data showed that full oxygen deprivation (0%O2) strongly 
influenced the release of VEGF both under physiological and high glucose 
concentrations in the MIO-M1 cells. Aiello et al., (1995) showed similar results with 
retinal pigment epithelial cells, pericytes, and microvascular endothelial cells in 
which hypoxia (0% to 5% O2), caused an increase in VEGF expression.  
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In a study by Hirata et al., (1997), human retinal Müller cells cultured in HG 
condition (17.5mM) followed by exposure to advanced glycation end products (AGE) 
for 12hrs increased expression of VEGF mRNA and protein. Introducing another 
important factor in diabetes, oxidative stress, VEGF release was found higher under 
normal glucose at 24hrs than with HG, and it does not seem that oxidative stress and 
HG work synergistically to induce VEGF release. Several studies have shown that 
high glucose conditions alone can increase the production of ROS in glial cells. 
Furthermore, high glucose conditions had a significant impact on production of ROS 
and production of inflammatory mediators in cultured mouse astrocytes (Shin et al., 
2014). High glucose treatment (30mM) depleted the cellular glutathione content of rat 
Müller cells by 60% after 48hrs (Jiang et al., 2012). In diabetic rat retinas and rMC-1 
cells exposed to elevated glucose concentrations (25mM), superoxide production was 
significant increased  (Du et al., 2003). In addition, MIO-M1 cells cultured with 
chronically HG concentrations  (17.5mM) demonstrated an increase in H2O2 levels 
compared to those cultured in normal glucose (5.55mM) conditions (Giordano et al., 
2015). The PKCβ inhibitor ruboxistaurin (LY333531) is a bisindolylmaleimide 
compound, which shows selectivity for PKCβI and βII over PKCα and other PKCs 
classes when administered in the nM range (Ishii et al., 1996; Jirousek et al., 1996). A 
study by Cha et al., (2000) found that a protein kinase C inhibitor -calphostin-C- 
inhibited glucose-induced increases in VEGF production in cultured in rat mesangial 
cells. In an attempt to block the stimulatory effect of glucose on VEGF release, PKC-
β-specific inhibitor LY-333531 was used in two doses in MIO-M1 cells exposed to 
conditions associated with DR. In the present study, the inhibitory effect of 
LY333531 on VEGF release was tested under conditions of HG, oxidative stress, and 
hypoxia. Results suggest that LY-333531-induced a trend towards reduction in VEGF 
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obtained under normal glucose (5.55mM) in the first 48hrs, which was not seen under 
HG (25mM).  
In addition, current data showed that high dose of LY-333531 (1μM) was effective in 
reducing hypoxia-induced VEGF release both under normal and high glucose levels. 
A significant reduction was found in the first 24hrs under high glucose condition but 
not at 48 and 72hrs. As the cells were treated once at the beginning of the experiments 
it is possible that the treated cells metabolize the drug, or it is broken down and would 
be less effective at later time points. These results can be compared to dose from 
primary cultured RPE, which showed that VEGF expression and release under HG 
and hypoxia is PKC-dependent (Young et al., 2005). In this case an inhibitor of PKC-
delta was used to reduce VEGF secretions under the examined condition (Young et al., 
2005). 
Considering the role of oxidative stress, studies have found that both factors increase 
VEGF expression. Exposure of rat mesangial cells to HG (25mM) for 48hrs increased 
oxidative stress and VEGF mRNA and protein, an effect that was suppressed by LY-
333531 (Xia et al., 2007).  Treatment of human RPE and rat glioblastoma to H2O2 
(400μM) and hypoxia-induced the expression of VEGF mRNA and increased protein 
production (Kuroki et al., 1996).  In vivo hypoxia in rats increased oxidative stress 
and VEGF protein expression (Sasaki et al., 2000). In the current experiments, no 
significant inhibition was seen when investigating the role of PKCß with HG and 
oxidative stress. The attempt to block VEGF release from MIO-M1 cells under the 
condition of hypoxia and oxidative stress with LY-333531 remained inconclusive. It 
would be particularly interesting to investigate whether PKC inhibition could block 
high glucose-induced VEGF secretion in HORC model.  
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Chapter 8 
General Discussion 
The aim of the present study was to investigate the effect of potential stressors in 
glaucoma, specifically oxygen and glucose deprivation (OGD; simulated ischemia) on 
the survival, proliferation and response of Müller cells, the major glial cell in the 
retina. This aim was achieved using the human Müller cell line (MIO-M1). These 
cells express markers of mature Müller cells, including cellular retinaldehyde-binding 
protein (CRALBP), glutamine synthetase, vimentin and epidermal growth factor 
receptor (EGF-R) and, therefore, represent a good model to study Müller cell 
response to pathological stimuli (Limb et al., 2002).  Furthermore, simulated ischemia 
and its effects on the survival of RGCs and gene expression were also investigated in 
the human retina, using the HORCs model. The model of organotypic culture enables 
to study the effect of different stressors on the retina such as OGD and could serve as 
a link between in vitro and in vivo models (Niyadurupola et al., 2011; Osborne et al., 
2015).  A summary of the major findings presented in this thesis is given in Figure 8.1. 
As discussed earlier, ischemia is part of the pathophysiology of glaucoma and may 
occur due to a reduction in blood flow as a consequence of the increase in IOP 
(Osborne et al., 1999) or vascular dysregulation (Ghanem et al., 2011). The model of 
simulated ischemia used in in vitro studies is based on the complete removal of 
oxygen from the glucose-free medium and growing the culture in a nitrogen 
atmosphere causing complete OGD. From a clinical standpoint, this is not a good 
correlation to in vivo ischemia, as the extent of blood flow reduction may be variable 
and may not reach the full deprivation.  
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Figure 8.1: Summary of the effect of oxygen and glucose deprivation on RGC and Müller cell 
survival and gene expression. For details about changes in gene expression under each condition refer 
to Table 4.1 and 5.1. 
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Full deprivation causes very fast damage while graded levels of deprivation give more 
insight to how cells behave under stress without losing viability. Graded-levels of 
oxygen and glucose deprivation gave detailed information about the survival of MIO-
M1 cells and showed how they are resistance to these insults. A key finding of this 
research was that Müller cells (MIO-M1) respond to a degree of oxygen and glucose 
deprivation (1.11mMglucose/4%O2) and glucose deprivation (1.11mM) by 
proliferation. It is now well documented that glial cells proliferate in response to 
injury (Bianchi et al., 2015; Cho et al., 2015; Fan et al., 2013; Hollborn et al., 2004; 
Mascarelli et al., 1991; Moon et al., 2009; Romo et al., 2011). Their specialized 
energy metabolism, which depends up to 80-90% on anaerobic glycolysis, contributed 
to their survival in anoxia and ischemia (Poitry-Yamate et al., 1995; Tsacopoulos et 
al., 1998; Winkler et al., 2000). Studies have found that the utilization of Müller cells 
of lactate, pyruvate, glutamine or glutamate to generate energy by the tricarboxylic 
acid cycle increasing their survival in the absence of glucose (Winkler et al., 2000). 
However, the later amino acids did not support survival in the current experiments 
under full OGD.  
The results in this thesis support that glucose is of key importance for MIO-M1 cells 
and they can withstand oxygen but not glucose deprivation. In the retina, low glucose 
supply as a result of an ischemic event or intense activity causes Müller cells to shift 
into anaerobic metabolism to provide the monocarboxylates such as lactate and 
pyruvate to photoreceptors and neurons (Winkler et al., 2000; Winkler et al., 2003). 
This process has also been proposed to occur in the brain and is called activity-linked 
neuron lactate shuttle hypothesis (ANLSH) and occurs in rat C6 glioma cells and 
astrocytes (Bouzier et al., 1998; Bouzier-Sore et al., 2003; Genc et al., 2011; Pellerin, 
2003). Frenzel et al., (2005) showed that rabbit Müller cells incubated in 0.555mM 
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glucose maintained similar ATP levels to control (11mM) and survived oxidative 
stress induced by NO. It has been found that the presence of pyruvate or other 
monocarboxylates can protect Müller cells when cultured in deprived glucose 
conditions. This protection is abolished in the complete absence of glucose (Frenzel et 
al., 2005). This is supported by the findings presented in this thesis where MIO-M1 
cells survived different levels of deprivation, but not full glucose deprivation. It is of 
particular interest to find that glucose is the main factor for MIO-M1 cells survival 
rather than oxygen. Others have reported that oxygen deprivation causes glial cell 
death (Bondarenko and Chesler, 2001; Callahan et al., 1990; Kelleher et al., 1993; 
Tan et al., 2015; Yan et al., 2005; Yu et al., 1989). In this research, it has been 
reported that MIO-M1 cells survive hypoxia (0 and 4%) for up to 72hrs with no 
evidence of death.   
In the present research, exposure of MIO-M1 cells to 2% and 4%O2 caused significant 
cell proliferation compared to the atmospheric control level although most gene 
expression including VEGF did not alter under reduced oxygen level (4%O2), most 
changes were obtained with full hypoxia (0%O2). Other researchers have also found 
that low O2 concentrations (1–5%O2) stimulate cell proliferation in different cell lines 
(Cipolleschi et al., 2000; Guzy and Schumacher, 2006; Hermitte et al., 2006; Ivanovic 
et al., 2000; Jiang et al., 1996).  These low oxygen concentrations are thought to be 
enough to produce energy by mitochondrial respiration allowing cell proliferation 
while full oxygen deprivation or anoxia would permit the shift into anaerobic 
glycolysis to maintain the energy level without allowing cell proliferation (Guzy and 
Schumacher, 2006; Ivanovic, 2009; Jiang et al., 1996). However, this is not the case 
with Müller cells, as they are known to prefer anaerobic glycolysis to obtain energy 
even in the presence of glucose and oxygen, and they are characterized by a very low 
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rate of oxygen consumption (Winkler et al., 2000). It has been found that the oxygen 
concentration in the retina varies from 1 to 5% (Buerk et al., 1993; Yu and Cringle, 
2005). This level of oxygen refers to “physiological hypoxia” and is thought to occur 
during development and is well tolerated by the tissue being sufficient for the normal 
function and does not induce any pathologic events (Chan-Ling et al., 1995; Guzy and 
Schumacher 2006). It has been argued that the atmospheric O2 concentration is too 
elevated for the cells of most tissues, and experimental conditions should be 
compared to physiological hypoxia, and the atmospheric oxygen culture condition 
should be considered as hyperoxia (Ivanovic et al., 2009). Most research data is 
derived from experiments at 20–21%O2 including the experiments presented in this 
thesis but certainly it is an important point to consider. There are many technical 
difficulties, which prevented experiments under physiological hypoxia including the 
availability of hoods and incubators set at that level of oxygenation. It is also 
important to consider that the cells were previously exposed to levels of 20–21%O2 
during isolation, growing, and splitting stages making this the control level they were 
exposed to, and, therefore, any level below that would be considered as hypoxia.   
To further understand if cell proliferation under 1.11mM glucose and 4% oxygen 
could cause expression of survival factors, important neuroprotective angiogenic 
growth factors, and excitotoxicity (glutamate and ATP) related genes were 
investigated. Changes in gene expression were seen. Before discussing these it is 
worth considering that the increase in expression in mRNA may be due to either 
enhanced mRNA stability or de novo transcription. As the level of mRNA within a 
cell depends on both synthesis and decay rate, both can regulate the levels of cellular 
messenger RNA transcripts and, therefore, affect the expression of specific genes 
such as cytokines and growth factors. Interestingly, the regulation of mRNA stability 
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is found to occur in the pathways whereby tissues and organs respond to stresses 
including starvation, infection and inflammation (Ross, 1995). From the current 
experiments it is not possible to determine whether changes in synthesis or turn over 
were responsible for changes in expression that were seen.  
Significant upregulation of VEGF mRNA was found with complete deprivation of 
oxygen and/or glucose. Although the VEGF mRNA was not significantly elevated 
under reduced levels (1.11mMglucose/4%O2), evidence of VEGF protein secretion by 
MIO-M1 cells was found for up to 72hrs.  Studies have indicated that VEGF 
expression and release play an important role in ischemic injury in neovascular 
glaucoma (Chalam et al., 2014; Lim et al., 2009; Pe'er et al., 1998; Tripathi et al., 
1998).  Therefore, the use of anti-VEGF treatments could be used in future 
experiments to test their effect on cell survival and preventing ischemia-induced 
damage. The intracellular signaling pathways of different growth factors were not 
investigated in the current study, but it is important to discuss possible pathways. 
Studies have shown that ERK1/2, the p38 kinase family, and the c-Jun N-terminal 
kinase (JNK) family are the major mitogen-activated protein kinases (MAPKs) 
involved in the proliferation and stimulatory effects of growth factors and cytokines 
(Hollborn et al., 2004; Milenkovic et al., 2003).  Activation of MAP kinases occurs in 
the cytoplasm and causes translocation into the nucleus (Roskoski et a., 2012). 
Activation of ERK1/2 and c-Fos in Müller cells are important mechanisms, which 
rescue retinal neurons from cell death (Peng et al., 1998; Rohrer et al., 1999; Akiyama 
et al., 2002; Nakazawa et al., 2008). In the current research, the expression of PDGF 
did not change with reduced levels of oxygen and glucose but were significantly 
reduced with full OGD. It is less likely that PDGF is involved in MIO-M1 cells 
proliferation in contrast to the findings of Moon et al., (2009) that PDGF-stimulated 
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Müller cell proliferation through JNK and Akt signaling pathways.  Also, it was found 
that bFGF is significantly increased in full glucose deprivation while reduced with 
1.11mM glucose. Studies found the neuroprotective effects of bFGF to occur via 
activation of ERK1/2 and c-Fos in Müller cell (Walhin et al., 2000, Walhin et al., 
2001).  Current data showed that the expression of PEDF was significantly reduced 
with full OGD and hypoxia. The beneficial effect on neuronal survival by PEDF has 
been proposed through different pathways including p38 MAP kinase (Chen et al., 
2006), ERK-1/-2 MAP kinase (Sanchez et al., 2012), stress-activated phospho-kinase 
(JNK) (Konson et al., 2011), and phosphatidylinositol 3-kinase/Akt signaling 
cascades (Haribalaganesh et al., 2010). From the discussion above, it is clear that 
there is significant overlap of the intracellular signaling cascades activated in response 
to different growth factors. These pathways may play a role in MIO-M1 cells 
response to hypoxia and/or glucose deprivation, which needs to be determined in 
future experiments. Importantly, the present research has found that human Müller 
cells may release cytotoxic factors under a stressful condition such as glucose 
deprivation, which may kill RGCs rather than protect them. As MIO-M1 cells 
survived for 24hrs under conditions of 1.11mM glucose and, indeed proliferate, it was 
assumed that the cells were releasing survival factors. Culturing retinal explants on a 
monolayer of MIO-M1 cells caused increased damage to HORCs even under control 
condition.  The molecular mechanisms by which glial cells modulate neuronal death 
have not been investigated in the current study and remain to be determined in future 
experiments. Many investigators have reported that activation of glial cells causes 
production of neurotoxic molecules such as nitric oxide, ROS, TNF-α and IL-1 
(Cotinet et al., 1997; Fuchs et al., 2005; Kawasaki et al., 2000; Yoshida et al., 2004). 
Therefore, It would be interesting to analyze the conditioned medium from MIO-M1 
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cells for released cytotoxic molecules or cytokines to try to determine the factors 
responsible for the observed damage. Interestingly, Xie et al., (2004) found that co-
culture of glial cell (astrocytes and microglia) caused neuronal death possibly via 
increased upregulation of iNOS and IL-1 with activation of MAPK signaling 
pathways. Inhibition of p38 and JNK partially protected neurons from glia-induced 
death. In activated Müller cells (MIO-M1), IL-6, IL-8 production is mediated through 
the p38 MAPK pathway (Liu et al, 2014; Liu et al, 2015).  Therefore, it is essential to 
investigate the contribution of these pathways to glial activation and subsequent 
neuronal death as modulation of these responses may help in the development of 
therapeutic interventions.  
To simulate glaucomatous retinal ganglion cell (RGC) degeneration in vitro, oxygen 
and/or glucose deprivation was also investigated using the human organotypic retinal 
culture (HORC) model. In HORCs, graded levels of glucose provided a useful 
indicator of how glucose can cause death to retinal cells. The greater the deprivation, 
the more TUNEL-positive cells were absent in different retinal layers.  Oxygen-
glucose deprivation (OGD) was capable of reducing NeuN and significantly increases 
TUNEL-positive RGCs. It is interesting to find that oxygen deprivation alone was 
unable to increase LDH levels or cause significant loss of RGCs in the HORC model.  
Depletion of ATP stores due to the absence of glucose and oxygen causes energy 
failure and initiation of disruption of the ionic balance and changes in levels of 
neurotransmitter as well as metabolites (Lipton, 1999). Excitotoxic damage induced 
by excess glutamate is proposed to play a central role in ischemic retinal death 
(Lipton, 1999). Glucose deprivation under normoxic conditions increased the 
susceptibility of cerebral neuron neurons to low glutamate concentration (Kimura et 
al., 1999; Nishizawa, 2001). Other responses found by other researchers to contribute 
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to retinal ischemic injury include the increase in potentially toxic inflammatory 
mediators such as TNF-α, NO and IL-1 (Morgan et al., 1999; Rathnasamy et al., 2014; 
Roberge et al., 1988; Yoshida et al., 2004). Hypoxia is a potent stimulator of 
angiogenic factors, most importantly VEGF, a growth factor whose expression is 
controlled by hypoxia-inducible factor (HIF). Furthermore, glucose deprivation (Chen 
et al., 2015; Nishimoto et al., 2014) and sub-lethal OGD (Huang et al., 2014) has also 
been found to increase HIF1-α and leads to anti-apoptotic effects in cancer cells 
(Nishimoto et al., 2014). Findings by Stein et al., (1995) showed that exposure of C6 
cells, a clonal glial cell line, to hypoxia or hypoglycemia resulted in increase 
expression of VEGF.  Data from this research showed that expression of VEGF 
increases in MIO-M1 cells and HORCs under certain deprivation conditions.  Future 
experiments are needed to investigate the expression of HIF1-α under conditions of 
glucose deprivation and reduced level (1.11mM glucose/4%O2) in MIO-M1 cells and 
HORCs. This research also found that the MIO-M1 cell line could be utilized in a 
model of simulated hyperglycemia in vitro and to investigate the mechanisms of high 
glucose, oxidative stress, and hypoxia induced-VEGF production. One of the 
shortcomings of this model is the time required for simulating the pathology of 
diabetes. In the current model, MIO-M1 cells were exposed to high glucose for a 
relatively short period compared to that which they would be exposed to in in vivo 
models or in human diabetes. In addition, oxidative stress and hypoxia develop in 
advance stage of the disease accompanied with microvascular abnormalities so 
mimicking the entire pathophysiological progression of the disease is difficult in cell 
culture (Arden and Sivaprasad, 2011). Cultured Müller cells (MIO-M1) were 
sensitive to the combination of HG and H2O2 and lost viability after 48hrs exposure, 
and this limited the experimental condition to 24hrs period only.   
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The experimental hyperglycemia was induced in this thesis by high glucose medium 
of a maximum 25mM. It should be noted that some cells in cultures are routinely 
grown in this concentration (Russell et al., 1999; Vincent et al., 2005) but as MIO-M1 
cells are routinely cultured in 5.55mM glucose then the higher level of 25mM was 
considered enough to produce a hyperglycemic insult without causing death. In 
contrast, other researchers have found that 25-50mM can induce apoptotic cell death 
in neuronal retinal culture (Santiago et al., 2006; Costa et al., 2012; Oshitari et al., 
2010) as well as in Müller cell lines (Du et al., 2003; Han et al., 2015; Muto et al. 
2014; Trueblood et al., 2011, Xi et al., 2005).  The time of exposure to HG, which 
caused cell loss, was variable between different studies. In some studies, death was 
reported after 24hrs (Trueblood et al., 2011), 48hrs (Han et al., 2015; Matteucci et al., 
2014), or 72hrs (Xi et al., 2005).  Others reported longer survival time for five days 
exposure (Chavira-Suarez et al., 2011; Du et al., 2003).  
The current research has reported 72hrs survival after exposure to HG but not if it is 
combined with oxidative stress.  This evidence of different susceptibility highlights 
the need for more experiments to characterize the precise time course of HG-induced 
stress and cell death.  In conclusion, the present research has provided insight to the 
survival and alteration in gene expression of different growth factors, glutamate and 
glial activation markers in human Müller cells (MIO-M1) when exposed to stressors 
associated with the development of glaucoma. More evidence was obtained from 
exposure of HORCs to oxygen and glucose deprivation, which caused a reduction in 
RGC survival and changes in genes expression. Moreover, both models can be also 
used to simulate hyperglycemia in diabetic retinopathy. These models may therefore 
be of benefit in investigation of potential therapeutic interventions to retinal 
neurodegenerative disease, including glaucoma 
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List of Abbreviation 
AGEs Advanced glycation end products 
α-SMA Alpha-smooth muscle actin 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
ANOVA A one-way analysis of variance 
ADP Adenosine diphosphate 
A1-3  Adenosine receptors 1-3 
AQP4  Aquaporin-4 channels 
ATP Adenosine 5′-triphosphate 
BDNF Brain-derived neurotrophic factor 
bFGF (FGF2) Basic fibroblast growth factor 
CAIs Carbonic anhydrase inhibitors 
cDNA Complementary Deoxyribonucleic acid 
COAG  Chronic open angle glaucoma 
CNS Central Nervous System 
CNTF Ciliary neurotrophic factor 
CRBP Cellular retinol binding protein  
CRALBP Cellular retinal binding protein 
CYC-1  Cytochrome c-1 
DAG Diacylglycerol 
DMEM Dulbecco’s Minimum Essential Medium 
DMSO Dimethyl sulfoxide 
DPBS Dulbecco’s Phosphate Buffered Saline solution  
DR Diabetic retinopathy 
EAAT1-5 Excitatory amino acid transporter 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
ELAM-1 Endothelial leukocyte adhesion molecule-1 
ELISA Enzyme Linked-Immuno-Sorbent Assay 
EMEM Eagle’s Minimum Essential Medium 
eNOS Nitric oxide synthase 
ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase 2  
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ERK Extracellular-signal-regulated kinases 
ET Endothelin 
FBS Foetal bovine serum 
GABA  Gamma-aminobutyric acid 
GAD1 Glutamate decarboxylase 1 
GCL Ganglion cell layer 
GFAP Glial fibrillary acidic protein 
GLAST Glial glutamate transporter  
GLUL Glutamate-ammonia ligase (Glutamine Synthetase) 
GLUT 1-4 Glucose transporters 1-4 
GS Glutamine synthetase 
H2O2 Hydrogen perodxide 
HBSS Hank’s balanced saline solution 
HG High glucose  
HGF Hepatocyte growth factor 
HO-1 Heme oxygenases 1 
hONAs Human optic nerve head astrocytes  
HORC Human organotypic retinal culture 
hRPE Human retinal pigment epithelium  
HSPs Heat shock proteins 
HSPA1B Heat shock 70kDa protein 1B 
HIF-1α Hypoxia-inducible factor-1α 
IGF-1 Insulin-like growth factor-1 
IL-1β Interleukin-1 beta 
INL Inner nuclear layer 
Kir4.1 Inwardly rectifying K+ channel of the 
IOP Intraocular pressure 
IPL Inner plexiform layer 
JNK c-Jun N-terminal kinases 
LDH Lactate dehydrogenase 
LIF Leukemia inhibitory factor 
LPA Lysophosphatidic acid 
LPC Lysophosphatidylcholine 
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LY333531 The PKCβ inhibitor ruboxistaurin 
MFC Mass flow controllers 
MHC Major histocompatibility complex 
mRNA Messenger RNA 
MTS CellTiter 96® AQueous One Solution Cell Proliferation 
MIO-M1 Moorfields/Institute of Ophthalmology-Müller 1 
NADPH Nicotinamide adenine dinucleotide phosphate  
NeuN Neuronal Nuclei 
NGF Nerve growth factor 
NHS National health service 
NMDA N-methyl-D-aspartate receptor 
NO Nitric oxide 
NTG Normal tension glaucoma 
OCT Optimal cutting temperature medium 
OGD Oxygen-glucose deprivation  
ONH Optic nerve head 
ONL Outer Nuclear Layer  
OPL Outer plexiform layer 
PACG Primary angle-closure glaucoma 
PANX1 Pannexin 1 
PBS Phosphate-buffered saline 
PDGF Platelet-derived growth factor  
PEDF Pigment epithelium derived factor 
PKC Protein kinase C 
POAG Primary open angle glaucoma  
PS phosphatidylserine 
PVR Proliferative vitreoretinopathy 
QRT-PCR Quantitative reverse transcription polymerase chain reaction (RT-PCR) 
RGCs Retinal ganglion cells 
RLT RNeasy lysis buffer  
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPE Retinal pigment epithelium 
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TESPA 3-triethoxysilylpropylamine 
TGF-β Transforming growth factor beta  
THY-1 Thy-1 Cell Surface Antigen 
TM Trabecular meshwork 
TNF-α  Tumor necrosis factor alpha 
TOP-1 Topoisomerase I 
TSP-1 Thrombospondin-1 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
VEGF Vascular endothelial growth factor  
WHO 
World Health Organization 
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Appendix A: Average threshold cycle (CT) values from QRT-PCR of different genes investigated in MIO-M1 cells 
under control, 1.11mM glucose, hypoxia (4%O2) and 1.11mMglucose/4%O2 conditions at 24hrs (n=4). 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Genes Control 1.11mM glucose Hypoxia (4%O2) 1.11mMglucose/4%O2 
VEGF 27.99 27.56 27.86 27.58 
PDGF 29.77 29.67 29.87 29.79 
bFGF 28.59 28.56 28.30 28.95 
PEDF 30.29 30.59 30.38 30.98 
LIF 32.18 32.44 31.88 32.34 
SLC1A3 28.50 28.60 28.40 28.92 
GLUL 26.16 25.78 26.20 25.98 
GAD 31.12 31.36 31.31 31.67 
PANX1 22.91 22.38 23.07 22.34 
ENNP2 29.67 29.43 29.55 29.45 
GFAP 29.54 29.69 28.91 29.36 
HSPA1B 25.36 25.10 25.34 25.33 
CYC1 25.53 25.15 25.20 25.28 
TOP1 27.18 27.16 27.15 27.23 
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Appendix B: Average threshold cycle (CT) values from QRT-PCR of different genes investigated in MIO-M1 cells 
under control, no glucose, hypoxia and full OGD conditions at 3,6,12 and 24hrs (n=4).   
   
 
 
 Control No glucose Hypoxia Full OGD 
Genes 3hrs 6hrs 12hrs 24hrs 3hrs 6hrs 12hrs 24hrs 3hrs 6hrs 12hrs 24hrs 3hrs 6hrs 12hrs 24hrs 
VEGF 26.71 26.14 26.38 25.53 25.93 26.18 24.97 24.77 25.95 23.15 21.55 23.15 25.40 23.40 22.35 21.48 
PDGF 27.24 27.41 27.28 27.63 26.87 27.20 27.34 28.13 27.07 27.11 28.26 28.17 27.02 27.27 28.03 28.74 
bFGF 29.86 29.85 29.62 29.94 29.61 30.17 29.50 29.69 29.48 30.02 30.20 30.07 29.73 30.19 30.18 30.33 
PEDF 30.26 30.75 29.41 29.03 30.19 30.52 29.36 29.54 29.96 30.48 29.89 30.09 30.23 30.44 29.92 30.23 
LIF 31.99 32.15 30.58 30.38 29.20 30.25 30.07 30.61 31.24 30.98 30.10 29.32 29.07 29.69 30.38 31.27 
SLC1A3 26.99 27.21 27.61 28.17 26.76 27.58 28.33 28.97 26.60 27.05 28.00 28.43 26.91 27.30 28.08 29.30 
GLUL 24.32 24.93 24.26 24.70 24.22 24.92 24.36 24.96 24.20 24.59 23.75 24.90 24.42 24.68 24.37 24.70 
GAD    31.24    31.51    32.10    31.30 
PANX1    22.09    21.93    22.10    21.40 
ENNP2 27.64 28.13 27.57 28.01 27.31 28.06 27.18 27.97 27.10 27.68 27.44 28.06 27.18 27.61 27.69 27.91 
GFAP 26.49 26.80 27.19 26.55 26.36 26.72 27.10 26.97 26.42 26.69 27.58 27.07 26.49 26.50 27.21 27.76 
HSPA1
B 
25.19 24.88 24.96 24.87 23.02 24.80 24.13 24.49 24.94 25.14 25.63 25.38 22.28 23.63 21.78 22.8 
CYC1 24.42 24.66 24.42 24.48 24.30 24.50 24.16 24.78 24.24 24.50 24.87 25.17 24.35 24.53 24.74 24.95 
TOP1 26.18 26.65 26.15 26.36 25.73 26.57 26.10 26.61 25.88 26.50 26.81 26.88 25.73 26.40 26.58 27.06 
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Appendix C: Average threshold cycle (CT) values from QRT-PCR of different genes investigated in HORCs under control, 
1.11mM glucose, hypoxia (4%O2) and 1.11mMglucose/4%O2 conditions at 24hrs (n=4).   
 
Genes Control 1.11mM glucose Hypoxia (4%O2) 1.11mMglucose/4%O2 
VEGF 23.42 23.42 22.84 23.44 
PDGF 28.41 28.42 28.81 29.49 
bFGF 27.32 28.86 27.62 28.94 
PEDF 26.07 26.45 26.42 27.35 
LIF 23.31 25.29 24.63 26.01 
SLC1A3 24.37 24.62 24.61 25.47 
GLUL 22.69 21.46 22.25 22.15 
GAD 25.64 25.25 25.15 25.23 
PANX1 27.51 27.26 27.43 27.79 
ENNP2 30.38 30.70 30.29 31.32 
GFAP 24.33 24.86 24.67 24.44 
HSPA1B 20.30 18.79 19.66 19.09 
CYC1 24.55 24.69 24.81 25.36 
TOP1 25.47 25.81 25.98 26.38 
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Appendix D: Average threshold cycle (CT) values from QRT-PCR of different genes investigated in HORCs under control, 
No glucose (0mM), hypoxia (0%O2) and full OGD conditions at 24hrs (n=4).   
 
Genes Control No glucose Hypoxia (0%O2) Full OGD 
VEGF 23.01 22.07 21.49 22.28 
PDGF 28.54 29.09 28.58 28.48 
bFGF 27.76 29.58 26.98 28.90 
PEDF 30.35 31.02 29.70 29.97 
LIF 25.54 28.52 27.00 29.84 
SLC1A3 24.35 24.38 24.59 24.65 
GLUL 22.31 21.27 22.07 21.88 
GAD 25.49 25.14 25.43 25.11 
PANX1 27.67 26.77 27.34 27.57 
ENNP2 26.69 26.32 26.86 26.70 
GFAP 24.03 24.38 23.85 24.27 
HSPA1B 19.82 19.43 19.67 19.90 
CYC1 25.15 25.36 25.02 25.49 
TOP1 26.50 26.46 26.22 27.04 
 
 
 
